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Abstract 
Azo-drugs are among the earliest fully synthetic chemotherapeutic agents known (Prontosil 1935). 
However the synthesis and application of phenylazo compounds in the area of medicinal chemistry 
has largely been restricted to derivatives of primary aromatic amines. This has been due, in the most 
part, to a perceived view that azo compounds not containing two aromatic groups are unstable. The 
syntheses of a number of novel heterocycles including important medicinal structures directly 
linked to an arylazo moiety are reported. The literature survey introduces a range of four and five 
membered heterocycles with established pharmaceutical activity. In particular the attention is drawn 
to molecules containing the azo functional group. This thesis contains a chapter detailing the 
introduction of a variety of alkyl and aryl groups into novel β-lactam molecules bearing the arylazo 
and arylazoxy functional groups. The succeeding chapter investigates the role of the azocarbinol 
group as an intermediate in the rearrangement of azoacetates to N-acyl hydrazides. The 
deacetylation reactions of azoacetates derived from L-threonine are also described. This work 
resulted in the synthesis of novel oxazolidinone and hydantoin species, also with phenylazo 
attachments. The final chapter describes the incorporation of a cyanide unit into heterocyclic 
compounds through intermolecular cyclisations of a range of substituted azoacetates when 
potassium cyanide is employed as base. It is shown that the azo group may be incorporated into the 
cyclic system to produce pyrazoles, or as an exocyclic pendant group attached to a 2-
iminopyrrolidin-5-one; X-ray crystal structures of these compounds are reported. The 2-
iminopyrrolidin-5-one was easily modified to produce the corresponding pyrrolidine-2,5-dione 
(succinimide) derivative. All of the heterocycles reported were generated from azoacetates derived 
from simple, cheap and readily available starting materials (ethylacetoacetate and L-threonine), thus 
showing azoacetates to be versatile and valuable building blocks in the field of heterocyclic 
chemistry. 
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1.1 Introduction 
1.1.1 The early history of antibiotics 
The history of antibiotics can be traced back to observations made by tribal peoples 
who noticed that certain plants could be used to stave off infection. For centuries natives of 
South America have chewed the bark of the cinchona tree as a treatment for malaria. 
According to the Ebers papyrus (1500 BC), beer yeast was used on wounds by the Egyptians. 
The ancient Greeks and ancient Chinese also noticed that certain moulds and plants were 
effective treatments for infections. 
Some would argue that salt was the first antibacterial agent, reference to salt being 
used as a food preservative can be found in the earliest documents surviving in most cultures. 
Most historians agree that the practice probably predates most written language. The 
connection between the toxic effects of NaCl on food-spoiling bacteria would not have been 
fully understood but the health benefits of employing the procedure of salt-based meat curing 
would have been obvious. 
In the late 19th century some of the most significant breakthroughs were made.  In 
1871, Joseph Lister1 noticed that some moulds could inhibit the growth of certain microbes. 
Unfortunately the significance of this work was not realised immediately and it would be 
decades before the full potential of this discovery was explored fully. 
In 1877, Louis Pasteur showed that anthrax could be countered in animals with the injection 
of saprophytic bacteria found in soil.2 Louis Pasteur's pupil Paul Vuillemin coined the term 
'antibiosis' in 1889 to mean a process by which life could be used to destroy life. 3 Emmerich 
and Freudenreich among others made similar observations in relation to other pathogens 
including important contributions towards the treatment of cholera and diphtheria.4 In 1897 
Ernest Duchesne a French medical student first uncovered the potential antibiotic properties 
of the penicillium mould.5 Duchesne studied the interaction between Escherichia coli and 
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Penicillium glaucum; He had observed how stable boys kept their saddles in a dark and damp 
room to encourage mould to grow on them because the mould helped to heal the saddle sores 
on the horses. Later he found that after preparing solutions of the mould and injecting them 
into diseased guinea pigs, they recovered. However his discoveries went largely unnoticed by 
the scientific community. 
But the most significant step forward came with the discovery by Alexander Fleming 
that a product in human tears could lyse bacterial cells.   Fleming’s finding, which he called 
lysozyme, was the first example of an antibacterial agent found in humans. Lysozyme would 
prove to be a dead end in the search for an efficient antibiotic, because it destroyed non-
pathogenic bacterial cells. In 1928 however, Fleming discovered another antibacterial agent.6  
Upon looking through a set of old plates that he had left out, Fleming found that colonies of 
Staphylococcus which had been streaked out had lysed.  The observation that lysis had 
occurred adjacent to some mould that had grown on the plate and the realisation that a 
product of the mould had caused the cell lysis, would become probably the most important 
observation in the history of medical research.  
Through follow-up work, Fleming showed experimentally that the mould produced a 
small substance that diffused. He named this substance penicillin after the Penicillium mould 
that had produced it.  By extracting the substance from the plates, Fleming was then able to 
directly show its effects.  Important to its discovery was that penicillin had destroyed a 
common bacterium, Staphylococcus aureus, associated with sometimes deadly skin 
infections. From that time up to the present day the vast majority of commercially available 
antibacterial agents have been structural variations of the β-lactam core of that original 
penicillin skeleton. 
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1.1.2 The emergence and development of β-lactam antibiotics  
When the structural elucidation of the active structures in penicillin (1, Figure 1.1) 
was eventually achieved in the mid 1940’s the drive to find useful derivatives of the molecule 
began in earnest.7 The benefits of these new drugs had been brought clearly into focus with 
the onset of the Second World War. In 1942 the U.S. government made an appeal to 
companies to join the race to see which one would develop a way to mass-produce the 
world's first broad-spectrum antibiotic. In response Pfizer developed a production technique 
that allowed large quantities of penicillin to be produced and shipped to the troops on the 
frontlines saving countless lives before the end of the war. 
 
 
 
 
 
 
 
1.1.3 Ring numbering and nomenclature  
There has been some inconsistency in the use of numbering systems for β-lactam ring 
systems, particularly in the case of monocyclic β-lactams, for the sake of clarity the system 
shown below (Figure 1.2) has been adopted in this thesis and will be used throughout.  
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Figure 1.2 β-Lactam ring numbering 
 
Figure 1.1 General structure penicillins (1) (2 = penicillin V, 3 = penicillin G) 
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1.1.4 Semi-synthetic variations of penicillin 
Initial attempts at producing new useful β-lactam compounds centred around making 
structural changes to the side chain at position C6 on the penicillin skeleton. 
 
 
 
 
 
 
 
This was initially achieved by removing the naturally occurring acyl groups to give 
compound 4, 6-aminopenicillanic acid. Addition of new acyl groups afforded the new and 
useful semi-synthetic derivatives ampicillin8 5, carbenicillin9 6 and oxacillin 7 (Figure 1.3). 
1.1.5 Structural diversity in the β-lactam skeleton 
After the preliminary studies on the activity of penicillin, analogous studies uncovered 
various active compounds similar in structure to the penicillins, containing the β-lactam 
skeleton as part of the structure. The first of these to emerge was the cephalosporins in 1948 
(Figure 1.4); Giuseppe Brotzu isolated these compounds from cultures of Cephalosporium 
acremonium from a sewer in Sardinia.10 These compounds were found to be somewhat 
effective against typhoid fever.  
 
 
 
 
 
Figure 1.3 Semi-synthetic penicillin derivatives 
 
Figure 1.4 Cephalosporins 
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Research was carried out at the Sir William Dunn School of Pathology at the University of 
Oxford and the compound cephalosporin C 9 was isolated.11 This compound was found to be 
less potent in terms of antibiotic activity than penicillin however it showed good stability 
towards β-lactamases. It was also found, in a similar fashion to penicillin, that isolation of the 
parent structure, 7-aminocephlosporanic acid (7-ACA, 8, Figure 1.4) gave a synthetic route to 
many new and potent antibiotics. The first of these new compounds to become commercially 
available was the antibiotic cephalothin (cefalotin) 10 (Eli Lilly-1964).  
 
 
 
 
 
    
Subsequently large arrays of cephalosporin based antibiotics were introduced to the 
pharmaceutical market. In 1995 cephalosporins were the largest selling type of antibiotic 
worldwide, generating almost 8.5 billion US$ in revenue for the vendors, with penicillins 
being the second largest seller (4.4 billion US$).12 The development of cephalosporins has 
given rise to several generations of subsequent derivatives, examples of which include, 
cephalothin 10 (first generation),13 cefuroxime 11 (second generation), and ceftriaxone 12 
(third generation) (Figure 1.5). 
1.1.6 Other important bicyclic β-lactams    
1.1.6.1 Carbapenems 
Another important addition to the bicyclic β-lactams came with the discovery of 
carbapenems in the late 1970s at Beecham and Merck.14 Thienamycin (13, Figure 1.6), which 
was isolated from the mould, Streptomycin cattlea, was found not only to be an extremely 
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Figure 1.5 Structural diversity in cephalosporins (1st, 2nd and 3rd generation) 
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potent antibiotic but also an effective β-lactamase inhibitor. The main feature that 
distinguishes thienamycin from similar bicyclic β-lactams is the presence of the sulphur atom 
exocyclic to the five membered ring system. Thienamycin could not be released onto the 
market despite initial promising biological results. It was found that although the compound 
was a potent antibiotic it had a tendency to undergo an intra-molecular reaction involving the 
amide group and the β-lactam ring at certain concentration levels. The problem was 
overcome by chemically altering the amide functionality to an imine, a group that did not 
interfere with the β-lactam ring and did not have a detrimental effect on the potency of the 
compound. The new drug Imipenem (14, Figure 1.6) was successfully marketed as an 
antibiotic and also has good activity against β-lactamases. However imipenem is rapidly 
degraded by the renal enzyme dehydropeptidase if administered alone, for this reason the 
drug is co-administered with cilastatin, a dehydropeptidase inhibitor, cilastatin blocks the 
effects of the renal enzyme.  
 
 
 
 
 
 
Since the release of imipenem a number of useful carbapenems have been developed and they 
have been found to be among the broadest spectrum anti-microbial agents available. 
1.1.6.2 Penems 
Penems evolved out of the desire by synthetic chemists to incorporate some of the 
structural features that were known to convey biological activity in penicillins and 
cephalosporins into a molecule more readily synthesised in the lab. A team at the Woodward 
N
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Figure 1.6 Carbapenems 
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Research Institute in Basel achieved the synthesis of such a molecule containing both the 
bicyclic structure and a double bond in 1975.15 The initial compounds synthesised were of the 
general type shown (Figure 1.7). 
 
 
 
 
It was the discovery of clavulanic acid (19, Figure 1.13) as a potent β-lactamase 
inhibitor and of thienamycin as a powerful broad-spectrum antibiotic that rose hopes that 
interesting biological activity in compounds with a penem skeleton. However the challenge 
facing researchers was finding the delicate balance between the inherent reactivity of the β-
lactam system and reasonable levels of stability within the systems being manufactured. 
Interestingly the first attempts at addressing this problem of balance centred around the 
synthesis of compounds with alkyl groups attached to position 6 on the ring (Figure 1.8).  
 
 
 
 
 
The penem 15 was synthesised with the intention of providing a route to active 
antibiotics, however it was found that the molecule had little or no antibiotic activity but was 
a promising candidate as a β-lactamase inhibitor, showing good activity towards the β-
lactamases from P. aeruginosa 18SA and Enterobacter P99.16 In results similar to clavulanic 
acid and thienamycin it was found that the antibiotic activity imparted by the amide group on 
the ring was not a vital element in the observed activity against β-lactamases.  
N
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Figure 1.8   Early penem showing activity towards β-lactamases 
 
Figure 1.7 General structure of first synthetic penems 
 
15 
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1.1.7 Mode of action of β-lactams 
β-Lactam antibiotics are bacterial cell wall biosynthesis inhibitors, active against 
mainly Gram-positive bacteria. To understand how β-lactams disrupt the synthesis of the cell 
wall, a basic knowledge of the make up of the bacterial cell wall is necessary (Figure 1.9). 
The Gram-positive bacterial cell wall is made up of petidoglycan layers usually 50-100 
molecular layers thick.  
 
 
 
 
 
 
            
  
            
The peptidoglycan layer gives strength and rigidity to the cell and determines its shape. The 
peptidoglycan layer is made up of a repeating unit of disaccharide (NAG 16 and NAM 17 
Figure 1.10) linked to a tetrapeptide. These peptides are, in turn, cross-linked by a peptide 
chain, (e.g. Staphylococcus aureus is cross-linked by a pentaglycyl peptide chain Figure 1.9).   
 
 
 
 
 
 
Figure 1.9 Gram positive bacterial cell wall 
 
Figure 1.10 Sugars making up the disaccharide-repeating unit of peptidoglycan  
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It is at the point of formation of these essential cross linkages that inhibition of cell 
wall synthesis by β-lactams takes place. β-Lactams compete for the binding site on the 
enzyme that catalyses the cross linking process. There are several of these binding sites 
within the bacterial cell known as penicillin binding proteins (PBPs). 17 The PBP discussed 
here is commonly known as PBP-1, and contains a serine residue that facilitates the cross-
linking procedure. In the case of its reaction with β-lactam molecules it produces a 
bacteriocidal effect resulting in cell lysis.  The β-lactam ring is a highly strained entity and as 
such is a highly reactive moiety. It has been proposed that the cyclic nature of the β-lactam 
ring contributes to its reactivity relative to similar acyclic amides; this is due to a reduced 
ability to allow delocalisation of the nitrogen lone pair. A feature of the β-lactam amide is 
shortened carbonyl bond length together with an elongated C—N bond. The difference 
between the types of amide can be seen in the I.R. carbonyl stretch of β-lactams (v(C==O) 
1775-1795 cm-1) and acyclic amide (v(C==O) 1640 – 1690 cm-1).18 
 
 
 
 
 
 
 
 
This difference is directly attributable to the ring strain common in these smaller rings 
and is the nature of the susceptibility of β-lactams to nucleophilic attack. Another feature of 
penicillins considered to be a factor in their activity is the structural similarity to the D-Ala-
D-Ala terminus 18 of the peptide chain in peptidoglycan (Figure 1.11). This capacity to 
Figure 1.11 Comparison between penicillin and D-Ala-D-Ala peptide terminus  
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mimic the enzyme-binding site coupled with the inherent reactivity of the β-lactam ring is 
seen as the source of the activity of penicillins (Figure 1.12). It should be noted however that 
some potent β-lactam antibiotics do not share all of these characteristics associated with 
penicillins. Monocyclic β-lactams for instance do not usually share the same level of 
structural similarity to the D-Ala-D-Ala terminus 18 but do bind effectively to PBP-3. As a 
result the Structure Activity Relationship (SAR) has been revised many times in accordance 
with new information about the system. 
 
 
 
 
 
 
 
As mentioned previously β-lactams function as bacteriocidal inhibitors. They bind 
irreversibly to the serine residue of the transpeptidase enzyme thereby blocking the enzyme 
from carrying out its essential function in the cross-linking process (Scheme 1.1). 
 
 
 
 
 
 
 
 
Figure 1.12 Inhibition of cross-linking process in Gram-positive bacterial cell wall 
 
Scheme 1.1a Action of transpeptidase enzyme on Terminal D-Ala-D-Ala Residue 
 
Scheme 1.1b Action of transpeptidase enzyme on Penicillin 
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1.1.8 Development of resistance to β-lactam antibiotics (β-lactamases). 
The development of resistance to antibiotics by bacterial cells was in many ways an 
inevitable development. Observations made by Darwin long before the development of 
modern antibiotics could be seen to auger the development of resistance.19 His observation 
that in every environment competition dictates the selection of the strain most likely to 
survive in that environment has turned out to be exactly what has been observed over and 
over in the domain of bacteria. The large numbers of bacterial cells, combined with the short 
generation times facilitate the development of mutants. In a typical bacterial population of 
1011 bacterial cells (i.e. in an infected patient) there can easily be 1000 mutants. If a mutant 
confers a selective advantage upon the bacterium (i.e. the ability to survive in the presence of 
an antibiotic) then that resistant bacterium will be selected and continue to grow while its 
neighbours perish. This can happen in a matter of days in patients being treated with 
antibiotics. These resistant species multiply, until the entire population is composed of 
resistant bacteria. This type of action of the bacteria is known as the selection of resistant 
mutants. For example approximately 10 years after the introduction of penicillin, penicillin-
resistant Staphylococcus aureus was observed. In response modified penicillins were 
produced that were resistant to this specific strain of β-lactamases. Before long, strains of 
bacteria containing β-lactamases with different mechanisms of action were selected and soon 
became the predominantly observed strain. This cycle has been repeated since the 
introduction of antibiotics and remains the predominant problem facing researchers trying to 
stay one step ahead of the development of bacteria. 
Several mechanisms of resistance to antibiotics exist, the most effective are: 
(i) The prevention of build up of antibiotic in the cell (decrease in uptake, or increase in 
efflux), 
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(ii) Alteration of the target site to reduce the affinity for the antibiotic by mutation or 
modification, 
(iii) Inactivation of the antibiotic by hydrolysis or modification 
Although the first two mechanisms are a considerable problem the most troublesome 
in terms of β-lactam antibiotics is the inactivation by hydrolysis due to the presence in 
the cell of β-lactamases. 
 It has been shown that the activity of the β-lactam  antibiotics is due to their inhibitory 
effect on the transpeptidase enzyme, combining with the PBP to inactivate the enzyme and 
thus causing cell death due to weakened cell walls. The presence of β-lactamases in the cell 
provides another target for penicillin with a similar binding site, the success of the β-
lactamase is dependant on the propensity of the β-lactam to bind preferentially to the β-
lactamase over the transpeptidase. Both contain a serine residue that is central to the activity 
of the enzyme, this structural similarity combined with the similar mechanism of action 
suggests that the β-lactamase may have developed as a defence mechanism directly from the 
PBP. 
The preference for reaction with the β-lactamase can be accounted for in terms of the 
rate of deacylation of the intermediate formed between the β-lactam and the β-lactamase, this 
occurs relatively rapidly to return the intact β-lactamase enzyme. 
 
1.1.9 β-Lactamase Inhibitors 
Probably the most important member of this group is clavulanic acid (19, Figure 1.13) 
which was isolated from Streptomyces clavuligerus in 1976.20  Clavulanic acid was the first 
suicide inhibitor of β-lactamases to be described in the literature. The clavam structure was 
the first naturally occurring bicyclic β-lactam described that did not possess a penicillin or 
cephalosporin nucleus. This is significant in that it led the way for later research into the 
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potential of β-lactams without the structural features hitherto considered essential for 
imparting activity.  
 The similarity in chemical structure allows the molecule to act as a competitive 
inhibitor of β-lactamases secreted by certain bacteria to confer resistance to β-lactam 
antibiotics. The clav ring is similar to the penicillins except at three moieties: at ring position 
4 oxygen replaces sulphur, at position 3 a hydroxyethylidene group replaces two methyl 
groups, and at position 6 there is no substituent. 
 
 
 
 
The exact mechanism of action of clavulanic acid is thought to be quite complex, including 
several different processes in which the β-lactamase enzyme can be either reversibly or 
irreversibly inhibited. However, in general terms the main reaction of clavulanic acid with the 
β-lactamase molecule is similar to that observed with penicillin (Scheme 1.2).21  
 
 
 
 
 
 
 
 
However, unlike penicillin, the initial acyl-enzyme intermediate can rearrange into a 
chemically inert enamine, whose further reaction the enzyme is unable to catalyse.22 
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Scheme 1.2 Mechanism of inhibition of β-lactamase by clavulanic acid 
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Clavulanic acid has been shown to be a potent inhibitor of β-lactamases produced by 
staphylococci and plasmid-mediated β-lactamases of E. coli, as well as examples from 
Klebsiella, Proteus, and Hemophilus. Although it has proven to be one of the most successful 
β-lactamase inhibitor yet discovered the molecule does not possess sufficient activity against 
transpeptidase molecules for it to be administered unaccompanied. The most common 
formulations of this drug are in combination with another antibiotic, (e.g. Augmentin, 
amoxicillin and clavulanic acid). The inhibitory effects of the clavulanic acid allow enhanced 
performance of the co-administered drug. 
 
1.1.10 Monocyclic β-lactams (Monobactams and Azetidinone) 
In the overall scheme of β-lactam research, the emergence of chemical and 
biosynthetic pathways to the monocyclic β-lactam compounds is a relatively new field. The 
first reported isolation of nocardicins from the fermentation broth of a strain of Actinomycetes 
(strain WS 1571, was identified as Nocardia uniformis subsp. tsuyamanensis ATCC 21806)23 
was followed in quick succession by alternative syntheses of both the core structure (3-ANA) 
3-aminonocardicinic acid 20 and nocardicin A 21 (Figure 1.14). 24,25  
 
 
 
 
 
Unfortunately the nocardicins proved to have limited effectiveness against pathogenic 
bacteria. Nocardicin A was found to show selective antibacterial activity, with moderate 
activity against a range of Gram-negative bacteria including Proteus and Pseudomonas. 
However it had no inhibitory effect on Staphylococcus, Mycobacterium, fungi and yeast. 
Figure 1.14 Structure of nocardicins, (3-ANA) 20 and nocardicin A 21 
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Shortly after the nocardicins came to light, the isolation of another group of 
monocyclic β-lactam derivatives was reported in a series of papers by researchers at Squibb.26 
The so-called monobactams isolated from strains of Chromobacterium violaceum, 
Acetobacter sp., and Agrobacterium radiobacter were characterized by a central β-lactam 
ring with N-acyl side chains at position 3 and a sulphate moiety attached to the ring nitrogen 
(Figure 1.15). Most naturally occurring monobactams also bear a methoxy group at ring 
position 3, but examples where it is not present have also been isolated.27 The initial 
exploitation of the penicillins and the consequent synthesis of derivatives through the 
modification of the side chain were wholly dependant on the development of efficient 
fermentation procedures for the mass production of the parent compound. In the case of the 
monobactams the relative simplicity of the monocyclic system allowed access to the core 
structure through chemical synthesis in good yield. The synthesis of (3-AMA) 3-
aminomonobactamic acid (22, Figure 1.15) the central unit, to which subsequent 
modifications were made was achieved by Squibb chemists in 1982.28   
 
 
 
 
 
 
 
Unfortunately much like the naturally occurring nocardicins, the isolated 
monobactams SQ 26,180 23, SQ 26,445 24, and SQ 26,812 25 (Figure 1.15) showed little 
potential as antibiotic. However after much experimentation with side chain modifications 
aztreonam (Azactam®, 26, Figure 1.16) was first synthesised. This potent antibiotic was a 
Figure 1.15 Structures of 3-AMA, SQ 26,180, SQ 26,445, and SQ 26,812. 
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combination of the core 3-aminomonobactamic acid with the side-chain of the cephalosporin 
ceftazidime. The compound is active against Gram-negative bacteria, including Pseudomonas 
aeruginosa and Haemophilus influenzae, but was found to perform poorly against Gram-
positive organisms. A further attractive characteristic was found to be high degree of 
resistance to enzymatic hydrolysis by most of the common β-lactamases. 
 
 
 
 
 
 
Until recently, interest in newly generated β-lactams tended to focus solely on their ability to 
induce bacterial cell death due to their historically successful application in this role.  
However β-lactams have now come to the attention of researchers in a diverse range of 
medicinal fields. Compounds of a combinatorial monocyclic β-lactam library synthesised 
using the Ugi 4CC four-component condensation reaction were found to be apparently 
uncompetitive inhibitors of HIV-1 protease, providing lead compounds for a new class of 
HIV protease inhibitors.29,30 
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Figure 1.16 Aztreonam: β-lactamase resistant Gram negative antibiotic 
 
Scheme 1.3 Ugi 4CC multi-component synthesis of β-lactam based HIV protease 
inhibitors 
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The combinatorial library produced a total of 126 compounds based on the starting β-amino 
acid 27, aldehyde 28 and isocyanide 29 (Scheme 1.3). High throughput screening of those 
compounds showed three, 30, 31 and 32 (Scheme 1.3) to be active HIV protease inhibitors 
showing greater than 60% inhibition.  
In yet another role, monocyclic β-lactam analogues have been proven effective in 
human clinical trials as agents capable of inhibiting the absorption of cholesterol. The goal of 
the work was the generation of an agent for the prevention of atherosclerotic coronary artery 
disease (CAD) through the generation of AcylCoA: cholesterol acyltransferase (ACAT) 
inhibitors, blocking the formation of intestinal cholesteryl esters. In vitro testing showed the 
azetidinones to have a modest inhibitory effect on ACAT, however when in vivo testing in 
hamsters was completed the studies indicated that the action of the substrate was at the 
intestinal wall to inhibit cholesterol absorption through a mechanism not involving ACAT 
inhibition. 31 
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Figure 1.17 Basic pharmacophore for β-lactam based ACAT inhibitor and structurally 
similar inactive analogues. 
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Preliminary SAR studies showed that the azetidinone ring was an essential element in the 
most active compound 33 (Figure 1.17). The analogous thioazetidinone 34 and uncyclised β-
amino acid 35 were found to be ineffective. Additional features necessary for the conferral of 
activity were identified and a basic pharmacophore was developed (Figure 1.17). 
 
1.1.11 Anti-cancer activity of β-lactams 
Due to the toxic nature of many of the currently available anti-cancer agents, the 
search for reagents equally effective, but without the detrimental effects on the patient has 
been ceaseless. Recently the search has focused on β-lactam containing molecules. This has 
come about partly due to the recent abundance of novel β-lactams appearing in the literature 
in response to the search for more resilient compounds capable of withstanding the resistance 
developing in many strains of bacteria.32 The proliferation of these compounds has led to 
their being reassessed as possible agents capable of bringing about apoptosis in cancerous 
cells. The β-lactam structure has been found to date to have very low toxicity in most cases 
and this characteristic makes them an excellent candidate for further development if it can be 
shown that the potential exists to create ant-cancer compounds with similar efficacy and low 
toxicity levels. Recently strides have been made towards achieving this goal, with an 
increasing number of publications showing promising results in this area. In 2002 for the first 
time the ability of β-lactams to induce cell death in cancerous cells was reported.33  
 
 
 
 
 
 
36, o-Chloro, R = S-CH3  40, m-Chloro, R = S-CH3 
37, o-Chloro, R = H   41, p-Chloro, R = S-CH3 
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Some basic SAR and mechanistic studies were carried out on the compounds, and although 
the direct target of the lactam substrate was not identified, valuable insight into the processes 
resulting in cancer cell death was gathered. It was found that compounds with an N-
methylthio group were able to induce DNA damage and inhibit DNA replication in human 
leukaemic (Jurkat T) cells within a 2-h treatment. This was followed by p38 mitogen-
activated protein (MAP) kinase activation, S phase arrest, and apoptotic cell death. The p38 
(MAP) kinase was found to play a central role in β-lactam induced apoptosis. It was found 
that the rank of potencies of the lactams to induce DNA damage matches precisely the order 
for activation of p38 MAP kinase and the N-methylthio group was a required element for 
activity. In other words increasing the number of carbons on the N-thio constituent of the 
lactams was accompanied by a stepwise decrease in the ability of these compounds to induce 
DNA damage and also directly correlated to the ability to cause p38 phosphorylation, 36 (S-
CH3) > 38 (S-CH2-CH3) > 39 (S-CH2-CH2-CH3) (Figure 1.18). 
Apoptosis can be thought of as a means of inducing the target cell to actively commit 
suicide. Apoptosis is characterized by shrinkage of the cell, reorganization of the nucleus, 
active membrane blebbing, and fragmentation of the cell into membrane-enclosed vesicles. 
The most potent β-lactam selected in this study, was able to induce apoptosis in human 
leukaemic (Jurkat T), breast (MCF7, MDA-MB-231), prostate (PC-3), and head and neck 
(PCI-13) cancer cell lines. The best results observed were those associated with apoptosis in 
human leukaemic (Jurkat T) cells where the β-lactam bearing the o-chlorophenyl and N-
thiomethyl moieties 39 achieved an IC50 value of 32µM (Figure 1.18).  
After initial investigations by Banik et al on the potential of certain acyclic 
polyaromatic amine derivatives as novel anticancer agents it was decided to investigate the 
synthesis and activity of a cyclic analogue based on the  β-lactam skeleton.34 The potent 
biological effects of the commercially available β-lactams compared to similar acyclic 
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systems has long been known to be linked to the reactivity imparted by ring strain associated 
with β-lactam based structures. It was hoped that the combination of some of the structural 
elements shown to be effective in the acyclic system (43, Figure 1.19) would be further 
enhanced in the strained  β-lactam ring.  
 
 
 
 
 
 
 
The Staudinger reaction was used to condense previously synthesized polyaromatic 
imines with the appropriate acid chlorides to give β-lactam as product (Scheme 1.4).35 (Note: 
Syntheses of 21 azetidinone compounds with a range of polyaromatic appendages are 
reported; only those showing anticancer activity are described here). Although the 
synthesized compounds did not possess all of the elements present in the acyclic analogues, 
the desired β-lactam polyaromatic amines system was achieved.  
 
 
 
 
 
In vitro anticancer testing on the synthesized compounds showed that they had good activity 
for a range of cancer cell lines. As anticipated, it was found that in general the β-lactam based 
compounds showed significantly improved activity over the similarly substituted acyclic 
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Scheme 1.4 Anticancer β-lactams via the Staudinger reaction 
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systems. However, no efforts were made to identify the target or the mechanism of the 
subsequent anti-tumour activity of these novel agents. In the tests carried out cisplatin was 
used as a comparison for the compounds being tested. 
 
1.2 Alternatives to the penicillins 
At a certain point in the history of β-lactam antibiotics it became clear that the rate of 
proliferation of resistant strains of bacteria would eventually render the search for new 
variations of β-lactams ineffective. This realisation gave rise to a renewed interest in 
developing other antibiotic molecules. The research followed two general trends. The first 
was the continued search for new natural products preferably with mechanisms of action 
differing from that of the β-lactams, thus minimising (or somewhat slowing) the development 
of bacterial strains resistant to the new molecules. The strategy was generally the same as that 
adopted for penicillin and the β-lactams, the arduous search for a lead compound with good 
activity followed by Structure-Activity Relationship (SAR) studies. After the elements 
necessary to confer activity are identified, an abundance of structurally similar substances are 
synthesised and assessed for any discernable change in the effects or side effects compared to 
the lead compound (Summary in Table 1.2). In addition to the natural product approach to 
drug design, there has been a history of purely synthetic drug design and testing that has led 
ultimately to the synthesis of innovative compounds such as linezolid. 
 
Early synthetic Anti-biotics (Prontosil) 
There is a long history of using the azo linkage in the pharmaceuticals industry. 
Gerhard Domagk is generally credited with the discovery of the antimicrobial potential of 
sulphonamides for which he received the Nobel Prize in medicine (1939). Prontosil 49, the 
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world’s first commercially available antibiotic was originally synthesised by Josef Klarer and 
Fritz Mietzsch, colleagues of Domagk at the Bayer Company in Germany. 36 
 
 
 
 
 
 
In 1932 while testing a large number of dyes and azo-compounds produced by Bayer, 
Domagk uncovered the great potential of Prontosil as an antibiotic. It was not until 1935, 
after Bayer had received a patent on Prontosil, that Domagk published his results. It was 
quickly discovered that Prontosil was a pro-drug, and that the active part of the molecule was 
in fact the simple compound sulfanilamide 50 that is released upon reduction in the digestive 
system when taken orally. 
 
 
 
 
The major indicators that Prontosil was not the direct cause of the antibiotic activity were its 
relative insolubility, the observed activity in vivo and total lack of activity in vitro and the 
fact that it was sulphanilamide that was excreted from the body and not Prontosil. Since the 
discovery that sulphanilamide was biologically active compound was made quite quickly, the 
commercial success of Prontosil was limited. Following to the development of Prontosil 
many useful biological compounds have been isolated and studied that utilise azo bond 
cleavage brought about by intestinal azo-reductase enzymes (51, 52 and 54, Table 1.1). 
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Figure 1.21 Sulfanilamide 
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Table 1.1 Phenylazo drugs 
 
Name Structure Clinical uses Mode of 
action 
No. 
Olsalazine37,38  
 
 
 
 
Anti-
inflammatory 
Azo-reductase 
activation 
51 
sulfasalazine39,40  
 
 
 
 
Anti-
inflammatory 
Anti-cancer 
Azo-reductase 
activation 
52 
Pyridine-2-azo-p-
dimethylaniline 
cephalosporin 
(PADAC) 41,42 
 
 
 
 
 
 
 
 
β-lactamase 
detection 
 
β-lactamase 
activated  
 
53 
NCS 79068, R1 = Et43   
NCS 59492, R1 = Me 
 
 
 
 
 
Anti-cancer  Azo-reductase 
activation 
54a 
and b 
Cyclic-phenylazo 
sulfone 44,45,46 
 
 
 
 
 
Anti-cancer Garratt–
Braverman 
rearrangement 
55 
 
1.2.1 The search for synthetic alternatives 
The period between 1941 and 1962 is often thought of as the golden era of antibiotic 
discovery. During this period it is estimated that more than 7000 compound showing 
antibacterial activity were discovered; the majority through the process of whole cell 
screening of fermentation broths of cultured organisms. However, by the late 1980s 
motivation to pursue this avenue of approach was low due to the large array of antibiotic 
drugs already on the market, the increased difficulty and cost of drug discovery by traditional 
methods (screening, purification and structural characterisation). During the late 1980s and 
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early 1990s many pharmaceutical companies abandoned the search for new antibiotics due to 
the abundance of generic drugs available on the market. The threat from Gram-positive 
bacteria was considered low during this period due to the success of vancomycin, with no 
signs of the resistant strains from 1956 up until 1988.  
Table 1.2 Post-penicillin natural product derived antibiotics 47 
 
 
 
 
 
 
 
 
 
 
 
 
During this period greater emphasis was placed on the search for compounds active 
against Gram-negative bacteria. The perception by clinicians that the pharmaceutical industry 
had reached a point where treatments were available for the majority of serious bacterial 
infections was a major contributing factor in the subsequent development of resistant strains 
of bacteria. This period of complacency and reduced vigilance saw the emergence of VRE 
(Vancomycin Resistant Enterococci), a strain of bacteria resistant to the super drug once seen 
as the last line of defence in the battle against serious bacterial infections. This development 
in combination with the development of MRSA (Methicillin-Resistant Staphylococcus 
Aureus) does not augur well for ongoing conflict between bacteria and the treatment of 
Antibiotic 
Class  → 
Aminoglycosides Tetracyclines Cyclic peptides Macrolide antibiotics 
Year of 
Discovery 1943 1945 1956 
Isolated 1949 
Launched commercially 
1952 
First 
Example Streptomycin Chlortetracycline Vancomycin Erythromycin 
Discoverer Selman A Waksman 
Dr Benjamin Duggar 
Modified by 
Lloyd H. Conover 1952 
Pittenger and Brigham 
Submitted by A. Aguilar 
Developed by J. M. McGuire 
At Eli Lilly 
Natural 
Source 
actinobacterium 
Streptomyces griseus 
Found in the soil bacteria 
Streptomyces 
aureofaciens.  
Sanborn fields USA 
Found in the soil 
bacteria Nocardia 
orientalis in India  
Streptomyces erythreus 
Other examples 
Gentamycin, 
Tobramycin, 
Amikacin 
Doxycycline 
Demeclocycline 
Tetracycline 
Streptogramins, 
Polymyxins 
azithromycin  
clarithromycin  
dirithromycin  
Mechanism of 
action Bacteriostatic Bacteriostatic Bacteriocidal Bacteriostatic 
Mode of Action 
Protein synthesis 
inhibitor 
(binds to the 23S 
rRNA  of the bacterial 
ribosome) 
Protein synthesis 
inhibitor 
(Binds to the 30S subunit 
of the bacterial 
ribosome) 
Cell wall biosynthesis 
inhibitor 
Protein synthesis inhibitor 
Inhibits elongation at 
transpeptidation step. 
Active Against 
Gram-negative 
bacteria, 
Pseudomonas, 
Acinetobacter, and 
Enterobacter 
Chlamydia (Trachoma, 
Psittacosis, salpingitis, 
Non-specific urethritis 
and Lymphogranuloma 
venereum) 
Staphylococcus 
pseudomembranous 
colitis 
Legionella pneumophila 
Mycoplasma pneumoniae 
Anaerobic cocci & bacilli 
Resistance first 
Observed  1959 1953 1988 1988 
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bacterial infections. The relentless use of vancomycin as the drug of choice in the treatment 
of MRSA produces a scenario where vancomycin resistance in the Enterococci realistically 
threatens transfer of vancomycin resistance to the Staphylococci, and a vancomycin- and 
multidrug-resistant Staphylococcus strain threatens to be essentially untreatable. 
Another factor that has to be taken into consideration when comparing present rates of 
drug discovery and release with those in the 50’s and 60’s is the increased levels of safety 
and testing required in the modern era. For instance streptomycin was discovered in 1943 and 
was introduced to clinics in 1944, by comparison the potential antibiotic activity of 
oxazolidinones was discovered in 1979 however it was not until 2001 that linezolid appeared 
on the market as research had been totally abandoned for several years due to safety concerns 
regarding early versions of the drug.  
 
1.3 Background chemistry 
Throughout this thesis the cyclisation reactions of azo compounds derived from 
simple β-ketoesters and anilides are described, and the reactions of these compounds are 
novel in terms of azoacetate chemistry. However if the presence of the azo group (G1, 51-56, 
Scheme 1.5) is ignored briefly, it becomes clear that in most cases the chemistry is familiar 
and has been previously reported for functionalised propionamide derivatives. The majority 
of the azoacetates investigated in this thesis have a configuration similar to the basic 
propionamide structure, and these similarities have been exploited by our group in order to 
adapt this fundamental chemistry to our needs. The introduction of neighbouring functional 
groups used to facilitate these cyclisations is at the core of the work presented in this thesis. 
How these groups have been introduced at the appropriate positions is discussed within the 
relevant synthetic chapters of the thesis. 
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However, for a fuller understanding of how these groups have been used in our work 
a discussion of their chemistry and how they have been previously been used will follow. In 
many cases variations of the chemistry of interest to us has been previously used with simpler 
substrates to produce useful therapeutic compounds in a diverse range of fields. It was 
therefore of great interest to us to capitalise on the known elements of propionamide 
chemistry in order to expand the range of attainable compounds based on the reactions of 
azoacetates rather than simple propionamides.  
 
Scheme 1.5 General overview of propionamide reactions used. 
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1.3.1 Cyclisation of halopropionamides  
 The syntheses presented in chapter 2 of this thesis are primarily concerned with the 
generation β-lactams through the N1-C2 bond formation. Procedures for this cyclisation using 
a range of leaving groups have been previously reported. Of these one of the most versatile 
and frequently used is the cyclisation of halopropionamides. Reports of the synthesis of β-
lactams 65a from haloamide 64a by the treatment of strong bases have been appearing in the 
literature since the late 50’s.48 When the procedure was investigated using various base 
solvent systems in the 1960’s by Manhas and Jeng they found that the desired β-lactam could 
be isolated with a yield of 96 % when NaH/DMSO was used. 49 
 
 
 
 
PCP = Para-methoxyphenyl 
 
The success of these procedures is principally dependant on the relative acidity of the amido 
proton and the tolerance of other functional groups present to the strong basic condition. 
Although the formation of elimination products were not reported in this case, in general, if 
the amido proton is not sufficiently acidic, competing elimination reactions tend to be the 
predominately observed processes when other ionisable groups are present. Wasserman et al 
in similar studies on these systems found that when NaH in DMF/CH2Cl2 was used β-
elimination was the predominately observed process in the majority of cases (66, Scheme 
1.6). However after variations of the dilution, rate of addition of the substrate to the base and 
choice of halide as leaving group were examined, they found that the desired β-lactam (65b, 
Scheme 1.6) could be isolated as the major product.50 A significant breakthrough in the 
Scheme 1.6 Cyclisation of halopropionamides to β-lactams 
64 65 
1 
2 3 
4 
64a to 65a, R = Ph, 65a yield = 96 % using (NaH/DMSO) 
64b to 65b, R = CH2-PMP, 65b yield = 60 %, 66b yield = 6 %, using (NaH/DMF/CH2Cl2) 
66 
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search for a reliable procedure for the synthesis of these systems was made when it was 
discovered by Miller et al that heteroatom activation of the N-H bond considerably improved 
selectivity for ionisation at this position. It was also found that if this was the only ionisable 
position the reaction gave the cyclisation product (68, Scheme 1.7) in very high yield.51 
 
 
 
 
 
 
When the scope of the investigation was broadened to include systems where competition 
between ionisable protons was possible 69, it was similarly found that the desired β-lactam 
(70, Scheme 1.8) products could be isolated selectively. 52 
 
 
 
 
 
1.3.2 Cyclisation via Mitsunobu reaction  
The cyclisation of β-lactams using the Mitsunobu reaction is another commonly used 
method of N1-C2 bond formation and was first reported by Miller et al in the same paper as 
their work with halopropionamides. When β-hydroxyhydroxamates (71, Scheme 1.9) were 
used as substrates the desired β-lactam (72, Scheme 1.9) could be isolated without competing 
elimination products and with retention of chirality.  
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Scheme 1.7 High yielding cyclisation using heteroatom activator at N-H 
Scheme 1.8 Stereoselective cyclisation without competitive elimination 
67 68 
69 70 
Yield = 74-88 % 
 29 
 
O
OMe
Ph
OAc
O
OMe
Ph
OH
O
NH
CH3
H
OAc
CH3
H3C
PCP O
NH
CH3
H
OH
CH3
H3C
PCP
Et3N/MeOH
KCN/n-PrOH
 
 
 
 
 
 
This procedure became popular because it did not require the strong basic conditions 
necessary for the cyclisation of halopropionamides and therefore allowed a more diverse 
range of functional groups to be present before cyclisation. It was found that the procedure 
worked equally well with both seryl and threonyl derivatives.  
 
 
 
 
 
 
 
 
PCP = Para-chlorophenyl 
Techniques for the generation of these hydroxy substrates through the deacetylation 
of the appropriate acetate analogues using triethylamine in methanol were adapted from the 
work of Garay, and Cabaleiro (Scheme 1.10).53 Within our group a KCN/propanol system 
was used to produce similar substituted 3-hydroxyproipinamide derivatives (Scheme 1.11).54 
 
 
Scheme 1.9 Stereoselective cyclisation using Mitsunobu conditions. 
Scheme 1.11 Deacetylation of N-(4-chlorophenyl)-2,2-dimethyl-3-acetoxybutanamide 
Scheme 1.10 Deacetylation of 3-acetoxy-3-phenylpropanoate 
73 74 
75 76 
Yield = 62-89 % 
Yield not reported 
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1.3.3 Cyclisation of azoacetates 
When the deacetylation procedures described in the previous section were applied to 
the azoacetates 133 of interest to our group it was found that the substrate underwent 
lactamisation to 134 (Note: See chapter 2 for details of synthesis of 133 and 134), 
accompanied by rearrangement to an N-acyl hydrazide derivative (77, Scheme 1.12). The 
rearrangement product 79 isolated from the reaction of the azoacetate ester 78 was 
subsequently cyclised (in several steps) to form an aza-β-lactam (80, Scheme 1.13).  
 
 
 
 
 
 
 
 
 
 
The rearrangement resulting in the N-acyl hydrazide is thought to have come about after 
initial deacetylation followed by a 1,2 carbon to nitrogen migration. Also, the rearrangement 
was found to occur irrespective of whether an ester or anilide was present. These results were 
published in a brief communication by the group in 1992.55  
 
 
 
 
N N
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Scheme 1.14 Barton deacetylation of azoacetate 
81 82 
Scheme 1.13 Rearrangement of azoacetates ester derivatives 
Scheme 1.12 Lactamisation and rearrangement of azoacetates anilide derivatives 
133 f or j 134 f or j 
 
77f or j 
78 79 80 
f, R = Ph or j, PCP, (PCP = Para-chlorophenyl, PNP = Para-nitrophenyl) 
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Although the reaction was assumed to proceed via initial deacetylation, the azocarbinol 
intermediate was not isolated. However in studies carried out by Barton et al on similar 
substrates it was found that by using a sterically hindered base (2-t-butyl-1,1,3,3-
tetramethylguanidine) it was possible to isolate the azocarbinol product (82, Scheme 1.14) of 
the deacetylation.56 
1.3.4 Cyclisation of cyanoamide to 2-iminopyrrolidin-5-ones and succinimides 
The use of relatively simply substituted 3-cyanopropionamide derivatives in the 
construction of succinimide rings has been previously reported (Refer to reactions of 61 in 
scheme 1.5). While investigating biosynthetic research on vitamin B12, Battersby and 
Westwood identified 2-(2-methoxycarbonylethyl)-3-methoxycarbonylmethyl-3-
methylsuccinimide, (usually called the ring-B imide) as a key building block and set about its 
synthesis.57 Central to this synthesis was the construction of the succinimide ring 85. Several 
routes to these compounds were investigated including via initial formation of 2-
iminopyrrolidin-5-one 84 from the appropriate cyanamide 83 followed by acid hydrolysis to 
the succinimide 85. 
 
 
 
 
 
 
 
Another reaction mechanism was investigated by Nisole et al. The ring expansion of some β-
lactams (86, Scheme 1.16) has been reported using trimethylsilyl-cyanide (TMSCN) in the 
presence of AlCl3 in a one-pot synthesis of 2-iminopyrrolidin-5-ones (88, Scheme 1.16). 
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Scheme 1.15 Barton deacetylation of azoacetate 
83 84 85 
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However the stepwise reaction involving initial formation of a cyanamide (87, Scheme 1.16) 
using (TMSCN) followed by cyclisation using AlCl3 was also investigated. 58  
 
 
 
 
 
 
 
 
Succinimide (pyrrolidine-2,5-dione) derivatives have been investigated in a wide and diverse 
range of roles within the field of medicinal chemistry as well as being commonly encountered 
as synthetic intermediates. 
Table 1.3 Succinimide based drugs 
 
Name Structure Clinical uses Mode of 
action 
No. 
Ethosuximide59,60,61 
(Zarontin®  
Emeside®) 
 
 
 
 
 
anticonvulsant 
agent 
T-type calcium 
channel 
blocker 
89 
Succinimide-3-
benzylcarbamate62 
 anticonvulsant 
agent 
unknown 90 
3-(2-chlorophenyl)-
1-((4-(3-
chlorophenyl) 
piperazin-1-
yl)methyl) 
succinimide63 
 
 
 
 
 
anticonvulsant 
agent 
unknown 91 
TDS264  
 
 
 
 
 
HIV protease 
inhibitor 
Tat HIV-1 
inhibitor65 
92 
N
N
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Scheme 1.16 One and two step reaction pathways from β-lactam to 2-iminopyrrolidin-5-one 
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Within the medicinal chemistry sphere, succinimides are probably best known as 
anticonvulsant agents (89, 90 and 91 Table 1.3).66 However they have received some 
attention recently as a possible source of HIV protease inhibitors (92, Table 1.3). 
1.3.5 Pyrazole synthesis 
The synthesis of 5-amino pyrazoles 95 has been previously achieved through the 
condensation of ethyl cyanoacetate 94 with a hydrazidic halide 93 in a sodium 
ethoxide/ethanol system followed by spontaneous cyclisation (Refer to reactions of 60 in 
scheme 1.5).67 
 
 
 
 
 
 
 
 
 
PNP = Para-nitrophenyl 
 
More recently the synthesis of similar compounds (100,  Scheme 1.18) have been reported 
using the more commonly reported type of condensation involving condensation of a 
hydrazine with an appropriate ketone,68 in this case involving (Z)-2-Cyano-3-methoxy-but-2-
enoic acid ethyl ester 98 and phenylhydrazine 99.69 Pyrazoles and their derivatives are an 
important class of heteroaromatic ring systems that find extensive use in the pharmaceutical 
and agrochemicals industries. Substituted pyrazoles are important synthetic targets because 
Scheme 1.17 Pyrazole synthesis from ethyl cyanoacetate/hydrazidic halide condensation 
93 
94 95 
96 97 
NaOEt/ethanol 
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the pyrazole ring makes up the core structure of important biological compounds including 
drugs such sildenafil (Viagra™, 101,  Table 1.4) 
 
 
 
 
 
 
Another important medicinal role to have emerged for pyrazole based systems (104,  Table 
1.4)  is that of inhibitors of the p38 mitogen-activated protein (MAP) kinase. Since the 
discovery of p38 kinase, it has been intensively pursued as a target for the development of 
disease-modifying antirheumatic drugs (DMARDs). 
Table 1.4 Examples of biologically active pyrazoles 
Name Structure Clinical uses Mode of 
action 
No. 
sildenafil 70 
Viagra™ 
 
 
 
 
 
Anti-impotence PDE5 
enzyme 
inhibitor 
101 
Fipronil®71,72  
 
 
 
 
insecticide GABA-gated 
chloride 
channel 
inhibition 
102 
2-(dimethylamino)-
N-(4-((3-ethyl-4-
oxo-1-(2,4,6-
trichlorophenyl)-1H-
pyrazolo[3,4-
d]pyrimidin-6-
yl)methyl)phenyl)ace
tamide73,74 
 Anti-cancer CDK4/cyclin 
D1 inhibitor 
103 
4-(3-(4-
chlorophenyl)-5-
(piperidin-1-yl)-1H-
pyrazol-4-
yl)pyridine75,76 
 
 
 
 
disease-
modifying 
antirheumatic 
drugs 
(DMARD) 
p38 MAP 
kinase 
inhibitor 
104 
EtOH 
∆ 
Yield = 87% 
Scheme 1.18 Pyrazole from phenylhydrazine 
98 
99 
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1.3.6 Thesis statement 
As introduced in the previous section, our group had identified that certain 
azoacetates could be cyclised to form β-lactams with a phenylazo group attached through 
reactions similar to those commonly used in the cyclisation of N-aryl propionamide 
derivatives. Though the reactions of our group used the acetate moiety as the leaving group 
the realisation that the cyclisation was unaffected by the presence of the phenylazo group 
prompted the search for propionamide cyclisation reactions that might be similarly adapted. 
After a review of the relevant literature, several potentially suitable reactions were identified. 
Of particular interest to our group were those reactions resulting in the generation of small 
heterocycles from families of compounds known to exhibit medicinal effects.  
Our initial interest was on follow-up work on the original proof of concept studies. It 
was anticipated that if a series of phenylazo compounds containing the basic N-aryl 
propionamide structure could be synthesised that these compounds might provide a starting 
point for a series of studies investigating the cyclisation to the β-lactam. A review of the 
relevant literature suggested that known reactions from the chemistry of hydrazones provide a 
means of introducing potential alternative leaving groups (LG, II, scheme 1.8) while 
preserving the phenylazo group intact. The introduction of other attachments of interest (R1, 
Ar1, Ar2, scheme 1.8) is made possible by making simple alterations to the reaction sequences 
used by the original researchers. The β-lactam syntheses reactions are dealt with in chapter 2 
of the thesis. 
 
 
 
 
 
Scheme 1.19 General scheme outlining β-lactam synthetic strategy 
 
I II III 
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The other important discovery identified by the original researchers was a 
rearrangement product that accompanied the β-lactam cyclisation process. It had been 
proposed that the reaction took place via initial deacetylation followed by a 1,2 carbon to 
nitrogen migration. However several years after the publication of our groups’ results (1992) 
a group led by Sir Derek Barton (1996) published a paper involving the deacetylation 
reactions of similar azoacetates under similar reaction conditions (i.e. base and alcoholic 
solvent, scheme 1.14). 56 However in that case it was found that the isolation of azocarbinol 
products was possible. This encouraged an interest in re-examining the deacetylation of our 
azoacetates with a view to isolating analogous azocarbinols from our azoacetate substrates.  
 
 
 
 
 
  
The aim of this section of the research (chapter 3) was to explore whether or not it 
would be possible to isolate azocarbinols from our azoacetates substrates using reaction 
conditions previously found to be successfully used for this transformation.  
The second part of chapter 3 is concerned with the further exploration of the 
deacetylation reactions of azoacetates in an environment where cyclisation to oxazolidinones 
was the most likely outcome. From an examination of what is known about the cyclisation of 
simple protected threonyl anilides it seemed that the most likely outcome of the base 
treatment of these compounds might be the formation of β-lactams or oxazolidinones, both 
possibilities were of interest to our group. The synthesis of β-lactams (VII, scheme 1.21)  
would expand the range of phenylazo substituted examples of these compounds synthesised 
Scheme 1.20 Proposed route to azocarbinols 
 
R = Ph, PCP or OEt (PCP = Para-chlorophenyl, PNP = Para-nitrophenyl) 
 
IV V 
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by our group. The synthesis of oxazolidinones (VIII, scheme 1.21) would be another 
example of the deacetylation of the acetate group in azoacetates. Cyclisation reactions of 
protected threonyl compounds in general are well known, but again the cyclisation reactions 
of analogous azoacetate compounds VII have not been previously studied. 
 
 
 
 
 
 
 
 
 
 
The synthesis of the azoacetates (VI, scheme 1.21) necessary for cyclisation studies 
was not trivial. Neither the peptide chemistry literature nor previously published hydrazone 
chemistry give specific information as to the full synthesis of these compounds. To the best 
of our knowledge investigations into the oxidation of hydrazones to azoacetates of this type 
(VI, scheme 1.21) has never before been undertaken. These azoacetates synthesised from N- 
protected threonyl anilides, once again, have the central propionamide shape (Scheme 1.5) 
that has been the focus of our other work.  
The many repetitions of the cyclisation reaction used in the synthesis of β-lactams led 
to the discovery that a further product could be isolated from the reaction. Chapter 4 of this 
thesis focuses heavily on the isolation, identification and characterisation of these newly 
discovered phenylazo substituted 2-iminopyrolidin-5-one derivatives (X, scheme 1.22). The 
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Scheme 1.21 Interesting potential cyclisation reactions of threonyl azoacetates 
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formation of these compounds was unexpected as it had not been reported by members of our 
group carrying out similar studies. It would seem that the ratio of KCN to substrate in the 
reaction vessel drastically affects the role of the cyanide ion in the reaction. Higher 
concentrations of KCN in the reaction mixture were found to favour the formation of 
nucleophilic substitution products with a unit of cyanide being incorporated into the product 
(Scheme 1.22).  
2-iminopyrolidin-5-ones are most commonly encountered in the chemistry literature 
as precursors to succinimides (Scheme 1.15). This synthetic exploitation of the 2-
iminopyrolidin-5-ones in that role was also of interest to us due to the many reported 
medicinal applications of succinimides. 
The 2-iminopyrolidin-5-ones X initially proved difficult to characterise from their 
spectra. The NMR spectra proved particularly difficult to interpret due to unusual line 
broadening and signal dampening effects observed in the both the 1H NMR and 13C NMR 
spectra. These unusual spectra and the measures taken to elucidate the structure of the 
products from them are one of the main focal points of chapter 4. 
 
 
 
 
 
 
 
 
 
 
XII 
X IX 
XI 
Scheme 1.22 Main reactions from chapter 4 
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The discovery that cyanide can act as a nucleophile in substitution reactions with 
azoacetates prompted the assessment of other azoacetates under similar conditions, ultimately 
producing pyrazole products (XII, Scheme 1.21). The incorporation of the cyanide unit in 
both of these systems (2-iminopyrolidin-5-ones X and pyrazole XII, Scheme 1.21) are novel 
results in terms azoacetate chemistry and therefore have been studied in some detail. 
 
1.4 Conclusion 
The development of antibiotics effective against pathogenic bacteria has gone through 
several phases of evolution, prompted initially by pure necessity and more recently as a result 
of the development of highly virulent and resistant strains of bacteria. The process of drug 
discovery in this area has seen a shift in focus from the traditional sources of lead 
compounds. The aim of this chapter has been to highlight the diverse range of medicinal roles 
attributed to heterocyclic compounds similar to the compounds synthesised and characterised 
within this thesis. It has also been shown that one of the responses to modern requirements 
has been the reinvestigation of known classes of compounds in previously unexplored roles.  
 From a review of the literature it seemed clear that there was great potential to adapt 
reactions that are relatively well known in the chemistry of propionamide for use with the 
azoacetates of interest to our group. The chemistry of these compounds dealing specifically 
with the azoacetate group has been thoroughly explored within our group. However the 
structural similarity between the specific azoacetates of interest to us and functionalised 
propionamides allowed us to begin the investigation of the reactions of these compounds 
from a different perspective than the previous studies.  
Of interest amongst the reactions reviewed were those involving cyclisations of 
propionamides as these might provide further insight into the formation of the products 
previously published by our group.44 The deacetylation reactions of azoacetates were also of 
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interest since it was suspected that this reaction plays a role in the formation of the novel N-
acylhydrazide rearrangement product published by our group. The process was chosen for 
further study because since the original work had been carried out, several insightful and 
relevant works dealing with similar systems had been published by other groups. 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 2 
 
 
 
 
Synthesis and characterisation of the novel phenyl-azo bearing β-lactams 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
contraria contrariis curantur 
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2.1 Introduction  
The focus of the studies carried out in this chapter is the further development of work 
done towards the synthesis of β-lactams from azoacetates by previous members of our group 
as introduced in chapter 1. The original researchers had proved the concept that substituted 
azoacetates derived from acetoacetanilides could be cyclised to give β-lactams using the 
acetate moiety as leaving group.  However the work resulted in the production of only two 
structurally similar examples of these compounds (134, Chapter 1) and until now no further 
studies had been undertaken. The syntheses of molecules incorporating the azo linkage have 
proved to be attractive targets for prodrug synthesis due to the affinity of this group for 
reduction upon the action of intestinal azo-reductase enzymes (Chapter 1).  
Due to the novel nature of these compounds they seemed worthy of further study. The 
area of most interest to us initially was the further investigation of the early sequence of 
reactions ultimately leading to the cyclisation of the β-lactam (Scheme 2.1). Each of these 
steps involves the introduction of new groups into the system, and each is a relatively well 
known reaction. This offered the opportunity to investigate the introduction of groups 
alternative to those previously used, and also the potential for the expansion of a new series 
of compounds into a library for future biological testing. With similar motivation, the 
modification of the phenylazo group on the β-lactam to the corresponding phenylazoxy 
moiety was undertaken. This is a structure that, to date, has not been previously reported in 
the medicinal chemistry literature. 
Investigations into the use of alternative leaving groups for the cyclisation were also 
carried out in the hopes of improving the existing procedure. Several potential alternative 
substrates for cyclisation were synthesised, in particular it was hoped that the well 
documented procedures for cyclisation of halopropionamides could be adapted for use with 
our system. 
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2.2 Results and Discussion 
2.2.1 Synthetic strategy towards β-lactam analogues 
 The synthesis of monocyclic β-lactams bearing the phenyl-azo functional group had 
been previously achieved, however, it remained unclear whether not the range of compounds 
synthesised could be expanded. This chapter includes work to investigate some of these 
issues. Examination of the basic structure previously investigated allows for functional group 
diversification within the system (Figure 2.1).  
 
 
 
 
 
 
 
Figure 2.1 Overview of target structures compared to starting materials. 
It was decided to attempt to systematically alter the groups present at each position. It seemed 
prudent to initially attempt to modify the substituents of the system individually whilst 
keeping the remaining substituents as close to the original structure as possible. 
 The aim of the original research (Schemes 1.12 and 1.13) was to develop procedures 
to synthesise potential biological molecules using facile procedures and simple, cheap and 
readily available starting materials.55 For this reason it was decided that the methyl group at 
ring position 2 (105 R3 = CH3 Figure 2.1) would remain unchanged since it was an inherent 
element of both the ethyl acetoacetate and acetoacetanilide starting materials. Whereas raw 
materials analogous to the acetoacetanilide starting materials with alternative groups at this 
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position are available commercially, they are significantly more expensive and less readily 
available (in SigmaAldrich™ rare chemicals library).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1 Synthetic route to β-lactams. 
 Scheme 2.1 shows a general synthetic pathway to the β-lactams of interest. 
Highlighted are the targeted insertion points for the introduction of functionalities alternative 
to those previously investigated. The introduction of different leaving groups and the 
cyclisation will be dealt with separately as these processes ultimately do not lead to any 
change in the groups present in the final product. Since the synthetic steps used to produce 
the original β-lactams had been tried and tested, it was decided that the strategy adopted 
would be the one that adhered most closely to the original procedures. For this reason the 
processes where functional group diversity was introduced last were the first to be tested.  
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 Introduction of alternative functional groups at R4 (Figure 2.1) 
The first challenge undertaken was an attempt to alter the groups present on the 
phenyl azo ring system (R4). To this end a simple di-methylated analogue of acetoacetanilide 
(131f, scheme 2.2) was synthesised as a starting point (synthesis of 131f and analogous 
compounds described in section 2.2.4). At this point attempts were made to synthesise a 
number of phenyl-hydrazone derivatives of this basic structure by substituting a variety of 
phenyl hydrazines into the synthetic procedure in place of the 4-nitrophenyl hydrazine 
hitherto used throughout. 
This approach yielded mixed results; it was found that in the majority of cases that the 
product formed was not the desired hydrazone, but in fact a cyclised by-product of the 
hydrazone reaction. The creation of the pyrazolone derivatives is due to cyclisation of the 
hydrazone immediately upon formation. This is a well known detrimental reaction to the 
formation of phenylhydrazones from β-ketoesters.77 The formation of these compounds was 
investigated in some detail by previous researchers and were not explored further. 78 
 
 
 
 
 
 
 
Scheme 2.2 Attempted synthesis of hydrazones resulting in pyrazolones. 
The only successfully isolated hydrazone from this set of experiments was the 4-cyano 
analogue (116, Figure 2.2). Interestingly this seems to suggest an important role for the 
strong electron withdrawing group in a position para- to the azo group for the stabilization of 
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H3C
H3C
O NH
CH3
N N
H
CN
the newly formed hydrazone.79 Especially in light of the failure to isolate the ortho-nitro 
substituted species which might have been expected to yield similar results to the para-nitro 
analogue. It would seem that the acidic conditions necessary for the condensation of the 
hydrazine with the substituted acetoacetanilide favours spontaneous cyclisation unless the 
electron withdrawing group is in a para position. Also of note is the dominance of the 
cyclisation even when an acetoacetanilides are used as substrates as opposed to β-ketoesters. 
H3C
H3C
O NH
CH3
N N
H
CN
 
Figure 2.2 4-Cyanophenylhydrazone condensation product. 
The subsequent formation of the corresponding azoacetate was also achieved using 
the procedure employed previously for the generation of the analogous 4-nitrophenyl 
derivatives.78 Stirring the substrate overnight with a 1.1 molar excess of lead tetraacetate gave 
the desired azoacetate (117, Scheme 2.3).80 
 
 
 
 
 
  
Scheme 2.3 Azoacetate of 4-cyanophenylhydrazone. 
Attempts at the cyclisation of the azoacetate 117 to the β-lactam using the previously 
established base induced ring closure produced the pyrazolone (118, Scheme 2.4) analogous 
116 
116 
H3C
H3C
O NH
CH3
N N
CN
OAc
AcOH
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117 
Yield = 60% 
Yield = 63% 
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to those previously observed (112-115) to form from the other substituted hydrazones. 
Similar transformations from azoacetates have also been previously observed by Gladstone et 
al.81 Attempts at altering the basic media (K2CO3/Acetone, KCN/Propanol and 
tBuOK/Acetonitrile) failed to produce the desired β-lactam. 
 
 
 
 
 
Scheme 2.4 Attempted cyclisation resulting in pyrazolone. 
2.2.2 Introduction of alternative functional groups at R2 and R3 (Figure 2.1). 
The introduction of an aryl group at position R2 or R3 was seen as the next logical step 
to test the robustness of the system towards modifications. The benzyl group was chosen over 
a phenyl substituent due to the advantage of a carbon spacer reducing the possibility of steric 
factors having a detrimental effect on the reaction or subsequent reactions in the series. As a 
starting point a mono-methyl analogue of 4-chloroacetoacetanilide was prepared. Mono-
methyl chloroacetoacetanilide was prepared by slow addition of 1 molecular equivalent of 
methyl iodide to a refluxing solution of the substrate in acetone with 1 molecular equivalent 
of K2CO3 suspended. It was found that a reasonable yield (71%) of the desired product (121 
Scheme 2.5) could be isolated from the dimethyl by-product after several recrystallizations. 
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Scheme 2.5 Monomethylation of 4-chloroacetoacetanilide 
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Reaction of the mono-methylated species under similar alkylating condition using benzyl 
chloride produced the desired benzylated product (120, Scheme 2.6). The introduction of this 
group saw the creation of a chiral centre that would be present in the final cyclisation 
product. 
O
CH3NH
O
O
CH3NH
O
H3C
K2CO3
*
Cl
Cl Cl
*
 
Scheme 2.6 Benzylation of α-methyl-4-chloroacetoacetanilide 
In line with the synthetic strategy outlined previously (Scheme 2.1), 4-
nitrophenylhydrazone analogues were used in all subsequent syntheses. The reaction 
conditions used previously to produce the 4-nitrophenyl hydrazone of the di-methylated 
compound were employed.82 The desired hydrazone was isolated in reasonable yield (39%) 
after overnight stirring. Although the yield was slightly lower than that of the di-methyl 
hydrazones (Scheme 2.10), the steric bulk of the benzyl substituent was not seen to have a 
catastrophic effect on the reaction product (122, Scheme 2.7). 
 
 
 
 
Scheme 2.7 Formation of 4-nitrophenylhydrazone 
The production of the azoacetate 123 from the reaction of the hydrazone 122 with 
lead tetraacetate (Scheme 2.8) was synthetically consistent with the previously observed 
O
CH3NH
O
H3C *
Cl
O
CH3NH
N
H3C *
Cl
NH
NO2
NO2
H
NH2N
120 121 
121 122 
MeOH/AcOH  
overnight stirring 
 
Yield = 39% 
Yield = 90% 
 49 
 
results. A yield of 56% once again suggested that the procedure was not drastically affected 
by the presence of the steric bulk of the benzyl group. 
 
 
 
 
 
Scheme 2.8 Formation of azoacetate 
Since in this case the substrate leading to the formation of the azoacetate already had 
a chiral centre present, the product was isolated as a mixture of diastereomers. Examination 
of the TLC of the reaction showed the presence of two product spots with very similar Rf 
values. At this point a decision was made not to attempt the isolation of the individual 
isomeric pairs before the cyclisation step. It was deemed that the chromatographic process 
necessary to isolate such closely related compounds would, in all likelihood, have a drastic 
effect on the quantity of compound available for cyclisation. Since the products of the 
cyclisation (124 a and b Scheme 2.9) were unlikely to be affected by the presence of the 
diasteromeric mixture of starting materials it seemed prudent to attempt the separation of the 
isomers after the cyclisation step. 
 
 
 
 
 
Scheme 2.9 Cyclisation to β-lactam  
O
CH3NH
N
H3C *
Cl
N
NO2
OAc
*
O
CH3
N
N
H3C *
Cl
N
NO2
*
K2CO3 / Acetone
122 123 
123 
124 
O
CH3NH
N
H3C *
Cl
NH
NO2
O
CH3NH
N
H3C *
Cl
N
NO2
OAc
*
Pb(OAc)4
AcOH Yield =71% 
Yield 124a =8.3% 
Yield 124b = 11.6% 
 
 50 
 
After the cyclisation step, the β-lactam product consisting of a diastereomeric mixture of 
products which could be chromatographically separated into the constituent enantiomeric 
pairs. The R,R and S,S enantiomeric pair and the R,S and S,R enantiomeric pair (Figure 2.4). 
The most prominent spectral feature that distinguished these isomeric pairs was a shift in the 
proton spectrum associated with the non-aromatic benzyl protons (Figure 2.3). The 
characteristic splitting patterns observed in these enantiotopic protons, can be observed in the 
precursor molecules containing this functionality. However the large chemical shift observed 
between the two diastereomeric forms is due to the proximity of this group to the adjacent 
chiral centre. 
 
 
 
 
 
 
 
Figure 2.3 1H NMR signals of non aromatic benzyl protons of β-lactam diastereomeric pairs 
(a and b), and the corresponding proton signals from the mixture of azoacetate (c). 
The conformational locking of these centres within a constrained ring system would also 
seem to be an important factor in the magnitude of the observed shift. As mentioned earlier 
the azoacetate precursor of these cyclised products were not chromatographically separated 
prior to the reaction. The 1H NMR spectrum of this compound did show support of the 
presence of the two component elements of the mixture (Figure 2.3 c). This was evidenced by 
a relatively small chemical shift difference between the two isomeric components (Figure 2.3, 
c). 
a (174a) a = (174b) c = 173 
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a 
b 
c 
d 
Figure 2.4 3D ball and stick models and 2D diagrams of the isomeric conformations of β- 
lactam 124 (a-d) and 1 isomer of the azoacetate precursor 123 (e). 
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The diastereomeric forms of the azoacetate did not show the same level of variation in 
chemical shift as the isolated β-lactam isomeric pairs (Figure 2.3, a and b), lending weight to 
the assertion that the rigid ring system has a marked effect on the electronic properties of the 
different components. This is a function of the magnetic shielding effect of the adjacent 
groups. The appearance of the azoacetate proton signals at a relatively low field would be 
expected, due the possibility of free rotation of the groups surrounding the benzyl protons in 
order to orientate themselves in solution to give maximum shielding effect. When the 
conformation is locked in a ring system the possible orientations are reduced, with essentially 
two possibilities, “more favourable for shielding” and “less favourable for shielding”. Figure 
2.4 shows the possible conformations of the β-lactam molecule, in the 3D representations it 
can be seen clearly that the benzyl group attached to the β-lactam molecule is restricted to 
orientations allowed by rotation around the benzyl CH2. One isomer of the azoacetate 
precursor is also shown to highlight the possibility of rotation around the central carbon-
carbon bond between the chiral centres. 
2.2.3 Introduction of alternative functional groups at R5 
In contrast to the attempts to alter the phenyl substituents at R4, introduction of 
alternative phenyl groups at R5 was relatively straightforward. This involved using alternative 
acetoacetanilides as starting materials. Where possible commercially available 
acetoacetanilides were used as starting materials, the remainder were generated by simply 
heating the appropriately substituted aniline (125-129) (1 molar equivalents) with ethyl 
acetoacetate (107) (5 molar equivalents) to 160 ºC until the evolution of ethanol had ceased, 
after removing the bulk of the remaining ethyl acetoacetate by vacuum distillation the desired 
acetoacetanilides could be easily crystallized by scratching the reaction vessel (Table 2.1).83 
The crude acetoacetanilides were further purified by recrystallization from EtOAc:Hex. 
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Table 2.1 Synthesis of acetoacetanilides from ethyl acetoacetate 
 
 
 
 
 
 
 
Substrate R1 R2 R3 Product Yield 
125 H H Br 130a 90 
126 H H OMe 130b 88 
127 Me Me H 130c 91 
128 H H Me 130d 85 
129 H H CO2Et 130e 77 
 
Dimethylation of the acetoacetanilides (119 and 131a-i) was achieved by refluxing overnight 
in acetone with an excess of methyl iodide (6 molar equivalents) and potassium carbonate (3 
molar equivalents) (Table 2.2). 
Table 2.2 Dimethylation of anilides 
 
 
 
 
 
 
Substrate Ar Product Yield (%) 
 R1 R2 R3   
130a H H Br 131a 79 
130b H H OMe 131b 78 
130c Me Me H 131c 80 
130d H H Me 131d 83 
130e H H COOEt 131e 70 
130f b H H H 131f 80 
130g b Me H Me 131g 67 
130h b Me H H 131h 75 
130i b OMe H H 131i 74 
119 b H H Cl 131j 69 
bStarting materials were commercially available acetoacetanilides 
130a-e 
O
O OEt
H2N
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O
O NH
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O NH
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4-Nitrophenylhydrazone derivatives were prepared for all of the α,α-disubstituted 
acetoacetanilides (131a-j) (Scheme 2.10) by stirring the substrates in a slight excess (1.1 
molar equivalents) of 4-nitrophenylhydrazine in MeOH under mild acidic conditions (~5% 
acetic acid).  This procedure routinely furnished the desired hydrazones in reasonable yields 
(50-72%). 
 
 
 
 
(With reference to aromatic group, Ar, substitutions at R1, R2 and R3 are as shown in Table 2.2) 
 
The synthesis of the azoacetates of these hydrazones was found to be equally facile 
(Scheme 2.11), once again it was found that merely stirring the hydrazones overnight in a 
mildly acidic CH2Cl2 solution (10% acetic acid) containing a slight excess (1.1 molar 
equivalents) of Pb(OAc)4 was sufficient to effect the desired transformation.  After a standard 
work-up, flash chromatography was used to separate the azoacetates from any persistent lead 
salt residues. 
 
 
 
 
 
(With reference to aromatic group, Ar, substitutions at R1, R2 and R3 are as shown in Table 2.2) 
 
After some experimentation with possible base/solvent systems, based on results by the 
previous researchers in this group (K2CO3/acetone, t-BuOK/acetonitrile), cyclisation of the 
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Scheme 2.10 Formation of 4-nitrophenylhydrazones 132a-j 
Scheme 2.11 Formation of azoacetates 133a-j 
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azoacetates was found to be best achieved using KCN/propanol. The results achieved with 
this system were found to be the most consistent (Table 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cyclisation of the azoacetates to β-lactams using this system had been previously 
reported to produce N-acyl hydrazide derivatives as rearrangement products.44 The formation 
of these compounds is discussed later in chapter 3. It was also found that in some cases 2-
iminopyrrolidine-5-ones could be isolated from the reaction mixture. The formation of these 
compounds was found to be as a result of the intermolecular reaction of the azoacetate with 
the cyanide ion. The formation of 2-iminopyrrolidine-5-ones is discussed fully in chapter 4. 
Noteworthy amongst the β-lactam products isolated was the formation of the propanol 
transesterification product of β-lactam (134e, Figure 2.5). Since cyanide is known to promote 
Substrate Ar Product Yield (%) 
 R1 R2 R3   
133a H H Br 134a 16 
133b H H OMe 134b 20 
133c Me Me H 134c 25 
133d H H Me 134d 15 
133e H H COOEt 134e 11 
133f  H H H 134f 12 
133g  Me H Me 134g 25 
133h  Me H H 134h 22 
133i  OMe H H 134i 16 
133j H H Cl 134j 20 
Table 2.3 Synthesis of β-lactams 134a-j 
133 a-j 134 a-j 
N
O
NH
Ar
N
NO2
OAc
N
O
N
Ar
N NO2
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the transesterification process the formation of this compound using propanol as solvent was 
not entirely unexpected. 
 
 
 
 
 
Figure 2.5 Isolation of β-lactam transesterification product 134e. 
2.2.3.1 NMR studies of phenyl-azo β-lactams   
The reaction series resulting in the synthesis of the azo-substituted β-lactams also 
produced some interesting features in the 1H NMR spectra of the related compounds. The 1H 
NMR spectra of the di-methylated acetoacetanilide derivatives and also the subsequent 4-
nitrophenylhydrazones of these compounds both show the dimethyl peaks as a single signal 
appearing as a singlet and integrating as 6 protons relative to the other signals in the 
spectrum. However in the case of the azoacetate and β-lactam where the carbon adjacent to 
the α-carbon bearing the methyl groups is a chiral centre, two singlet signals appear each 
integrating as 3 protons relative to the other signals (Figure 2.7). These observed 1H NMR 
features are due to structural features inherent to each of the molecules (Figure 2.6). 
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Figure 2.6 Inherent structural features of β-lactam and precursor molecules 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 1H NMR spectrum of 134f 
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In the case of the acetoacetanilide and phenylhydrazone derivatives the methyl groups are 
enantiotopic and are therefore chemically equivalent and indistinguishable unless in a chiral 
environment. This is due to an internal plane of symmetry that exists within the molecule 
(Figure 2.8). 
 
 
 
 
 
 
 
 
 
Figure 2.8 3D diagram of α,α-Dimethyl acetoacetanilide 131f without hydrogen’s showing 
internal plane of symmetry. 
Since it is possible to interconvert the methyl groups through a symmetry operation they are 
equivalent in all meaningful ways. In contrast the β-lactam final product and its immediate 
precursor azoacetate have no such internal plane of symmetry due to the presence of a chiral 
centre adjacent to the methyl groups (Figure 2.9). The reaction of the phenylhydrazone with 
lead tetraacetate which produced the azoacetate resulted in the transformation of the 
enantiotopic face into a chiral centre and in so doing destroyed the plane of symmetry. The 
methyl groups in the product are therefore diastereotopic and not chemically equivalent. 
Since these groups are not equivalent they are distinguishable by 1H NMR. In addition to this 
experimentally observed NMR feature, it would be expected that the diastereotopic methyl 
 
Plane of symmetry 
Methyl groups can 
interconvert through 
plane of symmetry 
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groups would also exhibit different chemical properties such as reactivity, bond length and 
bond dissociation energies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.2 IR studies of phenyl-azo β-lactams 
The IR spectra of β-lactam molecules are one of the tools that aid in the identification 
of the compounds. Because of the inherent ring strain associated with the β-lactam ring due 
to the constrained nature of the system, the carbonyl stretch in these systems are seen at 
higher frequencies (wavenumbers) than similar acyclic amides such as the precursors to the 
β-lactams. Table 2.4 shows the carbonyl stretches of the β-lactam products 134a-j and for 
comparison the carbonyl stretches of the acyclic precursors to the 4-bromophenyl substituted 
No plane of symmetry. Methyl 
groups cannot interconvert 
through symmetry operation.  
Chiral centre 
Pro-S 
 Methyl 
group 
Pro-R 
Methyl 
group 
Figure 2.9 3D diagram of azoacetate 133f without hydrogen’s highlighting lack of 
symmetry plane. 
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β-lactam (130a, 131a, 132a, 133a). It can be clearly seen that the formation of the β-lactam 
ring can be confirmed by the change in the amide IR carbonyl stretch. 
Table 2.4 Amide IR carbonyl stretching vibrations of β-lactams 134a-j and precursors 130-133a 
 
 
 
 
 
2.3 Synthesis of Phenylazoxy β-lactam84  
After the successful synthesis of a group of β-lactams bearing a phenylazo side chain 
it was decided to attempt a modification of the azo linkage. The most obvious target for this 
type of alteration was the oxidation to the azoxy group. Although the phenylazo moiety might 
be assumed to react in a comparable way to similar systems, giving the azoxy compound as 
product, due to the novel nature of the system it was judged to be worty of investigation. It 
was hoped that the synthesis of the azoxy version of the compound might also help overcome 
problems with the reduction of the phenylazo group to the corresponding hydrazine. Apart 
from a few notable exceptions (Figure 2.10) very little research has been reported on the 
synthesis or potential applications of these compounds. Macrozamin85 discovered in 1951, 
was the first of a series of azoxy compounds found in nature. Many azoxy compounds have 
been found to be carcinogenic due to the generation of carbocations capable of DNA attack 
after metabolism.86 However some of these compounds have found use as antibiotic agents. 
Valanimycin, produced by Streptomyces viridifaciens MG456-hF10, has been shown to 
exhibit both antibacterial activity and potent cytotoxic activity against in vitro cell cultures of 
mouse leukaemia L1210, P388/S (doxorubicin-sensitive), and P388/ADR (doxorubicin-
resistant).87 
Compound 130a 131a 132a 133a 134a 134b 134c 
amide IR 
carbonyl 
stretch cm-1 
1661 1684 1671 1687 1755 1759 1757 
Compound 134d 134e 134f 134g 134h 134i 134j 
amide IR 
carbonyl 
stretch cm-1 
1751 1749 1759 1762 1761 1761 1753 
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Figure 2.10 Naturally occurring azoxy compounds 
The transformation of the azo group to the azoxy was successfully accomplished by 
employing a hydrogen peroxide and acetic acid oxidation system.88 In this system the 
peracetic acid is generated in situ.89 The substrate β-lactam 134h was introduced to a hot 
solution (80 oC) of acetic acid to which hydrogen peroxide was added incrementally over 24 
hours. After which time the product 141h was precipitated out of solution by the introduction 
of ice water (Scheme 2.12). 
. 
 
 
 
 
 
 
The synthesis of the azoxy group in this way does allow some scope for error in the 
assignment of the absolute structure. Several strategies have been previously adopted for the 
regiospecific synthesis of azoxy compounds.90 This can be done through the reaction of 
hydrazines or hydrazones with peroxy- acids (Peroxy acid = RCO3H).91 A reliable method for 
Scheme 2.12 Synthesis of phenylazoxy β-lactam  
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the production of azoxybenzene derivatives has proven to be the reaction of some 
hyroxylamines 142 with nitrobenzene 143 which returns azoxy compound with the aromatic 
moiety in the proximal position to the azoxy oxygen (Proximal→R-N(O)==N-R’←Distal) 
(Scheme 2.13). Comparisons of results using this method have allowed some general 
observations to be made regarding the effect of the azoxy group on the spectra of the groups 
adjacent to it. This information has been used to accurately identify the configuration of the 
group in compounds where regiospecific synthetic procedures were not used. Of particular 
interest were the studies carried out by Freeman.92 These studies catalogued the proton NMR 
shifts associated with unsymmetrical azoxy compounds and put forward a system for 
identification of the geometrical isomers of the compounds in question, based on the 
observed NMR chemical shifts of the attached groups. The main focus of the work was 
concerned with the assignment of the proton chemical shifts of alkyl protons attached directly 
to the proximal and distal carbons. In certain cases the azoxy group was attached to a phenyl 
ring for comparisons to be made between the proton in a proximal and distal positions. The 
synthesis of N-methyl-N’-phenyldiazine N’- oxide 145 led to an interesting observation. The 
compound was synthesised using two routes, one where the position of the azoxy oxygen 
could be controlled (Route 1, Scheme 2.13), and the other where selectivity was not assured 
(Route 2 Scheme 2.13). 
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However in both cases the same compound with the phenyl ring proximal to the azoxy 
oxygen was the dominant product. This observed selectivity for formation of the azoxy group 
proximal to the phenyl ring was unexpected and led the author to remark “The selectivity of 
these oxidations seems remarkable and no simple explanation suggests itself”. In terms of the 
general trends observed in the spectra of these compounds it is suggested that the oxidation of 
the azo group results in a downfield shift of both groups attached to the newly formed azoxy 
group as a result of a reduction in the electron density at both nitrogen centres, with the larger 
shift associated with the proximal group. It is with this in mind that the assignment of the 
position of the azoxy group was undertaken.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N N
O N
NO2
H3C
N N
O N
NO2
H3C
O
Figure 2.11 1H NMR spectra of phenylazo 134h and phenylazoxy 141h β-lactam 
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It can be clearly seen from the comparison of the 1H spectra of the azo- 134h and azoxy- 
141h bearing β-lactam molecules that the methyl protons nearest the azo- group have 
experienced a downfield shift after the oxidation (Figure 2.11). The shift from 1.07 to 1.29 
represents a total downfield shift of 0.22 ppm. However the shift experienced by the aromatic 
nitrophenyl- protons can be seen to be more dramatic, with a shift from 7.76 to 8.27, a total 
shift of 0.51 ppm. These results are consistent with the results of the oxidations carried out by 
Freeman. The isolation of a single product without the necessity for chromatographic 
separation suggests that the procedure selectively produces a single isomeric form of the 
azoxy compound. Analysis of the spectral information further suggests that it is the isomer 
with the aromatic group in a proximal position to the azoxy oxygen that was isolated. 
 
2.4 Alternative leaving groups 
The ring closure of azoacetates to form β-lactams is an interesting process. Using the 
acetate moiety as leaving group provided an unexpectedly facile procedure. In general good 
leaving groups can be broadly described as “the conjugate bases of strong acids”. Since 
leaving groups carry the bonding electrons after bond cleavage, the ease with which a leaving 
group leaves is related to its ability to stabilize the electrons after cleavage. In that regard the 
acetate leaving group could be expected to be quite a poor leaving group, since the acetate 
anion is the conjugate base of acetic acid, a relatively weak acid. 
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Figure 2.12 The acetate leaving group in azoacetates 
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The ability and indeed propensity of the acetate group to act as leaving group in this way 
raises the question of why a seemingly chemically inert species would behave in this 
uncharacteristic manner. However if the presence of the neighbouring azo group is taken into 
consideration a plausible explanation presents itself. The concept of a neighbouring 
unsaturated group providing anchimeric assistance could be the reason for the enhanced 
leaving group potential of an otherwise relatively inert species. Some preliminary tests of this 
hypothesis were made by the original researchers.43 These tests consisted of the synthesis and 
attempted cyclisation of a number of substrates containing the acetate group but without the 
presence of the phenylazo functionality 147 a and b (Scheme 2.14). When treated with a 
variety of bases these substrates underwent deacetylation to give the alcohol 148 a and b as 
opposed to the desired β-lactam product 149. The failure of these model systems to furnish 
the β-lactam product lends credence to the theory that the neighbouring phenylazo group does 
provide anchimeric assistance in the cyclisation of the azoacetate species. 
 
 
 
 
 
 
 
 
Instances of this type of enhancement effect by a number of functionalities are well 
known, including assistance from neighbouring double bonds.93 Although the exact nature of 
the assistance provided by the phenylazo group is unknown, systems similar to that shown in 
Scheme 2.15 have been proposed for other pi-bonded systems. The discovery of this effect led 
to the investigation of alternative leaving groups at this position. It was hoped that the 
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observed enhancement in reactivity provided by the phenylazo group could be harnessed for 
use with other systems.  
 
 
 
 
 
 
 
2.4.1 Alkoxy leaving groups 
The first system to be examined was a slight variation on the azoacetate procedure. In 
Barton’s paper concerning the oxidation of hydrazones using hypervalent organoiodine 
reagents, a straightforward procedure for the conversion of hydrazones to α-alkoxyazo 
compounds is presented.45 The procedure utilises Iodobenzene diacetate for the addition of an 
alcohol to the hydrazone. The procedure described was adapted for use with our substrate 
hydrazones, a mechanism analogous to that proposed by the Barton group is shown (Scheme 
2.17). Unfortunately, as expected the alcohol moiety introduced proved to be a poor leaving 
group. Although it was expected that this would be found to be the case, the ring closure had 
previously been achieved successfully with an acetate moiety, which would also have been 
expected to be a poor leaving group. The ring closure was attempted with a variety of bases 
and reaction conditions after which this group was ruled out as a means of achieving the 
desired ring closure. 
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2.4.2 Chlorine as leaving group 
The next leaving group to be considered was chlorine. In contrast to the systems used 
so far chlorine is recognised as a good leaving group; however introducing chlorine into the 
system in the correct position to act as a leaving group was not trivial. The chlorination of 
hydrazones to form α-chloro phenylazo compounds had been achieved, but to date only on a 
limited scale. Chlorination of phenylhydrazones was investigated in the early 70’s by M. W. 
Moon94 of the Upjohn Company, although the origins of the procedure can be traced back to 
the late 50’s. The chlorination was achieved using Cl2 solutions in 3-4 molar excess at   – 40 
0C,  
 
 
 
O2N
O2N
PhI
OAc
OAc
N NH
O
H
N
Cl
NO2
N N
O
H
N
Cl
NO2
O2N
N N
O
H
N
Cl
NO2
OMe
N N
O
H
N
Cl
NO2
I
Ph
O
OOH
Me
-AcOH
-AcOH
O2N
IBDA/MeOH 
Scheme 2.16 Barton type mechanism of formation of α-alkoxyphenylazo compounds 
153 154 
Scheme 2.17 Early hydrazone chlorination reported by Moon 
Cl2 (aq) 
-40 0C 
152 
157 
151 157 
 68 
Chapter 2: Synthesis of β-lactam analogues 
 
However, it was found that using this system when phenyl groups were present resulted in 
chlorination of the ring in addition to the desired chlorination α- to the azo group (Figure 
2.17). 
Unwanted over-chlorination is a commonly encountered problem associated with this 
reaction. The other commonly used system for the chlorination of hydrazones is using tert-
Butyl hypochlorite, prepared by the chlorination of t-BuOH with sodium hypochlorite 
(Schme 2.18). The reagent is best prepared fresh just prior to use, as it is prone to degradation 
when exposed to light; this necessitates the entire procedure being carried out in the dark.  
 
 
 
 
Substituents R1, R2 and R3 in the scheme are generally alkyl groups or highly substituted 
phenyl groups (usually 2,4,6-trichlorophenyl rings) as it also was found by these researchers 
that chlorination using t-butyl hypochlorite resulted in unwanted ring chlorination.  
 
 
 
 
 
As a precaution against this eventuality, in this case 2,4-dinitrophenylhydrazine was used in 
the generation of the hydrazones for these experiments. This did prevent unwanted 
chlorination on the nitro substituted ring; nevertheless in addition to the required chlorination 
rendering the α-chloro phenylazo compound, chlorination occurred at the 2- position on the 
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4-chloro substituted ring. Although this was unintentional it was not seen as a result that was 
detrimental to possible cyclisation of the product (Scheme 2.19). 
2.4.3.1 NMR spectra of the chlorination product  
The desired chlorination of hydrazone 157 to the α-chlorophenylazo derivative 158 
was confirmed by NMR spectroscopy. In the 1H NMR spectrum the presence of a single NH 
peak at 9.28 ppm due to the amide (confirmed as NH by HMQC and IR spectra) shows that 
the hydrazone has been converted to the desired product (Figure 2.13a and b). The integration 
and splitting patterns of the aromatic protons also show that the 4-chlorophenyl ring has been 
altered. 4-Chlorophenyl ring systems have a clearly defined splitting pattern not present in 
this proton NMR. This was further confirmed through analysis of the 13C NMR spectrum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.13a 1H NMR spectrum of hydrazone 157 
Figure 2.13b  1H NMR spectrum of α-chlorophenylazo derivative 157 
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4-Chlorophenyl rings give rise to 4 aromatic carbon signals due to the equivalence of the 
carbons at the 2 and 3 ring positions, whereas the carbon spectrum for this compound shows 
6 carbon signals due to the unsymmetrical 2,4-dichlorophenyl substituted ring (Figure 2.13c). 
The location of the chlorine at the 2 position on the ring was confirmed by combined analysis 
of all of the NMR spectra, though the HMBC spectrum proved particularly useful for this 
purpose. Chlorination at this position was expected due to the directing effects of the groups 
present before chlorination. Since the amide is a ring activating ortho/para directing group, 
and chlorine is a ring deactivating ortho/para directing group, the effect of the amide is more 
influential on the incoming group.   
It is interesting to note that in the case of this product 157 the splitting of the α-methyl 
groups into separate signals can be seen in the 13C NMR spectrum but not in the 1H NMR 
spectrum. It might have been expected to see separate 1H NMR signals due to the proximity 
of the newly formed chiral centre to the methyl groups as was seen to be the case with the 
azoacetates (section 2.2.4.1). This is possibly due to the relative size of the chlorine atom at 
the chiral centre having a less pronounced effect compared to the bulky acetate group. Since 
Figure 2.13c 13C NMR spectrum of α-chlorophenylazo derivative 157 
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the 13C NMR spectrum shows that the methyl groups are distinct and distinguishable it is 
presumed that the 1H NMR signals due to these groups are overlapping due to similar 
chemical shift. 
2.4.3.2 Cyclisation attempts with α-chloroazo group  
Attempts to achieve the cyclisation of this species to a β-lactam proved unsuccessful. 
NaH was used in initial attempts to close the ring as this type of ring closure is relatively well 
known (Scheme 2.20).95,96 
 
 
 
When these conditions were applied to our system results suggest that dehydrohalogenation 
had taken place. The formation of azoalkenes in this way have been previously reported. 
Eliminations of this kind have been observed by Rai et al where similar α-chloro-α-
methylphenylazo compounds gave azoalkenes analogous to those reported here (Scheme 
2.21).97 The elimination products isolated in that instance resulted from simply stirring the α-
chlorophenylazo derivative in triethylamine at room temperature for 15 minutes. This 
demonstrates the propensity of these compounds to undergo elimination under very mild 
basic conditions. 
 
 
 
 
 
 
 
O
N
H
Cl
R O
N
R
NaH
Scheme 2.20 General scheme showing chloro-propionamide ring closure to β-lactam  
Scheme 2.21 Reaction of α-chlorophenylazo 157 with NaH 
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Attempts to close the ring using alternative base/solvent systems also failed. This may be due 
in part to the nature of the aromatic substituent attached to the amide. Many cyclisations 
reported using this type of system are reported, though it is known that when chlorine is 
employed as leaving group in this type of cyclisation it is preferable to have a hydroxamate 
present.98 Though chlorine is a good leaving group, increasing the acidity of the NH group by 
employing the O-substituted hydroxamates was found to enhance the system towards 
cyclisation.99 It was hoped that the highly substituted nature of the α-chlorophenylazo 
derivative used here would favour cyclisation over elimination however that was not found to 
be the case.  
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Conclusion  
The original 1992 communication dealing with the synthesis of phenylazo substituted 
β-lactams reported the synthesis of two of these compounds, with different substituents 
attached to the N-aryl ring. Since the synthesis of the original members of this series of 
compounds was undertaken, little had been done to further assess the versatility of the 
compounds from a synthetic viewpoint. 
It was found that some modifications to the series of reactions leading to the formation 
of the β-lactams were possible without significantly affecting the success of the cyclisation 
step. It was also found that two of the three targeted insertion points for new groups could be 
utilised to bring some diversity into the system. 
The search for alternative leaving groups did not provide an alternative cyclisation 
process, but did show the synthesis of α-chloro and α-alkoxy phenylazo compounds from the 
hydrazones to be facile procedures. Although a complete alternative route proved elusive, 
several potential precursors to these β-lactams were successfully synthesised and are 
representative examples of novel classes of compounds containing the phenylazo moiety. 
 In addition investigations into the modification of the phenylazo group subsequent to 
cyclisation produced a β-lactam bearing the phenylazoxy moiety. Although the azo- to azoxy- 
transformation has been reported in many contexts, the direct attachment of this group to a β-
lactam has not been previously reported.  
Overall the work presented in this chapter aims to expand the understanding of both 
the limitations and synthetic potential of the procedures that originally led to the formation β-
lactams from their azoacetate precursors. To that end, a good deal of useful information has 
been gathered concerning the practical aspects of the synthesis of these novel compounds. 
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2.5 Experimental  
Ethyl acetoacetate, iodomethane, benzyl chloride and substituted acetoacetanilides were 
purchased from the Sigma Aldrich chemical company and were used as received. All solvents 
were dried or distilled prior to use. Melting points were determined using a Griffin melting 
point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 2000FT-IR 
spectrometer. NMR spectra were recorded using a Bruker AC 400 NMR spectrometer 
operating at 400 MHz for 1H NMR and at 100 MHz for 13C NMR. The 1H and 13C NMR 
chemical shifts (ppm) are relative to TMS and all coupling constants (J) are in Hertz (Hz).  
α-methyl-4-chloroacetoacetanilide (120)  
4-Chloroacetoacetanilide 119 (10.8 g, 51.2 mmol) was dissolved in acetone (75 ml) and 
K2CO3 (7.2 g, 52.0 mmol) was added and the reaction brought to reflux. Iodomethane (10.66 
g, 75.1 mmol) was added dropwise with stirring to the reaction vessel over 1 h and the 
reaction was heated under reflux for a further 2 h. The reaction mixture was cooled and 
poured into ice-water (150 ml) and allowed to stir for 30 min. A white precipitate (120) was 
collected and recrystallized several times from aqueous EtOH to remove any dimethylated 
product (131j). Yield: (8.59 g, 74.4%); mp 125-129 ºC; 1H NMR (400MHz, DMSO-d6): δ = 
1.23 (3H, d, CH3, J = 6.8), 2.17 (3H, s, CH3), 3.65 (1H, q, CH, J = 6.8), 7.37 (2H, d, ArH, J 
= 8.8), 7.50 (2H, d, ArH, J = 8.8), 10.34 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 13.0, 
28.2, 54.5, 120.8, 127.1, 128.6, 137.8, 168.9, 204.3. IR (KBr) 3241, 1720, 1654, 1604 cm-1. 
α-methyl-α-benzyl-4-chloroacetoacetanilide (121) 
α-Methyl-4-chloroacetoacetanilide 120  (6.8 g, 30.2 mmol) was dissolved in acetone 50 ml 
and  K2CO3 (7.2 g, 52.0 mmol) was added and the reaction brought to reflux. Benzyl chloride 
(6.58 g, 52.0 mmol) was added dropwise with stirring to the reaction vessel over 1 h and the 
reaction was heated under reflux overnight. The reaction mixture was cooled and poured into 
ice-water (150 ml) and allowed to stir for 30 min. A white precipitate (121) was collected and 
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recrystallized from an EtOAc:hexane 70:30 mixture. Yield: (8.53 g, 89.5%); mp 124-127 ºC; 
1H NMR (400MHz, DMSO-d6): δ = 1.27 (3H, s, CH3), 2.20 (3H, s, CH3), 3.07 (1H, d, CH2, J 
= 13.6), 3.36 (1H, d, CH2, J = 13.6), 7.11-7.23 (5H, m, ArH), 7.77 (2H, d, ArH, J = 8.8), 7.43 
(2H, d, ArH, J = 8.8), 9.68 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 18.7, 26.3, 39.7, 
61.3, 122.3, 126.5, 127.6, 128.0, 128.1, 130.1, 136.7, 137.5, 170.2, 206.3; IR (KBr) 3328, 
1720, 1654, 1604, 1543 cm-1. 
 
Preparation of acetoacetanilides  
4-Bromoacetoacetanilide 130a 
Ethyl acetoacetate 106 (65.1 g, 0.5 mol) was heated to 160 oC in a round bottomed flask with 
reflux condenser fitted. To this was added 4-bromoaniline (17.0 g, 0.1 mol). When the 
evolution of EtOH began the reaction was allowed to reflux for 2-3 h until the reaction was 
complete (TLC) before the EtOH was distilled off. The bulk of the remaining ethyl 
acetoacetate was removed by vacuum distillation at 90o C, 50mbar. The resulting oily residue 
was scratched with a glass rod to promote precipitation. The precipitate was filtered and 
washed with hexane before being recrystallised from an EtOAc:hexane 30:70 mixture. Yield  
(22.8 g, 90.1 %); mp 132-135 ºC; 1H NMR (400MHz, DMSO-d6): δ = 2.21 (3H, s, CH3), 3.56 
(2H, s, CH2), 7.48 (2H, ArH, J = 8.8), 7.55 (2H, d, ArH, J = 8.8) 10.21 (1H, s, NH); 13C 
NMR (100MHz, DMSO-d6) 30.2, 52.3, 114.9, 120.9, 131.5, 138.2, 165.2, 202.7; IR (KBr) 
3292, 1718, 1661  cm-1. 
4-Methoxyacetoacetanilide 130b 
Yield  (18.2 g 88%); mp 131-134 ºC; 1H NMR (400MHz, DMSO-d6): δ = 2.21 (3H, s, CH3), 
3.51 (2H, s, CH2), 3.72 (3H, s, CH3), 6.88 (2H, d, ArH, J = 8.8), 7.49 (2H, d, ArH, J = 8.8), 
9.79 (1H, s, NH); 13C NMR (100MHz, DMSO-d6)  30.1, 52.2, 55.1, 113.8, 120.6, 132.0, 
155.3, 164.5, 202.9; IR (KBr) 3299, 1730, 1554, 1490 cm-1. 
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2,3-Dimethylacetoacetanilide 130c 
Yield  (18.7 g, 91%); mp 142-146 ºC; 1H NMR (400MHz, DMSO-d6): δ = 2.10 (3H, s, CH3), 
2.23 (3H, s, CH3), 2.25 (3H, s, CH3), 3.58 (2H, s, CH2), 7.07-7.01 (2H, m, ArH), 7.19-7.17 
(2H, m, ArH), 9.40 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 13.9, 20.1, 30.1, 51.6, 
123.3, 125.1, 127.0, 130.1, 135.8, 136.9, 165.0, 203.0; IR (KBr) 3296, 1720, 1665 cm-1. 
 
4-Methylacetoacetanilide 130d 
Yield  (16.2 g, 85%); mp 122-126 ºC; 1H NMR (400MHz, DMSO-d6): δ = 2.21 (3H, s, CH3), 
2.25 (3H, s, CH3), 3.54 (2H, s, CH2), 7.10 (2H, d, ArH, J = 8.0), 7.47 (2H, d, ArH, J = 8.0), 
10.00 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 20.4, 30.1, 52.3, 119.6, 129.1, 132.3, 
136.4, 164.7, 202.9; IR (KBr) 3293, 1711, 1666 cm-1. 
 
4-Ethylesteracetoacetanilide 130e 
Yield  (19.2 g, 77%); mp 118-121 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.30 (3H, t, CH3, J 
= 6.8), 2.22 (3H, s, CH3), 3.61 (2H, s, CH2), 4.27 (2H, q, CH2, J = 6.8), 6.88 (2H, d, ArH, J = 
8.8), 7.49 (2H, d, ArH, J = 8.8), 10.41 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 14.13, 
30.2, 52.4, 60.4, 118.4, 124.3, 130.2, 143.1, 165.2, 165.6, 202.6; IR (KBr) 3286, 1723, 1675 
cm-1. 
 
Preparation of α,α-dimethylacetoacetanilides  
α,α-dimethyl-4-bromoacetoacetanilide 131a 
4-Bromoacetoacetanilide 130a (6.62 g, 25.9 mmol) was dissolved in 150 ml of acetone, to 
this was added K2CO3 (7.8 g, 56.4 mmol) and the reaction was set to reflux. Once the reaction 
had reached reflux temperature iodomethane (22.45 g, 158.2 mmol) was added and the 
reaction was allowed to reflux overnight. The solvent was reduced to 1/5 of the original 
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volume by rotary evaporation and the entire contents of the reaction vessel were poured into a 
beaker containing 200 ml of ice-water. The product formed an oil and was extracted with 
CH2Cl2 (5 x 50 ml). The organic extracts were combined, dried over magnesium sulfate and 
evaporated to an oil under reduced pressure. A small portion of the oil was removed and 
precipitation was induced by scratching, this was then returned to the bulk in order to seed the 
crystallization of the remaining oil. The solid was filtered and washed with hexane, this was 
further recrystallized from an EtOAc:hexane 70:30 mixture. Yield  (5.84 g, 79.4 %); mp 85-
87 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.37 (6H, s, 2 x CH3), 2.15 (3H, s, CH3), 7.48 
(2H, ArH, J = 9.2), 7.61 (2H, d, ArH, J = 8.8), 9.57 (1H, s, NH); 13C NMR (100MHz, 
DMSO-d6) 21.8, 25.7, 56.5, 115.3, 122.2, 131.3, 138.2, 171.8, 207.2; IR (KBr) 3361, 1684, 
1531 cm-1. 
α,α-dimethyl-4-methoxyacetoacetanilide 131b 
Yield  (4.77 g, 78 %); mp 88-87 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.36 (6H, s, 2 x 
CH3), 2.15 (3H, s, CH3), 3.72 (3H, s, OCH3), 6.88 (2H, d, ArH, J = 9.2), 7.50 (2H, d, ArH, J 
= 9.2), 9.33 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 21.9, 257, 55.1, 56.2, 113.6, 122.1, 
131.8, 155.5, 171.3, 207.2; IR (KBr) 3365, 1677, 1529, 1450 cm-1. 
 
α,α-dimethyl-2,3-dimethylacetoacetanilide 131c 
Yield  (4.85 g, 80 %); mp 102-105 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.45 (6H, s, 2 x 
CH3), 2.03 (3H, s, CH3), 2.21 (3H, s, CH3), 2.22 (3H, s, CH3), 6.92 (1H, d, ArH, J = 7.2), 7.01 
(1H, t, ArH, J = 7.6), 7.39 (1H, d, ArH, J = 8.0), 7.66 (1H, s, NH); 13C NMR (100MHz, 
DMSO-d6) 17.5, 20.5, 22.0, 25.8, 55.8, 126.4, 126.7, 130.7, 133.4, 133.7, 135.2, 171.6, 207.2; 
IR (KBr) 3366, 1688, 1530, 1495 cm-1. 
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α,α-dimethyl-4-methylacetoacetanilide 131d 
Yield  (4.73 g, 83 %); mp 81-83 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.38 (6H, s, 2 x 
CH3), 2.14 (3H, s, CH3), 2.25 (3H, s, CH3), 7.11 (2H, d, ArH, J = 9.2), 7.49 (2H, d, ArH, J = 
9.2), 9.37 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 17.8, 22.1, 25.6, 56.2, 120.4, 130.1, 
132.9, 135.3, 164.3, 203.7; IR (KBr) 3359, 1679, 1540, 1485 cm-1. 
 α,α-dimethyl-4-ethylesteracetoacetanilide 131e 
Yield  (5.04 g, 70 %); mp 82-85 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.30 (3H, t, CH3, J = 
6.8), 1.39 (6H, s, 2 x CH3), 2.16 (3H, s, CH3), 4.27 (2H, q, CH2, J = 6.8), 7.77 (2H, d, ArH, J 
= 8.8), 7.91 (2H, d, ArH, J = 8.8), 9.77 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 14.1, 
21.9, 25.8, 56.6, 60.4, 119.5, 124.5, 129.9, 143.3, 165.3, 172.2, 207.4. IR (KBr) 3352, 1690, 
1492 cm-1. 
α,α-dimethylacetoacetanilide 131f 
Yield  (4.26 g, 80 %); mp 67-69 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.38 (6H, s, 2 x 
CH3), 2.16 (3H, s, CH3), 7.08-7.05 (1H, m, ArH), 7.32-7.28 (2H, m, ArH), 7.64-7.62 (2H, m, 
ArH), 9.11 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 21.9, 25.8, 56.4, 120.4, 123.6, 128.4, 
138.8, 171.6, 207.2; IR (KBr) 3364, 1687, 1240, 1120 cm-1. 
α,α-dimethyl-2,4-dimethylacetoacetanilide 131g  
Yield  (4.08 g, 67 %); mp 93-94 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.39 (6H, s, 2 x 
CH3), 2.13 (3H, s, CH3), 2.19 (3H, s, CH3), 2.26 (3H, s, CH3), 7.04-6.97 (3H, m, ArH), 9.11 
(1H, s, NH); 13C NMR (100MHz, DMSO-d6) 16.5, 21.1, 23.3, 25.4, 59.0, 123.9, 126.5, 131.3, 
133.7, 134.0, 134.8, 172.2, 208.0; IR (KBr) 3355, 1687, 1526, 1490 cm-1. 
 α,α-dimethyl-2-methylacetoacetanilide 131h 
Yield  (4.27 g, 75 %); mp 93-95 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.41 (6H, s, 2 x 
CH3), 2.18 (3H, s, CH3), 2.20 (3H, s, CH3), 7.25-7.14 (4H, m, ArH), 9.2 (1H, s, NH); 13C 
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NMR (100MHz, DMSO-d6) 17.6, 22.0, 25.8, 55.8, 125.9, 126.1, 126.7, 130.2, 133.9, 136.0, 
171.6, 207.2; IR (KBr) 3361, 1684, 1531, 1488 cm-1. 
α,α-dimethyl-2-methoxyacetoacetanilide 131i 
Yield  (4.52 g, 74 %); mp 89-91 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.39 (6H, s, 2 x 
CH3), 2.20 (3H, s, CH3), 3.82 (3H, s, CH3), 6.93 (1H, t, ArH, J = 7.6), 7.05 (1H, d, ArH, J = 
8.0), 7.14 (1H, t, ArH, J = 8.0), 7.72 (1H, d, ArH, J = 8.0), 8.80 (1H, s, NH); 13C NMR 
(100MHz, DMSO-d6) 22.0, 25.9, 55.8, 56.1, 111.2, 120.2, 123.3, 125.5, 126.6, 150.9, 170.9, 
207.8; IR (KBr) 3365, 1692, 1490, 1311 cm-1. 
α,α-dimethyl-4-chloroacetoacetanilide 131j 
Yield  (4.29 g, 69 %); mp 108-110 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.38 (6H, s, 2 x 
CH3), 2.15 (3H, s, CH3), 7.35 (2H, d, ArH, J = 8.8), 7.66 (2H, d, ArH, J = 8.8), 9.57 (1H, s, 
NH); 13C NMR (100MHz, DMSO-d6) 21.9, 25.7, 56.4, 121.8, 127.2, 128.4, 137.8, 171.8, 
207.1; IR (KBr) 3365, 1688, 1528, 1488 cm-1. 
Preparation of 4-nitrophenylhydrazone derivatives 
N-(4-bromophenyl)-2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 132a 
2,2-Dimethyl-4-bromoacetoacetanilide 131a (4.0 g, 14.0 mmol) was dissolved in MeOH 75 
ml, 4-nitrophenylhydrazine (2.6 g, 16.8 mmol) was dissolved in warm acetic acid (3.25 ml) 
and added to the stirring reaction vessel. After 1-2 min a yellow precipitate began to fall from 
solution, the reaction was allowed to stir overnight and the precipitate collected and dried. 
Yield  (4.01 g, 68 %); mp 197-200 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.48 (6H, s, 2 x 
CH3), 1.96 (3H, s, CH3), 7.27 (2H, d, ArH, J = 8.8), 7.50 (2H, d, ArH, J = 9.2), 7.65 (2H, d, 
ArH, J = 8.8), 8.12 (2H, d, ArH, J = 8.8), 9.43 (1H, s, NH), 9.97 (1H, s, NH); 13C NMR 
(100MHz, DMSO-d6) 13.7, 23.5, 51.3, 111.6, 115.1, 122.5, 125.8, 131.2, 138.1, 138.5, 151.8, 
151.9, 173.5; IR (KBr) 3322, 1671, 1596 cm-1. 
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N-(4-methoxyphenyl)-2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 132b 
Yield  (2.85 g, 55 %); mp 144-147 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.44 (6H, s, 2 x 
CH3), 1.93 (3H, s, CH3), 3.72 (3H, s, OCH3), 6.86 (2H, d, ArH, J = 8.8), 7.24 (2H, d, ArH, J 
= 8.0), 7.49 (2H, d, ArH, J = 8.4), 8.10 (2H, d, ArH, J = 9.2), 9.14 (1H, s, NH), 9.92 (1H, s, 
NH); 13C NMR (100MHz, DMSO-d6): 13.8, 23.6, 51.1, 55.1, 111.6, 113.4, 122.4, 125.8, 
132.0, 138.0, 151.8, 152.2, 155.4, 172.9; IR (KBr) 3325, 1677, 1599, 1493cm-1. 
N-(2,3-dimethylphenyl)-2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 132c 
Yield  (3.66 g, 71 %); mp 161-165 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.47 (6H, s, 2 x 
CH3), 1.99 (3H, s, CH3), 2.02 (3H, s, CH3), 2.24 (3H, s, CH3), 7.07-6.97 (3H, m, ArH), 7.27 
(2H, d, ArH, J = 9.2), 8.12 (2H, d, ArH, J = 9.2), 9.01 (1H, s, NH), 9.94 (1H, s, NH); 13C 
NMR (100MHz, DMSO-d6): 13.9, 14.0, 20.0, 23.7, 50.7, 111.7, 124.7, 125.1, 125.8, 127.4, 
132.7, 136.3, 136.8, 138.0, 151.9, 152.3, 173.2; IR (KBr) 3325, 1677, 1599, 1488 cm-1. 
2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)-N-p-tolylbutanamide 132d 
Yield  (2.73 g, 55 %); mp 152-156 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.44 (6H, s, 2 x 
CH3), 1.93 (3H, s, CH3), 2.24 (3H, s, CH3), 7.08 (2H, d, ArH, J = 8.4), 7.24 (2H, d, ArH, J = 
8.4), 7.49 (2H, d, ArH, J = 8.8), 8.10 (2H, d, ArH, J = 9.6), 9.17 (1H, s, NH), 9.93 (1H, s, 
NH); 13C NMR (100MHz, DMSO-d6): 14.0, 17.7, 23.7, 50.8, 111.7, 125.8, 126.7, 130.1, 
133.8, 136.4, 138.1, 151.9, 152.3, 173.1 IR (KBr) 3329, 1676, 1599, 1498 cm-1. 
Ethyl 4-(2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamido)benzoate 132e 
Yield  (3.40 g, 59 %); mp 146-149 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.30 (3H, t, CH3, J 
= 6.8), 1.46 (6H, s, 2 x CH3), 1.94 (3H, s, CH3), 4.27 (2H, q, CH2, J = 6.8), 7.21 (2H, d, ArH, 
J = 9.2), 7.80 (2H, d, ArH, J = 8.8), 7.90 (2H, d, ArH, J = 8.8), 8.07 (2H, d, ArH, J = 9.2), 
9.59 (1H, s, NH), 9.96 (1H, s, NH); 13C NMR (100MHz, DMSO-d6): 13.6, 14.1, 23.4, 51.5, 
60.4, 111.6, 119.6, 124.3, 125.8, 129.8, 138.1, 143.5, 151.7, 151.8, 165.4, 173.9. IR (KBr) 
3330, 1665, 1594, 1491 cm-1. 
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2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)-N-phenylbutanamide 132f 
Yield  (2.90 g, 61 %); mp 136-138 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.46 (6H, s, 2 x 
CH3), 1.94 (3H, s, CH3), 7.04 (1H, t, ArH, J = 7.6), 7.31-7.24 (4H, m, ArH), 7.63 (2H, d, 
ArH, J = 8.0), 8.10 (2H, d, ArH, J = 9.2), 9.27 (1H, s, NH), 9.94 (1H, s, NH); 13C NMR 
(100MHz, DMSO-d6): 13.8, 23.6, 51.3, 111.6, 120.7, 123.4, 125.8, 128.3, 138.1, 139.0, 
151.8, 152.1, 173.3. IR (KBr) 3324, 1669, 1600, 1501 cm-1. 
N-(2,4-dimethylphenyl)-2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 132g 
Yield  (3.35 g, 65 %); mp 157-160 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.46 (6H, s, 2 x 
CH3), 1.98 (3H, s, CH3), 2.10 (3H, s, CH3), 2.25 (3H, s, CH3), 7.04-6.96 (3H, m, ArH), 7.27 
(2H, d, ArH, J = 8.8), 8.12 (2H, d, ArH, J = 9.2), 8.90 (1H, s, NH), 9.94 (1H, s, NH); IR 
(KBr) 3322, 1667, 1594, 1493 cm-1. 
2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)-N-o-tolylbutanamide 132h 
Yield  (3.57 g, 72 %); mp 157-159 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.48 (6H, s, 2 x 
CH3), 1.99 (3H, s, CH3), 2.15 (3H, s, CH3), 7.22-7.10 (4H, m, ArH), 7.27 (2H, d, ArH, J = 
9.2), 8.12 (2H, d, ArH, J = 9.2), 8.96 (1H, s, NH), 9.94 (1H, s, NH); 13C NMR (100MHz, 
DMSO-d6): 13.8, 20.4, 23.6, 51.2, 111.6, 117.4, 120.7, 125.0, 125.8, 128.7, 132.4, 136.5, 
138.0, 151.8, 152.1, 173.1 IR (KBr) 3323, 1668, 1592, 1490 cm-1. 
N-(2-methoxyphenyl)-2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 132i 
Yield  (2.59 g, 50 %); mp 147-149 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.46 (6H, s, 2 x 
CH3), 1.96 (3H, s, CH3), 3.69 (3H, s, OCH3), 6.91 (1H, t, ArH, J = 7.6), 6.98 (1H, d, ArH, J = 
7.6), 7.07 (1H, t, ArH, J = 7.6), 7. 28 (2H, d, ArH, J = 8.8), 7.88 (1H, d, ArH, J = 7.6), 8.13 
(2H, d, ArH, J = 9.2), 8.47 (1H, s, NH), 10.02 (1H, s, NH); 13C NMR (100MHz, DMSO-d6): 
13.7, 23.6, 51.1, 55.7, 110.9, 111.6, 120.3, 121.3, 124.6, 125.8, 127.0, 138.3, 149.6, 151.7, 
152.4, 172.3. IR (KBr) 3322, 1671, 1599, 1495 cm-1. 
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N-(4-chlorophenyl)-2,2-dimethyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 132j 
Yield  (2.98 g, 57 %); mp 181-183 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.44 (6H, s, 2 x 
CH3), 1.92 (3H, s, CH3), 7.23 (2H, d, ArH, J = 9.2), 7.34 (2H, d, ArH, J = 8.8), 7.66 (2H, d, 
ArH, J = 9.2), 8.09 (2H, d, ArH, J = 9.2), 9.40 (1H, s, NH), 9.94 (1H, s, NH); 13C NMR 
(100MHz, DMSO-d6) 13.7, 23.5, 51.3, 111.6, 122.1, 125.8, 127.0, 128.3, 138.0, 138.1, 151.8, 
151.9, 173.5. IR (KBr) 3322, 1671, 1596, 1499 cm-1. 
2-benzyl-N-(4-chlorophenyl)-2-methyl-3-(2-(4-nitrophenyl)hydrazono)butanamide 122 
Yield  (2.46 g, 39 %); mp 220-224 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.31 (3H, s, CH3), 
1.97 (3H, s, CH3), 3.19 (1H, d, ½ CH2, J = 13.6), 3.44 (1H, d, ½ CH2, J = 13.6), 7.23-7.12 
(7H, m, ArH), 7.36 (2H, d, ArH, J = 8.8), 7.64 (2H, d, ArH, J = 9.2), 8.09 (2H, d, ArH, J = 
9.2), 9.54 (1H, s, NH), 10.00 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 14.4, 20.5, 40.9, 
55.7, 111.7, 122.4, 125.8, 126.4, 127.3, 127.8, 128.3, 130.3, 137.6, 137.8, 138.2, 150.7, 151.7, 
172.1; IR (KBr) 3322, 1668, 1590, 1488 cm-1. 
 
Preparation of 2,4-dinitrophenylhydrazone derivatives 
N-(4-chlorophenyl)-3-(2-(2,4-dinitrophenyl)hydrazono)-2,2-dimethylbutanamide 157 
Yield  (3.52 g, 60 %); mp 199-201 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.51 (6H, s, 2 x 
CH3), 2.08 (3H, s, CH3), 7.35 (2H, d, ArH, J = 8.8), 7.65 (2H, d, ArH, J = 8.8), 7.91 (1H, d, 
ArH, J = 9.6), 8.39 (1H, m, ArH), 8.09 (2H, d, ArH, J = 2.8), 9.45 (1H, s, NH), 10.86 (1H, s, 
NH); 13C NMR (100MHz, DMSO-d6) 14.1, 23.6, 52.1, 116.7, 122.6, 123.3, 127.7, 128.7, 
129.6, 130.4, 137.4, 138.1, 145.1, 159.9, 173.1; IR (KBr) 3327, 1675, 1595, 1485 cm-1. 
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Preparation of α-substituted Phenylazo derivatives 
1. Azoacetates 133a-j and 123 
4-(4-bromophenylamino)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxobutan-2-yl acetate 
133a  
The hydrazone substrate 132a (3.0 g, 7.15 mmol) was dissolved in CH2Cl2 (100 ml). To this 
was added lead tetraacetate (3.8 g, 8.6 mmol) with stirring. 5 ml of glacial acetic acid was 
added to aid the dissolution of the lead tetraacetate and the solution was allowed to stir 
overnight. When the reaction was judged complete (TLC) the solvent volume was reduced by 
75% and the remaining CH2Cl2 solution was washed alternately with 5 x 50 ml portions of 
water and 5 % aqueous sodium bicarbonate solution. The organic portion was dried over 
magnesium sulfate and evaporated to dryness and any persistent lead residues were removed 
by flash chromatography using a 25 : 75 EtOAc : hexane mixture as eluent. Yield (2.80 g, 
82%); mp 202-205 ºC; 1H NMR (400MHz, DMSO-d6): δ =1.28 (3H, s, CH3), 1.40 (3H, s, 
CH3), 1.86 (3H, s, CH3), 2.18 (3H, s, CH3), 7.48 (2H, d, ArH, J = 8.8), 7.57 (2H, d, ArH, J = 
9.2), 7.75 (2H, d, ArH, J = 8.8), 8.37 (2H, d, ArH, J = 8.8). 9.19 (1H, s, NH); 13C NMR 
(100MHz, DMSO-d6) 17.2, 20.5, 20.6, 21.5, 51.0, 103.6, 115.5, 123.0, 123.2, 125.0, 131.2, 
138.0, 148.5, 153.9, 168.8, 171.1; IR (KBr) 3324, 1731, 1687, 1605, 1539 cm-1. 
4-(4-methoxyphenylamino)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxobutan-2-yl 
acetate 133b 
Yield (2.16 g, 72%); mp 149-152 ºC; 1H NMR (400MHz, CDCl3): δ = 1.25 (3H, s, CH3), 1.31 
(3H, s, CH3), 1.92 (3H, s, CH3), 2.15 (3H, s, CH3), 3.72 (3H, s, OCH3), 6.79 (2H, d, ArH, J = 
9.2), 7.28 (2H, d, ArH, J = 8.8), 7.67 (2H, d, ArH, J = 8.8), 7.81 (1H, s, NH), 8.23 (2H, d, 
ArH, J = 9.2), IR (KBr) 3326, 1688, 1600, 1536 cm-1. 
4-(2,3-dimethylphenylamino)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxobutan-2-yl 
acetate 133c 
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Yield (2.55 g, 85%); mp 168-172 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.31 (3H, s, CH3), 
1.39 (3H, s, CH3), 1.93 (3H, s, CH3), 2.07 (3H, s, CH3), 2.22 (3H, s, CH3), 2.25 (3H, s, CH3), 
7.07-6.95 (3H, m, ArH), 7.80 (2H, d, ArH, J = 8.8), 8.39 (2H, d, ArH, J = 8.8), 9.03 (1H, s, 
NH), 13C NMR (100MHz, DMSO-d6): 14.1, 17.3, 20.0, 20.8, 21.0, 21.6, 50.4, 103.8, 123.3, 
125.0, 125.1, 127.5, 133.0, 136.5, 136.8, 148.4, 153.9, 168.9, 171.0; IR (KBr) 3329, 1683, 
1605, 1545 cm-1. 
3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxo-4-(p-tolylamino)butan-2-yl acetate 133d 
Yield (2.42 g, 84%); mp 153-157 ºC; 1H NMR (400MHz, CDCl3): δ = 1.30 (3H, s, CH3), 1.38 
(3H, s, CH3), 1.88 (3H, s, CH3), 2.19 (3H, s, CH3), 2.25 (3H, s, CH3), 6.87 (2H, d, ArH, J = 
8.8), 7.44 (2H, d, ArH, J = 8.8), 7.76 (2H, d, ArH, J = 8.8), 8.37 (2H, d, ArH, J = 8.8), 9.00 
(1H, s, NH), 13C NMR (100MHz, DMSO-d6): 17.3, 20.5, 20.6, 50.8, 55.1, 103.7, 113.5, 
117.4, 123.0, 123.2, 124.9, 125.0, 131.6, 148.4, 153.9, 155.7, 168.8, 170.5; IR (KBr) 3330, 
1735, 1687 cm-1. 
Ethyl 4-(3-acetoxy-2,2-dimethyl-3-((4-nitrophenyl)diazenyl)butanamido)benzoate 133e 
Yield (2.30 g, 70%); mp 155-158 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.35-1.32 (6H, m, 2 
x CH3), 1.46 (3H, s, CH3), 1.91 (3H, s, CH3), 2.22 (3H, s, CH3), 4.31 (2H, q, CH2, J = 7.2), 
7.83-7.77 (4H, m, ArH), 7.94 (2H, d, ArH, J = 8.8), 8.07 (2H, d, ArH, J = 8.4), 9.38 (1H, s, 
NH); 13C NMR (100MHz, DMSO-d6): 14.2, 17.1, 20.5, 20.6, 21.5, 51.2, 60.4, 103.6, 117.4, 
120.2, 123.2, 125.0, 129.8, 143.0, 148.5, 153.8, 165.3, 168.7, 171.4. IR (KBr) 3331, 1735, 
1688 cm-1. 
3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxo-4-(phenylamino)butan-2-yl acetate 133f 
Yield (2.23 g, 80%); mp 136-138 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.30 (3H, s, CH3), 
1.40 (3H, s, CH3), 1.88 (3H, s, CH3), 2.19 (3H, s, CH3), 7.07 (1H, t, ArH, J = 7.2), 7.30 (2H, 
t, ArH, J = 7.2), 7.63 (2H, d, ArH, J = 7.6), 7.63 (2H, d, ArH, J = 8.4), 8.10 (2H, d, ArH, J = 
8.4), 9.09 (1H, s, NH), 13C NMR (100MHz, DMSO-d6): 17.2, 20.6, 20.7, 21.5, 50.9, 103.7, 
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121.2, 123.2, 123.8, 125.0, 128.4, 138.6, 148.5, 153.9, 168.8, 170.9. IR (KBr) 3320, 1687, 
1530 cm-1. 
4-(2,4-dimethylphenylamino)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxobutan-2-yl 
acetate 133g 
Yield (2.65 g, 89%); mp 161-165 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.30 (3H, s, CH3), 
1.37 (3H, s, CH3), 1.92 (3H, s, CH3), 2.14 (3H, s, CH3), 2.21 (3H, s, CH3), 2.25 (3H, s, CH3), 
7.02 (3H, m, ArH,), 7.80 (2H, d, ArH, J = 9.2), 8.40 (2H, d, ArH, J = 9.2), 9.09 (1H, s, NH), 
IR (KBr) 3324, 1690, 1610, 1545 cm-1. 
(E)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxo-4-(o-tolylamino)butan-2-yl acetate  
133h 
Yield (2.11 g, 73%); mp 159-161 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.31 (3H, s, CH3), 
1.38 (3H, s, CH3), 1.92 (3H, s, CH3), 2.19 (3H, s, CH3), 2.22 (3H, s, CH3), 7.22-7.11 (4H, m, 
ArH), 7.80 (2H, d, ArH, J = 9.2), 8.40 (2H, d, ArH, J = 9.2), 8.98 (1H, s, NH), 13C NMR 
(100MHz, DMSO-d6): 17.4, 17.8, 20.8, 21.0, 21.6, 50.5, 103.7, 123.3, 125.0, 126.0, 126.9, 
130.1, 134.0, 136.6, 148.5, 153.9, 168.9, 170.9; IR (KBr) 3324, 1677, 1535 cm-1. 
4-(2-methoxyphenylamino)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxobutan-2-yl 
acetate 133i 
Yield (2.64 g, 88%); mp 154-156 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.24 (3H, s, CH3), 
1.34 (3H, s, CH3), 1.88 (3H, s, CH3), 2.23 (3H, s, CH3), 3.84 (3H, s, OCH3), 6.95-6.90 (1H, 
m, ArH), 7.07-7.06 (2H, m, ArH), 7.78 (2H, d, ArH, J = 8.8), 8.09 (1H, d, ArH, J = 8.0), 8.38 
(2H, d, ArH, J = 9.6), 8.82 (1H, s, NH), 13C NMR (100MHz, DMSO-d6):17.1, 20.4, 21.0, 
21.4, 51.1, 55.8, 103.8, 110.8, 119.9, 120.5, 123.2, 1240, 125.1, 127.3, 148.5, 148.6, 153.8, 
168.5, 170.6; IR (KBr) 3324, 1679, 1611 cm-1. 
4-(4-chlorophenylamino)-3,3-dimethyl-2-((4-nitrophenyl)diazenyl)-4-oxobutan-2-yl acetate 
133j 
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Yield (2.63 g, 87%); mp 173-175 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.28 (3H, s, CH3), 
1.40 (3H, s, CH3), 1.86 (3H, s, CH3), 2.17 (3H, s, CH3), 7.36 (2H, d, ArH, J = 8.8), 7.61 (2H, 
d, ArH, J = 8.8), 7.75 (2H, d, ArH, J = 9.2), 8.38 (2H, d, ArH, J = 8.8), 9.21 (1H, s, NH), IR 
(KBr) 3324, 1688, 1616, 1525 cm-1. 
3-benzyl-4-(4-chlorophenylamino)-3-methyl-2-((E)-(4-nitrophenyl)diazenyl)-4-oxobutan-2-
yl acetate 123 
Yield  (2.52 g, 71 %); mp 70-72 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.05 (3H, s, CH3),  
2.01 (3H, s, CH3), 2.24 (3H, s, CH3), 2.85-2.78 (1H, m, ½ CH2), 3.90-3.75 (1H, m, ½ CH2),  
7.24-7.18 (5H, m, ArH), 7.38 (2H, d, ArH, J = 8.8), 7.62 (2H, d, ArH, J = 8.8), 7.78 (2H, d, 
ArH, J = 9.2), 8.39 (2H, d, ArH, J = 8.8), 9.36 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 
16.7, 17.0, 38.0, 55.2, 104.2, 122.8, 123.3, 125.0, 126.5, 127.6, 128.0, 128.4, 130.4, 137.0, 
148.6, 153.8, 168.8, 169.9; IR (KBr) 3300, 1752, 1686, 1492 cm-1. 
2.   α-methoxy phenylazo derivative 152 
N-(4-chlorophenyl)-3-((2,4-dinitrophenyl)diazenyl)-3-methoxy-2,2-dimethylbutanamide 
152 
IBDA (2.65 g, 8.25 mmol) was dissolved in methanol (100 mL) at room temperature under 
argon. The hydrazone 157 (3.14 g, 7.5 mmol) was added to the solution at room temperature 
and the reaction mixture was then stirred for three hours. The solution was evaporated and the 
residue was diluted with dichloromethane. The dichloromethane solution was then washed 
with an aqueous saturated sodium bicarbonate solution and water, dried, and evaporated. The 
residue was purified by column chromatography (hexane-Et0Ac, 80:20 to 20:80). Yield (2.42 
g, 80 %). 1H NMR (400MHz, DMSO-d6): δ = 1.32 (3H, s, CH3), 1.37 (3H, s, CH3), 1.52 (3H, 
s, CH3), 3.31 (3H, s, OCH3), 7.35 (2H, d, ArH, J = 8.8), 7.52 (1H, d, ArH, J = 8.4), 7.65 (2H, 
d, ArH, J = 8.8), 8.67-8.65 (1H, m, ArH), 8.93 (1H, s, ArH), 9.25 (1H, s, NH); 13C NMR 
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(100MHz, DMSO-d6) 14.7, 21.4, 21.7, 51.6, 52.1, 102.6, 120.8, 121.2, 122.6, 127.5, 128.6, 
129.8, 138.1, 145.2, 148.0, 172.8 
3.    α-chloro phenylazo derivative 158 
3-chloro-N-(2,4-dichlorophenyl)-3-((2,4-dinitrophenyl)diazenyl)-2,2-dimethylbutanamide 
158 
The substrate 157 (2.1g, 5 mmol) was dissolved in DCM 50 ml cooled to –50 0C and stirred in 
the dark. An excess of freshly prepared t-butyl hypochlorite (8 ml) was added to the solution 
and this was allowed to stir for a further 2 hours at -50 0C. The temperature was allowed to 
rise to 0 0C and the solution was placed in an ice-bath and left to stir overnight. The solvent 
was removed and the remaining yellow solid was separated from a small quantity of starting 
material by chromatography. Yield (1.61 g, 66%); 1H NMR (400MHz, DMSO-d6): δ = 1.62 
(6H, s, 2 x CH3), 1.95 (3H, s, CH3), 7.47-7.42 (2H, m, ArH), 7.76-7.65 (2H, m, ArH), 8.66 
(1H, s, ArH), 8.94 (1H, s, ArH), 9.27 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 22.2, 22.9, 
25.1, 53.0, 101.5, 120.9, 121.9, 128.0, 129.2, 129.5, 129.8, 130.6, 131.1, 134.4, 144.6, 148.1, 
172.0 
4.    phenylazo alkene derivative 160 
N-(2,4-dichlorophenyl)-3-((2,4-dinitrophenyl)diazenyl)-2,2-dimethylbut-3-enamide 160 
NaH (60% oil dispersion, 160 mg, 4 mmol) was dissolved in 12 mls of DCM and 2 mls of 
DMF. The solution was allowed to stir under dry conditions (drying tube) until the evolution 
of hydrogen had ceased. A solution of the substrate 158 (4 mmol) was made up in 2 mls DMF 
and added dropwise to the NaH solution via septum over two hours and the reaction was 
allowed to progress with stirring overnight. TLC showed the consumption of the starting 
material and the components were separated via column chromatography (hexane-Et0Ac, 
80:20 to 20:80) 
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160, Yield (0.47 g, 26%); 1H NMR (400MHz, DMSO-d6): δ = 1.50 (6H, s, 2 x CH3), 4.87 
(2H, s, CH2), 7.64-7.61 (2H, m, ArH), 7.69 (1H, s, ArH), 7.86 (1H, d, ArH, J = 8.8), 8.49-
8.45 (1H, m, ArH), 8.89 (1H, s, ArH), 8.94 (1H, s, ArH), 10.70 (1H, s, NH);  
Preparation of azetidinones derivatives (134f and 124) using K2CO3/Acetone 
Synthesis of azetidinone derivative (134f) using K2CO3/Acetone 
Anhydrous potassium carbonate (0.5 g, 3.6 mmol) was added to azoacetate 133f (1.2 g, 3 
mmol) in 50 ml of refluxing acetone. The solution was allowed to reflux for 22 h after which 
time (TLC) showed the reaction to be complete. The insoluble material was filtered from the 
solution and the filtrate evaporated to dryness. The azetidinone product (134f) was isolated 
after silica gel column chromatography using CHCl3 as eluent. Yield  (0.223 g, 22 %); mp 87-
89 ºC; 1H NMR (400MHz, CDCl3): δ = 1.08 (3H, s, CH3), 1.50 (3H, s, CH3), 1.92 (3H, s, 
CH3), 7.15-7.11 (1H, m, ArH), 7.35-7.03 (2H, m, ArH), 7.43 (2H, d, ArH, J = 8.8), 7.88 (2H, 
d, ArH, J = 8.8), 8.37 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 17.3, 19.1, 19.2, 
60.5, 90.2, 118.3, 123.4, 124.4, 124.9, 129.1, 137.2, 149.2, 154.1, 170.5; IR (KBr) 1759, 
1599, 1527, 1495 cm-1. 
 
Synthesis of azetidinone derivative (124) using K2CO3/Acetone 
(124a) Yield  (0.12 g, 8.3%); mp 139-141 ºC; 1H NMR (400MHz, CDCl3): δ = 0.85 (3H, s, 
CH3), 1.94 (3H, s, CH3), 3.01 (1H, d, CH, J = 14.4),  3.32 (1H, d, CH, J = 14.4), 7.27-7.07 
(9H, m, ArH,), 7.78 (2H, d, ArH, J = 8.8), 8.29 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, 
CDCl3) 16.8, 17.8, 30.6, 64.6, 91.1, 120.0, 125.3, 124.9, 127.2, 128.5, 128.5, 129.1, 129.9 
136.1, 136.6, 149.7, 154.2 170.0; IR (KBr) 1745, 1527, 1494 cm-1. Anal. Calcd. for 
C24H21ClN4O3: C, 64.21; H, 4.72; N, 12.48. Found: C; 64.01, H; 4.84, N; 12.18. 
(124b) Yield  (0.17 g, 11.6%); mp 137-139 ºC; 1H NMR (400MHz, CDCl3): δ = 1.43 (3H, s, 
CH3), 1.99 (3H, s, CH3), 2.67 (1H, d, CH, J = 14.4), 2.90 (1H, d, CH, J = 14.8), 7.27-7.10 
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(9H, m, ArH,), 7.87 (2H, d, ArH, J = 8.8), 8.36 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, 
CDCl3) 15.1, 15.9, 36.3, 62.7, 89.2, 118.0, 122.0, 123.3, 125.2, 126.7, 127.5, 127.9, 128.4, 
134.2, 134.7,147.8, 152.3, 168.0; IR (KBr) 1757, 1528, 1494 cm-1. 
Preparation of azetidinones derivatives (134a-j) KCN/Propanol 
Synthesis of azetidinone derivative (134a) using KCN/Propanol  
The azoacetate derivative 133a (1g, 2.1 mmol) was dissolved in hot propanol (40 ml) to 
which potassium cyanide (0.15 g, 2.3 mmol) was added. The solution was allowed to reflux 
for 30 min, after which TLC showed development of product spots and total consumption of 
the starting material, this was evaporated to dryness. Water (100 ml) was added to the reaction 
vessel and this was extracted with EtOAc (2 x 25 ml) followed by CH2Cl2 (2 x 25 ml). The 
combined extracts were dried over magnesium sulfate and upon evaporation to dryness an 
orange oil was collected. The product was isolated after column chromatography. Yield  (0.14 
g, 16 %); mp 155-158 ºC; 1H NMR (400MHz, CDCl3): δ = 1.19 (3H, s, CH3), 1.42 (3H, s, 
CH3), 1.62 (3H, s, CH3), 7.18 (2H, d, ArH, J =8.8), 7.55 (2H, d, ArH, J =8.8), 7.76 (2H, d, 
ArH, J = 9.2), 8.28 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 13.3, 17.8, 24.4, 49.3, 
83.0, 122.5, 123.4, 124.9, 127.7, 130.8, 132.4, 153.8, 174.0, 180.1; IR (KBr) 1755, 1520 cm-1. 
Anal. Calcd. for C18H17BrN4O3: C, 51.81; H, 4.11; N, 13.43, Found: C; 52.10, H; 4.28, N; 
13.21. 
Synthesis of azetidinone derivative (134b) using KCN/Propanol 
Yield  (0.15 g, 20 %); mp 95-98 ºC; 1H NMR (400MHz, CDCl3): δ = 0.98 (3H, s, CH3), 1.40 
(3H, s, CH3), 1.77 (3H, s, CH3), 3.71 (3H, s, OCH3), 6.77 (2H, d, ArH, J =9.2), 7.28 (2H, d, 
ArH, J =9.2), 7.79 (2H, d, ArH, J = 9.2), 8.28 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, 
CDCl3) 17.2, 19.1, 19.2, 55.5, 60.4, 90.3, 114.3, 120.3 123.3, 124.8, 130.2, 149.2, 154.1, 
156.5, 170.2; IR (KBr) 1759, 1513, 1392 cm-1
. 
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Synthesis of azetidinone derivative (134c) using KCN/Propanol 
Yield  (0.21 g, 25 %); mp 112-116 ºC; 1H NMR (400MHz, CDCl3): δ = 1.08 (3H, s, CH3), 
1.45 (3H, s, CH3), 1.62 (3H, s, CH3), 2.24 (3H, s, CH3), 2.25 (3H, s, CH3), 7.06-6.96 (3H, m, 
ArH), 7.76 (2H, d, ArH, J = 9.2), 8.29 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 
15.2, 17.4, 19.3, 19.9, 20.7, 59.6, 91.8, 123.2, 124.3, 124.9, 125.8, 129.8, 132.9, 135.1, 138.5, 
149.1, 154.2, 171.6; IR (KBr) 1757, 1526, 1471 cm-1. Anal. Calcd. for C20H22N4O3: C, 65.56; 
H, 6.05; N, 15.29, Found: C; 65.61, H; 6.02, N; 15.20. 
Synthesis of azetidinone derivative (134d) using KCN/Propanol 
Yield  (0.13 g, 15%); mp 103-107 ºC; 1H NMR (400MHz, CDCl3): δ = 1.07 (3H, s, CH3), 
1.49 (3H, s, CH3), 1.89 (3H, s, CH3), 2.33 (3H, s, CH3), 7.13 (2H, d, ArH, J =8.0), 7.32 (2H, 
d, ArH, J =8.4), 7.88 (2H, d, ArH, J = 9.2), 8.37 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, 
CDCl3)17.3, 19.1, 19.2, 21.0, 60.4, 90.1, 118.3, 123.4, 124.9, 129.6, 134.1, 134.6, 149.2, 
154.1, 170.3; IR (KBr) 1751, 1523, 1513 cm-1. Anal. Calcd. for C19H20N4O3: C, 64.76; H, 
5.72; N, 15.90, Found: C; 64.81, H; 5.73, N; 15.85. 
Synthesis of azetidinone derivative (134e) using KCN/Propanol 
In the case of azetidinone derivative (134e) it was the propanol transesterification product 
that was isolated 
Yield  (0.10 g, 11 %); mp 97-100 ºC; 1H NMR (400MHz, CDCl3): δ = 0.94 (2H, t J =7.6), 
1.00 (3H, s, CH3), 1.29 (2H,m), 1.31 (3H, s, CH3), 1.72-1.67 (1H, m), 1.88 (3H, s, CH3), 4.18 
(1H, t, J =6.4), 4.27 (1H, q, J =5.2), 7.38 (2H, d, ArH, J =8.8), 7.78 (2H, d, ArH, J =8.8), 
7.91 (2H, d, ArH, J = 9.2), 8.27 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 9.5, 13.3, 
16.5, 17.9, 18.1, 59.8, 65.5, 89.2, 116.3, 122.4, 123.9, 124.9, 129.7, 140.0, 148.3, 152.9, 
165.0, 169.6; IR (KBr) 1749, 1709, 1509 cm-1.  
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Synthesis of azetidinone derivative (134f) using KCN/Propanol 
 (134f) Yield (0.10 g, 12 %). Spectra identical to those reported using K2CO3/Acetone 
Synthesis of azetidinone derivative (134g) using KCN/Propanol 
Yield  (0.21 g, 25%); orange oil; 1H NMR (400MHz, CDCl3): δ = 1.06 (3H, s, CH3), 1.44 
(3H, s, CH3), 1.63 (3H, s, CH3), 2.23 (3H, s, CH3), 2.32 (3H, s, CH3), 6.88 (1H, d, ArH, J 
=8.0), 7.02 (2H, d, ArH, J =8.0), 7.75 (2H, d, ArH, J = 9.2), 8.28 (2H, d, ArH, J = 8.8); 13C 
NMR (100MHz, CDCl3) 17.5, 18.9, 19.3, 19.8, 21.1, 59.5, 91.7, 123.1, 124.9, 126.3, 127.1, 
130.5, 131.9, 136.2, 138.1, 149.1, 154.2, 171.5; IR (liquid film) 1762, 1527, 1504 cm-1. 
Synthesis of azetidinone derivative (134h) using KCN/Propanol 
Yield  (0.18 g, 22%); mp 108-110 ºC; 1H NMR (400MHz, CDCl3): δ = 1.06 (3H, s, CH3), 
1.45 (3H, s, CH3), 1.65 (3H, s, CH3), 2.37 (3H, s, CH3), 7.22-7.06 (4H, m, ArH,), 7.76 (2H, d, 
ArH, J = 8.8), 8.29 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 17.6, 19.1, 19.3, 19.9, 
59.6, 91.8, 128.2, 124.9, 126.2, 126.4, 128.2, 131.3, 133.3, 136.4, 149.1, 154.1, 171.3; IR 
(KBr) 1761, 1530, 1493 cm-1. Anal. Calcd for C19H20N4O3: C, 64.76; H, 5.72; N, 15.90. 
Found: C; 64.66, H; 5.69, N; 15.83. 
Synthesis of azetidinone derivative (134i) using KCN/Propanol 
Yield  (0.14 g, 16 %); mp 98-100 ºC; 1H NMR (400MHz, CDCl3): δ = 1.04 (3H, s, CH3), 1.44 
(3H, s, CH3), 1.60 (3H, s, CH3), 3.67 (3H, s, OCH3), 6.89-6.85 (2H, m, ArH,), 7.19-7.15 (1H, 
m, ArH,), 7.60-7.58 (1H, m, ArH,), 7.79 (2H, d, ArH, J = 9.2), 8.29 (2H, d, ArH, J = 8.8); 13C 
NMR (100MHz, CDCl3) 16.9, 18.9, 19.9, 55.6, 59.8, 91.5, 112.0, 120.8, 123.1, 123.9, 124.9, 
127.6, 128.4, 149.0, 153.9, 154.4, 172.4; IR (KBr) 1761, 1524, 1497 cm-1 
Synthesis of azetidinone derivative (134j) using KCN/Propanol  
Yield  (0.17 g, 20%); mp 132-134 ºC; 1H NMR (400MHz, CDCl3): δ = 0.98 (3H, s, CH3), 
1.42 (3H, s, CH3), 1.82 (3H, s, CH3), 7.18 (2H, d, ArH, J =8.8), 7.29 (2H, d, ArH, J =9.2), 
7.78 (2H, d, ArH, J = 8.8), 8.28 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 17.3, 
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19.0, 19.1, 60.7, 90.3, 119.5, 123.4, 124.9, 129.1, 129.5, 135.8, 149.3, 154.0, 170.3; IR (KBr) 
1753, 1534, 1346  cm-1. Anal. Calcd for C18H17ClN4O3: C, 57.99; H, 4.60; N, 15.03. Found: 
C; 57.99, H; 4.73, N; 14.81. 
 
Synthesis of azetidinone derivative (141h) 
The azetidinone derivative 134h (100 mg, 0.28 mmol) was dissolved in glacial acetic acid (25 
ml) and heated to 80 oC, to this was added 0.5 ml of hydrogen peroxide solution (35% by 
weight) at 15 min intervals over 3 h. After 5 h the reaction mixture was treated with 2 ml of 
the hydrogen peroxide solution and allowed to stir at 80 oC overnight. A further 2 ml of 
hydrogen peroxide solution was added to the reaction mixture and the reaction allowed to stir 
for a further 3 h after which no starting material could be detected by TLC The reaction was 
cooled to room temperature and poured into 150 ml of ice-water which induced precipitation 
of a pale yellow solid that was filtered from solution. Yield (66 mg, 63.9 %); mp 132-134 ºC; 
1H NMR (400MHz, CDCl3): δ = 1.29 (3H, s, CH3), 1.51(3H, s, CH3), 1.69 (3H, s, CH3), 2.37 
(3H, s, CH3), 7.24-7.17 (3H, m, ArH,), 7.38 (1H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 9.6), 
8.29 (2H, d, ArH, J = 10.0); 13C NMR (100MHz, CDCl3) 14.5, 17.7, 18.7, 19.0, 60.3, 86.3, 
123.4, 124.6, 126.6, 127.2, 128.6, 131.3, 132.5, 136.7, 149.9, 150.4, 171.0; IR (KBr) 1752, 
1535, 1485, 1465 cm-1. 
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3.1 Introduction 
Initial studies on the cyclisation of azoacetates to β-lactams carried out by this 
research group uncovered an interesting rearrangement involving the substrate azoacetates. It 
was found that both ester 78 and anilide 133 forms of these compounds underwent 
rearrangement to an acyl hydrazide (79 or 77, scheme 3.1).78 The rearrangement was thought 
to follow deacetylation of the azoacetate and a mechanism was later proposed. 
 
 
 
 
 
 
 
 
 
 
 
 
The focus of this chapter is the further investigation of this deacetylation process with 
a variety of azoacetates. The first part of this chapter describes attempts at isolating the 
azocarbinol intermediates of the deacetylation. The azoacetate bearing the ester substituent 
(78, Scheme 3.1) was chosen for these studies over the corresponding anilide (133, scheme 
13.1) form because the initial studies carried out within the group had found that this reaction 
was higher yielding with regard to the rearrangement product (35% for 79 compared to 13-
25% for the anilides 77). This reaction was also advantageous because it did not involve the 
Scheme 3.1 Proposed azoacetate to N-acyl hydrazide rearrangement mechanism 
78 
133f or j  
 
161 162 
79 
77f or j 
 
79, R = OEt, Yield = 35% 
77f, R = NH-Ph, Yield = 13% 
77j, R = NH-PCP, Yield = 25% 
PCP = p-chlorophenyl 
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competing β-lactam cyclisation reaction. Previous reports of the successful isolation of 
azocarbinols from azoacetates by the Barton45 and Warkentin100,101,102 research groups 
encouraged this line of research. Azocarbinols are a notoriously unstable entity, with 
relatively few stable solid examples having been isolated to date. They are commonly 
observed as unstable oils that decompose over short periods of time. 
The studies carried out by Barton were of particular interest due to the relative 
similarity between the substrates used by that group and the compounds observed to undergo 
rearrangement in our group (Figure 3.1). 
 
 
 
 
 
 
 The second part of this chapter deals with the synthesis and cyclisation of azoacetates 
derived from threonine to form hydantoins and oxazolidinones similar to the cyclisations 
commonly observed with threonyl derivatives.103  The base catalysed generation of 
hydantoins is encountered throughout peptide chemistry regardless of the nature of the first 
residue in the peptide chain. The generation of oxazolidinones is however specific to the 
chemistry of N-protected threonyl and seryl compounds because the reaction takes place at 
the threonyl or seryl hydroxy group (Scheme 3.2a).  
The synthesis of oxazolidinones from azoacetates (Scheme 3.2b) of this kind was of 
particular interest because it would most likely involve initial deacetylation through a process 
similar to that proposed in the formation of the N-acyl hydrazide rearrangement products 
(Scheme 3.1). The goal of this research was the further exploration of the deacetylation 
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Figure  3.1  Similarities between Barton’s substrate and that of the rearrangement substrate 
163 78 
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reactions of azoacetates in an environment where cyclisation to oxazolidinones was the most 
likely outcome. 
It was hoped that the propensity of these threonyl compounds to undergo cyclisation 
to oxazolidinones could be exploited in order to cyclise the azoacetate analogues of these 
compounds. This chemistry however depends on the initial base induced deacetylation of the 
acetate moiety as proposed in the rearrangement mechanism (Scheme 3.1). The acetate group 
is a more labile entity in basic conditions than the hydroxy hydrogen and this should favour 
the formation of the desired cyclisation products. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.2b  Desired cyclisation of threonyl azoacetate 
Scheme 3.2a  Known cyclisation of threonyl derivative 
164 165 166 
167 168 169 
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3.2 Results and Discussion 
3.2.1 Isolation of azocarbinols 
The reports of the instability of azocarbinols in general led to the decision to assess 
the viability of the various published procedures to synthesise these compounds. The 
immediate formation of the rearrangement product upon treatment with base observed 
previously by our group suggested that the isolation of the azocarbinol would not be trivial. It 
therefore seemed practical to carry out initial studies on substrates similar to those already 
shown to provide azocarbinol products. It was hoped that the contrasts and comparisons 
drawn from these tests would point towards the ideal conditions for investigation of the 
proposed azocarbinol intermediate. The synthesis of two simple azoacetates based on 4-
nitrophenylhydrazone similar to those used by the Barton and Warkentin groups were 
undertaken as a reference (Scheme 3.3). This was seen as an ideal starting point, allowing the 
various published methods to be compared in terms of efficiency of completing the desired 
conversion. 
 
 
 
 
 
 
 
 
 
 Scheme 3.3 Synthesis of model azoacetate systems. 
4-NP = 4-nitrophenylhydrazine 
4-NP Pb(OAc)4 
N
O
N NO2
O
N
O
N NO2
O
OEt
O
N
OAc
N PNP
R1
R2
N NH PNP
R1
R2
O
R1
R2
172a, Yield = 74% 
172b, Yield = 69% 
172a 
 
172b 
 
171a, Yield = 80% 
171b, Yield = 58% 
170a, R1 + R2 = Cyclohexyl 
170b, R1 = Me, R2 = CO2Et 
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This also allowed an assessment of the effect (if any) of the presence of the 4-nitrophenyl 
group on the stability of the synthesised compounds. The azoacetate derivative of 
cyclohexanone-4-nitrophenylhydrazone 172a was chosen as the starting substrate for studies 
on the transformation from azoacetate to azocarbinol. 
The various methods of transformation of azoacetates to azocarbinols were examined; in 
addition the basic conditions used for the cyclisation of azoacetates were assessed as means 
of achieving the transformation (Table 3.1). This set of experiments produced some 
interesting results. It was found that the published procedures for the isolation of azocarbinols 
did indeed achieve the desired transformation; however in the case of both substrates the 
transformation took place more efficiently using Barton’s base.104  
 
 
 
 
 
 
The MeLi procedure employed was found to give the desired azocarbinol in isolable 
quantities but the parent hydrazone was the major product. Strangely the isolation of the 
hydrazones upon treatment of azoacetates with base is rarely mentioned in the literature. 105 
Base/solvent  Substrate 
172 
173 171 
% Yield % Yield 
MeLi/DCM a 9 42 
b 11 38 
Barton’s base/EtOH a 49 Trace on TLC 
b 58 Trace on TLC 
KCN/n-EtOH a 31 19 
b 42 21 
K2CO3/Acetone a Not isolated 44 
b Not isolated 50 
t-BuOK/THF a Not isolated 30 
b Not isolated 31 
Table 3.1 Action of bases on azoacetates  
172a or b 
 
a, R1 + R2 = Cyclohexyl, b, R1 = Me, R2 = CO2Et 
 
173a or b 
 
171a or b 
 
Base 
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Figure 3.2b 13C NMR spectrum of 173a 
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It was also found that all of the bases used returned the parent hydrazone 171 (spectra 
identical to samples used to prepare azoacetates), either as the exclusive product, or as a by-
product. Perhaps the most interesting results were achieved while using KCN as base. It was 
found that KCN could be used to convert azoacetates 172 to azocarbinols 173 (Table 3.1), 
though not as efficiently as the other reagents tested. As mentioned in chapter 2, KCN is 
known to be a reagent capable of catalysing the transesterification process. Since Barton 
suggests that the Barton’s base transformation of azoacetates observed by his group were 
likely as a result of ethanolysis, it is conceivable that KCN acts in a similar manner. 
Basic spectral comparisons between these compounds, (1H and 13C NMR, Figure 3.2 a, b and 
c) showed that it was possible to isolate the unstable azocarbinols 173 in reasonable yields in 
some cases and that the presence of the nitro group in the system was not detrimental to the 
successful isolation of simple azocarbinols. It was clear from the results of these tests that the 
most promising candidate for further study in the isolation of the azocarbinol as an 
intermediate in the rearrangement of interest would be Barton’s base. The isolation of 
azocarbinols 173 using KCN was a positive result since this procedure has not been 
previously reported. In contrast to KCN, Barton's base is a strong, poorly-nucleophilic, 
neutral base that is often used in cases where electrophilic substitution of DBU or other 
amine bases is a problem. However, since it was suspected to have reacted via a similar 
mechanism to KCN, this result led to some reservations about the likelihood of success of 
using this reagent for the isolation of azocarbinols in the next set of experiments. 
It was hoped that using Barton’s base might favour the azocarbinol products 
analogous to 173a and b under identical conditions. However using Barton’s base resulted in 
the production of the rearrangement product 79 in a similar manner to the previously 
observed results with KCN, with the production of a small quantity of the parent hydrazone 
as by-product 174. The azocarbinol intermediate of interest was not isolated (Scheme 3.4). 
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The Warkentin lithiation procedure was also tested as a means of producing the 
desired azocarbinol.106 However, as expected, the parent hydrazone was found to be the 
major product of the reaction with only trace amounts of the rearrangement product evident 
on TLC. Once again no azocarbinol was isolated. Since Barton’s base was found to be the 
most reliable agent for the generation of azocarbinols but could not be used to isolate the 
desired compound; it seemed evident that the direct isolation of the suspected azocarbinol 
intermediate to the rearrangement product would not be possible.  
3.2.2 Structural studies of N-acylhydrazide 
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Scheme 3.4 Reaction of azoacetate 78 with Barton’s base 
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Figure 3.3 X-Ray crystal structure of N-acylhydrazide 79 
Yield 35 % 
Yield 20 % 
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The N-acyl hydrazide 79 was previously isolated and a crystal structure obtained 
(Figure 3.3).89 In order to obtain a complete set of data for the crystal suitable for publication, 
crystals of 79 were grown from the product of the reaction of Barton’s base with azoacetate 
78 
Crystals suitable for single crystal X-Ray crystallographic determinations of the N-
acylhydrazide 79 were grown in a saturated solution of ethyl acetate : hexane 50:50. The 
substrate molecule was dissolved in the solvent mixture and allowed to stand for 5 days 
undisturbed; slow evaporation was controlled by covering the vessel (clean new test tube) 
with perforated foil. The resulting crystals were colourless blocks. The N-acyl hydrazide 
crystallizes in the orthorhombic system with P212121 (#19) space group with 4 molecules per 
asymmetric unit (Table 3.3). It is this recently collected data that is reported here (appendix I) 
and appears in our current publication (appendix I). 
Table 3.2 Selected bond distances (Å) and angles (O) for N-acylhydrazide 79 with estimated 
standard deviations 
Bond distances (Å) 
N(2)–N(3) 1.3838(14) 
N(1)–O(1)  1.2301(15) 
N(1)–O(2)  1.2359(15) 
C(7)–O(3) 1.2284(16) 
C(7)–C(8) 1.5069(19) 
O(5)–C(13) 1.4539(16) 
Bond angles (O) 
C(6)–N(2)–N(3)  119.73(10) 
C(7)–N(3)–N(2) 120.04(11) 
N(2)–N(3)–C(9) 119.79(10) 
N(3)–C(7)–C(8) 118.13(12) 
O(3)–C(7)–N(3) 119.40(12) 
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Table 3.3 Crystal data and structure refinement for N-acylhydrazide 79. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantity Measurement 
Empirical formula  C14 H19 N3 O5 
Formula weight  309.32 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 (#19) 
Unit cell dimensions a = 10.6723(6) Å  α= 90°. 
 b = 11.7713(7) Å  β= 90°. 
 c = 12.3081(7) Å  γ = 90°. 
Volume 1546.23(15) Å3 
Z 4 
Density (calculated) 1.329 Mg/m3 
Absorption coefficient 0.102 mm–1 
F(000) 656 
Crystal size 1.00 x 1.00 x 0.90 mm3 
Theta range for data 2.39 to 30.50°. 
Index ranges –15<=h<=15, –16<=k<=16, –17<=l<=17 
Reflections collected 36459 
Independent reflections 2661 [R(int) = 0.0293] 
Completeness to theta = 99.7 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9138 and 0.8407 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 2661 / 0 / 275 
Goodness–of–fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0350, wR2 = 0.0892 
R indices (all data) R1 = 0.0360, wR2 = 0.0899 
Largest diff. peak and hole 0.443 and –0.150 e.Å–3 
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Figure 3.4 Mercury view of N-acylhydrazide 79 showing packing relative to the unit cell 
Figure 3.5 Mercury view of N-acylhydrazide 79 showing intermolecular hydrogen bonding 
interactions through the acyl carbonyl and hydrogen from the hydrazide 
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The hydrogen bonding through the ester carbonyl groups of the central N-acylhydrazide and 
nitro groups contribute most to the 3-dimensional packing within the structure of the crystal 
system (Figure 3.6). The interaction of these groups provides stability between the individual 
units within the lattice. 
3.3  Cyclisation of threonyl azoacetates 
The synthesis of azoacetates of N-protected threonyl anilides analogous to those used to 
generate the β-lactams in chapter 2 offered the opportunity to study these systems further. 
Suitable substrates (Cbz-threonyl anilides, 177, Scheme 3.5) for these reactions were 
synthesised using standard peptide chemistry procedures.107 
 
Figure 3.6 Mercury view of N-acylhydrazide 79 showing intermolecular hydrogen bonding 
interactions between the nitro group and ester 
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i a) 2N NaOH, Na2CO3, 0 0 C 4h, b)HCl, yield 93%. ii, aniline, DCC, HOBt, CH2Cl2 yield range 58-68% 
Ar = 177a NH-4-methoxyphenyl, 177b phenyl, 177c 4-chlorophenyl, 177d 3,4-dimethylphenyl. 
 
The synthesis of a number of Z-threonyl alkyl esters was also undertaken. Several of the 
reported literature procedures were examined. After some experimentation it was found that 
the reaction of the amino acid in excess alcohol in the presence of thionyl chloride routinely 
returned the desired esters in good yield (177, Scheme 3.6). 
 
 
 
 
 
 
3.3.1 Cyclisation of Z-threonyl anilides 
As mentioned at the beginning of this chapter the base induced cyclisation of N-
protected threonyl compounds (esters, anilides, peptides and proteins) are known to give a 
mixture of hydantoins and oxazolidinones.  
Ph O NH
O
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O OH
Ph O NH
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ii
Scheme 3.6 Esterification of Z-threonine  
176 178 a-c Yield 38-72% 
a R = Me, b R = Et,  c R = i-Pr. 
 
Scheme 3.5 Synthesis of Cbz-threonyl anilides 
175 
177, Yield 58-68% 
176, Yield 93% 
SOCl2, ROH 
Stirring 48h 
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Although the compounds of interest to us were cyclic derivatives of threonyl based 
azoacetates, a simple Z-threonyl anilide was cyclised in order to have samples for spectral 
comparison to the desired azoacetate based systems (Scheme 3.7). The formation of both 
products is as a result of the base induced abstraction of an acidic proton. 
Efforts were made to synthesise a larger peptide residue with the hope of forming a 
bicyclic system. To that end the Z-Thr-Ser-Gly-OEt tripeptide was synthesised using the 
azide coupling procedure to attach the terminal glycine ethyl ester residue.  
 
 
 
 
 
 
 
 
 
 
Scheme 3.7 Cyclisation of Z-Threonyl anilide to oxazolidinones 179a and hydantoins 180a 
O NH
O Me
OHN
Me
O
N
O Me
H
N
O
OH
OHN
OH
O
NH
Cbz
O Me
Yield 30 % Yield 27 % 177a 179a 180a 
181 182 
183 
184 Not isolated 
Scheme 3.27 Synthesis of Z-Thr-Ser-Gly-OEt 184 tripeptide from Z-Thr-Ser-OEt 181 
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It was hoped that, procedures similar to those that had been successfully employed to cyclise 
the threonyl anilides, could be used to isolate the oxazolidinone derivative of the tripeptide. 
Once this cyclisation had taken place it was planned to employ the Mitsunobu method of 
cyclisation to synthesise the β-lactam through the seryl residue, to give 185. 
 
 
 
 
However the desired oxazolidinone was not isolated after repeated attempts at the base 
induced ring closure. Because several cyclisation products were possible from the Mitsunobu 
cyclisation of the tripeptide without initial formation of the oxazolidinone ring, attempts to 
form the bicyclic ring were abandoned. 
3.3.2 Oxidation of N-protected Threonyl Analogues 
The objective of this step of the synthesis was the development of a method that allowed the 
oxidation of the hydroxy group in threonyl analogues to the corresponding carbonyl, with 
retention of chirality at the carbon adjacent to the newly formed carbonyl. This proved to be 
non-trivial. In a communication published in 1982 Andrew Stachulski of Beecham 
Pharmaceuticals research division remarked108 “The amino acid literature contains 
remarkably little information on the oxidation of serine and threonine side chain to the 
ketonic level.” References since that time to threonyl/seryl side chain oxidation could be 
described as sparse at best, and a comprehensive study on the oxidation in question has never 
been undertaken. Although the oxidations of alcohols to ketones are well known, the 
suitability of these reagents for oxidation of serine and threonine side chain to the carbonyl is 
not well understood. It would seem that the proximity of the amino group to the alcohol has 
an effect on the oxidation process. The literature available, dealt mainly with the oxidation of 
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Scheme 3.28 Planned synthesis of bicyclic β-lactam  
184 185 
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N-protected esters of threonine and serine. The following oxidation procedures were tested in 
an attempt to find the most suitable system.  
1. Chromium based reagents (Jones and PCC procedures) 109 
2. DMSO mediated reagents and analogues (Pfitzner-Moffatt and Swern) 110 
3. Organo-iodine reagents (Dess-Martin111,112 and IBX113,114,115) 
4. Dimethyl-dioxirane116 
Table 3.4 is a summary of the results achieved using the various oxidation procedures, 
showing whether the procedure furnished the desired product, whether the product had 
retained chirality and the range of percentage yields achieved for the various products. It 
should be noted that optical activity was determined by specific rotation measurement. 
Although this technique does not give information on enantiomeric excess, good agreement 
was found between values obtained for products of different oxidation procedures (DMD and 
IBX products). The DMSO mediated Pfitzner-Moffatt procedure, where racemization was 
expected, gave values of   = 0. 
Jones reagent (a chromium based system) worked well for esters of threonine, but not 
so for the analogous anilide compounds, whereas PCC returned the over-oxidised oximate 
product in all cases. The formation of this product was shown to occur through initial 
formation of the desired ketonic threonyl derivative followed by further oxidation to give the 
oximate. If the desired ketonic product is synthesised independently using alternative 
oxidative procedures, and is afterward treated with chromic acid, it results in the production 
of an oximate identical to that produced directly from chromic acid.  
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Substrate 
 Oxidation systems 
Chromium 
Organo-iodine c DMSO d DMD Jones PCC 
Ester a 
178 
Product 186 187 186 186 
N/Te Optically 
active No No Yes No 
Yield % 80-95 59-65 59-81 88-95 
Anilide b 
177  
Product 189 189 187 187 187 
Optically 
active 
No No Yes No Yes 
Yield % 65-77 65-79 58-85 77-90 77-83 
 
a, Esters, 178a Y = OMe, 178b OEt or 178c Oi-Pr; b, Anilides 177a Y = NH-4-methoxyphenyl, 177b 
NH-phenyl, 177c NH-4-chlorophenyl, 177d NH-3,4-dimethylphenyl; c, Organo-iodine = IBX or 
DMP; d, DMSO = Swern or Pfitzner-Moffatt procedure; e, N/T = not tested. 
 
3.3.3 Synthesis and cyclisation of Z-threonyl azoacetate derivatives 
186 and 187, prepared from the above oxidation were further converted to 4-
nitrophenylhydrazones (Scheme 3.8). This was achieved using the procedures utilized 
previously for the ethylacetoacetate and acetoacetanilide analogues.43  
 
 
 
 
 
a, Esters, 186a Y = OMe, 186b OEt or 186c Oi-Pr; b, Anilides 187a Y = NH-4-methoxyphenyl, 187b 
NH-phenyl, 187c NH-4-chlorophenyl, 187d NH-3,4-dimethylphenyl. 
 
Table 3.4 Oxidation of Z-threonyl esters and anilides  
Estersa 178a-c 
Anilidesb 177a-d 
186a-c 
187a-d 
188a-c 
189a-d 
186a-ca 
187a-db 
190a-c 
191a-d 
Scheme 3.8 Synthesis of 4-nitrophenylhydrazones of ketonic threonyl derivatives 
Methanol:AcOH 
90:10 
Yield 56-95% 
Yield 60-75% 
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Similarly, the azoacetates were synthesised using the previously described procedures 
(Scheme 3.9).43 The procedure gave azoacetates in good yields through reaction of the 
hydrazone with a slight excess of lead tetraacetate. 
 
 
 
 
 
 
 
a, Esters, 190a Y = OMe, 190b OEt or 190c Oi-Pr; b, Anilides 191a Y = NH-4-methoxyphenyl, 191b 
NH-phenyl, 191c NH-4-chlorophenyl, 191d NH-3,4-dimethylphenyl. 
 
 
With regard to the cyclisation of the azoacetate derivatives of Z-threonine it was hoped that 
success would be achieved using the ester derivatives as starting materials. This was because 
the substance of most interest to us was the oxazolidinone derivative (195, scheme 3.10). 
Since the ester derivatives do not carry a second nitrogen bearing moiety, the possibility of 
hydantoin formation is excluded. A variety of base/solvent systems (K2CO3/Acetone, t-
BuOK/THF, KCN/Propanol, NaOH/Ethanol) were examined as possible means of cyclising 
the azoacetates to the oxazolidinone, however none of these procedures were successful 
(Scheme 3.10). As was seen with the synthesis of the azocarbinols in some cases the parent 
hydrazone was the only compound that could be isolated in small quantities and identified.  
 
 
 
190a-ca 
191a-db 
192a-c 
193a-d 
Scheme 3.9 Synthesis of azoacetates of 4-nitrophenylhydrazone derivatives 
DCM:AcOH 
90:10 
Pb(OAc)4 
Yield 80-91% 
Yield 77-80% 
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Esters, 192a R = Me, 192b Et or 192c i-Pr; 
 
Fortunately efforts towards the desired cyclisation using the analogous anilide 
compounds as starting materials proved somewhat more successful (Scheme 3.11). The 
azoacetate derivatives of Z-threonyl anilides were subjected to similar conditions to the ester 
derivatives.  
 
 
 
 
 
 
 
a, 193a R = 4-methoxyphenyl, 193b phenyl, 193c 4-chlorophenyl, 193d 3,4-dimethylphenyl; b, products 196a 
and 197a only isolated. 
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Scheme 3.10 Attempted synthesis of oxazolidinones from azoacetate derivatives 
Scheme 3.11 Synthesis of oxazolidinone and hydantoin from azoacetate derivatives 
193a-da 
196b 
197b 
Yield 15% 
Yield 17% 
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It was found that in the case of the 4-methoxyphenyl azoacetate derivative 193 the 
desired oxazolidinone 196a (Figure 3.6a) and hydantoin 197a (Figure 3.6b) could be isolated 
when K2CO3/acetone conditions were employed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.6b 1H NMR spectrum of isolated hydantoin derivative 197a 
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Figure 3.6a 1H NMR spectrum of isolated oxazolidinone derivative 196a 
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The products of this reaction were isolated in low yield, however similar oxazolidinone 196 
and hydantoin 197 products were not isolated from the reactions of the other azoacetate 
derivatives 193b-d in the series.  
The azoacetate substrate 193a was also subjected to Mitsunobu reaction conditions 
(PPh3 and DEAD see chapter 1), a commonly utilised means of cyclisation of β-lactams . The 
substrate is somewhat similar structurally to the threonyl substrates often used in the 
mitsunobu cyclisation. It was hoped that this similarity, coupled with the tendency of the 
azoacetates to undergo deacetylation in basic conditions, might provide a route to a one pot 
synthesis of analogous β-lactams based on the azoacetate precursors. However, the spectra of 
the only product from the azoacetate under Mitsunobu conditions (PPh3, 
Diethylazodicarboxylate a.k.a. DEAD) were identical to those of the hydantoin product 197a 
isolated (scheme 3.12, see also scheme 3.11).  
 
 
 
 
 
 
The formation of the oxazolidinone from the azoacetate does not conclusively prove the role 
of the deactylation process in the formation of the oxazolidinone. However, when all of the 
evidence is taken together it presents a convincing case for the mechanism involving the 
initial deacetylation of the acetate group.  To recap, it has been shown that the KCN/propanol 
reaction conditions can be used to generate an azocarbinol from an azoacetate in a manner 
similar to known procedures from the literature (Barton or Warkentin procedures). It has also 
been shown that azoacetates based on N-protected threonyl anilides react to give products 
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Scheme 3.12 Formation of hydantoin product under Mitsunobu reaction conditions. 
193a 197a Yield 35% 
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analogous to those of simple N-protected threonyl anilides (Scheme 3.13), where reaction 
through the threonyl hydroxy group was established.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both produce hydantoins and oxazolidinones under the action of K2CO3/acetone. 
Scheme 3.13 Synthesis of the same ring systems from threonyl derivatives before and after 
azoacetate formation. 
177a 193a 
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3.4 Conclusion: 
The main focus of this chapter was the investigation into role of the deacetylation 
process in the formation of N-acyl hydrazides as rearrangement products from azoacetates. 
Although conclusive proof has not been established, good evidence to support the theory has 
been gathered and valuable insight into the chemistry of azoacetates has been achieved.  
The deacetylation reaction was successfully adapted as a means of cyclising 
azoacetates derived from threonine. Simple Cbz protected threonyl and seryl peptides are 
known to readily undergo cyclisation through their hydroxy group in basic media to give 
oxazolidinones. The isolation of oxazolidinones products from azoacetates that are 
structurally similar to the basic peptides suggests that the initial step in the cyclisation process 
is the deacetylation of the acetate group. The cyclisation reactions of these compounds are 
novel processes. Over the course of these investigations further examples of heterocyclic 
systems bearing the phenylazo side chain have been synthesised. These novel compounds 
represent members of important biological families of compounds (Chapter 1) carrying 
previously unreported appendages. The syntheses presented in this chapter show these novel 
azoacetates to be valuable precursors in the synthesis of heterocycles. 
The syntheses and chemistry of aryl hydrazones of protected threonyl anilides have 
been previously reported on a relatively limited scale. However, the reactions of these 
compounds with lead tetraacetate to give azoacetates, to date, have not been investigated.  
 
 
 
 
 
 
 117 
Chapter 3: Studies on the deacetylation reactions of azoacetates 
 
3.5 Experimental 
Amino acids were purchased from the Sigma Aldrich chemical company and were used as 
received. All solvents were dried or distilled prior to use. Melting points were determined 
using a Griffin melting point apparatus and are uncorrected. Infrared spectra were recorded 
on a Perkin-Elmer 2000FT-IR spectrometer. NMR spectra were recorded using a Bruker AC 
400 NMR spectrometer operating at 400 MHz for 1H NMR and at 100 MHz for 13C NMR. 
The 1H and 13C NMR chemical shifts (ppm) are relative to TMS and all coupling constants 
(J) are in Hertz (Hz).  
1-cyclohexylidene-2-(4-nitrophenyl)hydrazone) 171a  
Cyclohexanone (0.98 g, 10 mmol.) was dissolved in 10 ml of methanol. To this was added 4-
nitrophenyl hydrazine (1.75 g, 11.5 mmol.)  dissolved in 5 ml acetic acid with stirring over 30 
minutes. The solution was allowed to stir overnight, and the solid precipitate was filtered off. 
An analytical sample was prepared by dissolving a small portion in ethyl acetate and passing 
it through a short column of silica, otherwise the dried product was used as collected. 
Orange-Brown product, (Yield  1.86 g, 80%). 1H-NMR 400 MHz (DMSO-d6) : δ = 1.62-1.58 
(6H, m, 3 x CH2), 2.29-2.27 (2H, m, CH2), 2.46-2.43 (2H, m, CH2), 7.13 (2H, d, ArH, J = 8.8 
Hz), 8.05 (2H, d, ArH, J = 9.2 Hz), 9.96 (1H, s, NH). 13C-NMR 100 MHz (DMSO-d6) : 25.6, 
25.9, 26.9, 27.3, 35.4, 111.3, 126.2, 137.8, 152.2, 155.4;  
ethyl 2-(2-(4-nitrophenyl)hydrazono)propanoate 171b 
Ethyl pyruvate (5 g, 43 mmol.)  was dissolved in 70 ml of methanol. To this was added 4-
nitrophenyl hydrazine (7.25 g, 5.5 mmol.) dissolved in 7 ml acetic acid with stirring over 30 
minutes. The solution was allowed to stir overnight, and the solid precipitate was filtered off. 
the dried product was used as collected. Orange-Brown product, Yield (6.25 g, 58%) .1H-
NMR 400 MHz (DMSO-d6) : δ = 1.27 (3H, t, CH3, J = 6.8 Hz), 2.11 (3H, s, CH3), 4.21 (2H, 
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q CH2, J = 6.8 Hz), 7.36 (2H, d, ArH, J = 9.2 Hz), 8.16 (2H, d, ArH, J = 9.2 Hz), 10.49 (1H, 
s). 
α,α-Dimethylethylacetoacetate-4-nitrophenylhydrazone 
α,α-Dimethylethylacetoacetate (1.58 g 10 mmol.) was dissolved 30 ml of methanol. To this 
was added 4-nitrophenyl hydrazine (1.68 g, 11 mmol.) dissolved in 3 ml acetic acid with 
stirring over 30 minutes. The solution was allowed to stir overnight, and the solid precipitate 
was filtered off. the dried product was used as collected. Orange-Brown product, (Yield 2.25 
g, 77%) .1H-NMR 400 MHz (DMSO-d6) : δ = 1.17 (3H, t, CH3, J = 7.2 Hz), 1.36 (6H, s, 2 x 
CH3), 1.89 (3H, s, CH3), 4.11 (2H, q, CH2, J = 7.2 Hz), 7.18 (2H, d, ArH, J = 9.2 Hz), 8.10 
(2H, d, ArH, J = 9.2 Hz), 9.89 (1H, s, NH); 13C-NMR 100 MHz (DMSO-d6) :14.0, 14.3, 23.5, 
50.5, 60.9, 111.9, 126.2, 138.6, 151.6, 152.1, 175.0;  
Azoacetates 
1-((4-nitrophenyl)diazenyl)cyclohexyl acetate 172a 
The substrate hydrazone 171a (1.28 g, 5.4 mmol.) was dissolved in 20 ml of DCM to which 
was added lead tetra acetate (2.63 g, 5.94 mmol., 1.1 molar excess), a few drops of acetic acid 
were added dropwise to the solution to help dissolve the lead salts, and the solution was 
allowed to stir overnight. The reaction mixture was monitored by TLC to ensure completion 
of the reaction and then washed with (1 x 20 ml) portion of water followed by (1 x 20 ml) 
portion of NaHCO3 5% solution followed by (3 x 20 ml) portion of water. The solution was 
dried and passed through a short silica column to remove any remaining lead salts. The 
column was eluted with 50:50 ethyl acetate:hexane. The solvent was removed and an orange 
oil remained. (Yield 1.12 g, 71%). 1H-NMR 400 MHz (DMSO-d6) : δ = 1.34-1.32 (1H, m, ½ 
CH2), 1.84-1.56 (7H, m, 3½ CH2), 2.17-2.14 (5H, m, CH3 and CH2), 7.78 (2H, d, ArH, J = 
8.8 Hz), 8.36 (2H, d, ArH, J = 8.8 Hz); 13C-NMR 100 MHz (DMSO-d6): 21.7, 21.8, 24.7, 
33.0, 102.5, 123.3, 125.3, 125.3, 148.8, 154.5, 169.3. 
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ethyl 2-acetoxy-2-((4-nitrophenyl)diazenyl)propanoate 172b 
The azoacetate was synthesised using the procedure described for oxidation of cyclohexanol-
4-nitrophenyl hydrazone 
(Yield 1.15 g, 69%).  1H-NMR 400 MHz (DMSO-d6) : δ = 1.18 (3H, t, CH3, J = 7.2 Hz), 1.73 
(3H, s, CH3), 2.18 (3H, s, CH3), 4.21 (2H, q, CH2, J = 7.2 Hz), 7.87 (2H, d, ArH, J = 8.8 Hz), 
8.40 (2H, d, ArH, J = 8.8 Hz). 
ethyl 3-acetoxy-2,2-dimethyl-3-((4-nitrophenyl)diazenyl)propanoate 78 
The azoacetate was synthesised using the procedure described for oxidation of Cyclohexanol-
4-nitrophenyl hydrazone 
(Yield 2.63 g, 69%).  1H-NMR 400 MHz (DMSO-d6) : δ = 1.07 (3H, t, CH3, J = 8.8 Hz), 
1.26 (6H, s, 2 x CH3), 1.89 (3H, s, CH3), 2.11 (3H, s, CH3), 4.03-4.00 (2H, m, CH2), 7.87 
(2H, d, ArH, J = 9.2 Hz), 8.40 (2H, d, ArH, J = 9.2 Hz). 
Synthesis of 1-((4-nitrophenyl)diazenyl)cyclohexanol 173a (procedure 1, Barton’s Base)  
The substrate azoacetate 172a (0.291 g, 1 mmol.) was dissolved in 3 ml of ethanol and stirred 
at room temperature under argon. To this was added Barton’s base (0.171 g, 1 mmol.) and the 
reaction mixture was allowed to stir for overnight under an argon atmosphere. The solution 
was diluted with 20 ml of DCM, this was washed with (2 x 20 ml) portions of cold 5% HCl 
followed by (2 x 20 ml) portions of cold water. The organic extracts were dried over MgSO4 
and the solvent was removed under vacuum at room temperature. TLC testing of the 
remaining oil showed the presence of some starting material and a new compound. The oil 
was separated by careful chromatography using a gradient of solvents (Ethyl acetate:Hexane, 
10:90 -> 90:10). The product was recovered as an orange solid. (Yield 0.1 g, 40%, 25% 
starting material also recovered). 
1H-NMR 400 MHz (DMSO-d6) : δ = 1.35- 1.31 (1H, m, ½ CH2), 1.56-1.53 (2H, m, CH2), 
1.64-1.56 (5H, m, 2½ CH2), 1.77-1.84 (2H, m, CH2), 5.98 (1H, br s, OH), 7.81 (2H, d, ArH, J
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= 8.4), 8.37 (2H, d, ArH, J = 8.8); );  13C-NMR 100 MHz (DMSO-d6): 22.1, 25.3, 34.8, 96.1, 
123.2, 125.3, 148.4, 155.0. 
Ethyl-2-hydroxy-2-((4-nitrophenyl)diazenyl)propanoate 173b (procedure 1) 
2-Acetoxy(4-nitro-phenylazo)- propionic acid ethyl ester (1 g, 3.2 mmol.) was dissolved in 9 
ml of ethanol and stirred at room temperature under argon. To this was added Barton’s base 
(0.513 g, 3 mmol.) and the reaction mixture was allowed to stir for overnight under an argon 
atmosphere. The solution was diluted with 50 ml of DCM, this was washed with (2 x 25 ml) 
portions of cold 5% HCl followed by (2 x 25 ml) portions of cold water. The organic extracts 
were dried over MgSO4 and the solvent was removed under vacuum at room temperature. 
TLC testing of the remaining oil showed the presence of some starting material and a new 
compound. The oil was separated by careful chromatography using a gradient of solvents 
(Ethyl acetate:Hexane, 10:90 -> 90:10). The product was recovered as an unstable orange oil. 
(Yield 0.50 g, 58%, 17% starting material also recovered). 
1H-NMR 400 MHz (DMSO) 1.19 (3H, t, CH3, J = 7.2), 1.62 (3H, s, CH3), 4.17 (2H, q, CH2, J 
= 5.2), 7.38 (1H, br s, OH), 7.86 (2H, d, ArH, J = 9.2), 8.41 (2H, d, ArH, J = 9.2); 13C-NMR 
100 MHz (DMSO-d6): 14.4, 23.1, 61.6, 97.2, 123.5, 125.5, 149.1, 154.3, 170.1. 
Synthesis of 1-((4-nitrophenyl)diazenyl)cyclohexanol 173a (procedure 2, Methyl lithium)  
The substrate azoacetate 172a (0.873 g, 3 mmol.) was dissolved in 30 ml of anhydrous ether 
cooled to -10 0C using a bath of ice and salt and stirred under argon. To this was added CH3Li 
(6.6 mmol., 3.6 ml of a 1.84M solution in hexane) over 10 minutes. The solution was allowed 
to stir for a further 30 minutes and cold saturated ammonium chloride (30 ml) was added 
slowly. The organic layer was separated and the aqueous layer extracted with (2 x 20 ml) 
portions of ether. The combined organic extracts were dried over MgSO4 and evaporated 
without heating. TLC of the remaining oil showed the presence of two compounds and a 
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small amount of starting material. The components were separated using careful 
chromatography (Yield 0.07 g, 9% ).  
Spectral data of the azocarbinol identical to that acquired from Barton procedure. 
 
ethyl 2-hydroxy-2-((4-nitrophenyl)diazenyl)propanoate 173b (procedure 3, KCN) 
2-acetoxy(4-Nitro-phenylazo)-propionic acid ethyl ester  (1 g, 3.2 mmol.) was dissolved in 30 
ml of ethanol and stirred at room temperature under argon. To this was added KCN (0.27 g, 
4.1 mmol.) and the reaction was monitored by TLC. A new spot was seen to develop over the 
course of several hours, after 72 hours some starting material remained. The solution was 
diluted with 50 ml of DCM, this was washed with (5 x 25 ml) portions of cold water. The 
aqueous phase was poured directly into a ready prepared solution of sodium hypochlorite 
along with all of the glassware. The solvent was slowly blown off of the solution in the fume 
cupboard using nitrogen to give an orange oil. The oil was separated into its component parts 
by careful chromatography using a gradient of solvents (Ethyl acetate:Hexane, 10:90 -> 
90:10). The product was recovered as an unstable orange oil. (Yield 0.36 g, 42%) 
Spectral data identical to that of sample prepared using Barton Base procedure. 
N-acyl hydrazide derivative as rearrangement product  using KCN/Ethanol 79 
Synthesis of ethyl 2-(1-acetyl-2-(4-nitrophenyl)hydrazinyl)-2-methylpropanoate 79 
The azoacetate derivative 78 (1 g, 2.8 mmol) was dissolved in hot EtOH (40 ml) to which of 
potassium cyanide (0.24 g, 3.7 mmol) was added. The solution was allowed to reflux 
overnight, before being evaporated to dryness. Water (100 ml) was added to the reaction 
vessel and this was extracted with EtOAc : EtO2 (15:85). The combined extracts were dried 
over magnesium sulfate and upon evaporation to a reduced volume a pale brown solid 
precipitated. The precipitate was filtered off and washed with petroleum ether and dried. 
(Yield 0.31 g, 35 %); mp 172-174 ºC; 1H NMR (400 MHz, DMSO-d6): δ = 1.23 (3H, t, CH3, 
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J = 6.8), 1.27 (3H, s, CH3), 1.36 (3H, s, CH3), 1.88 (3H, s, CH3), 4.16-4.06 (2H, m, CH2), 
6.90 (1H, d, ArH
 
, J = 7.6), 7.15 (1H, d, ArH, J = 7.6), 8.11 (1H, d, ArH, J = 8.0), 8.17 (1H, 
d, ArH, J = 7.6), 9.58 (1H, s, NH); anal. Calcd. for C13H19N3O5 requires C, 54.36; H, 6.14; N, 
13.58; found C, 54.53; H, 6.29; N, 13.51. 
Azocarbinols  
Synthesis of Barton’s Base, 2-t-butyl-1,1,3,3-tetramethyl guanidine 
Barton’s original procedure was followed, although triphosgene was substituted for 
phosgene for safety reasons, also the quantity of triphosgene was reduced to 1/3. 
Triphosgene (16.576 g, 0.056 mol) was dissolved in 50 ml of cold dry toluene. To this was 
added dropwise with stirring N,N,N’,N’-tetra methyl urea (10 g, 0.086 Mole) dissolved in 40 
ml of dry benzene. The solution was allowed to stir for 1 hour after which the solvent was 
removed by distillation between 30-35 0C at reduced pressure. The white crystalline 
Vilsmeier salt that remained was taken up in 30 ml of acetonitrile and cooled to 00C while 30 
ml of t-butylamine was being added. Next the mixture was refluxed for 18 hours cooled and 
the solvent removed at 30 0C under reduced pressure. The gummy residue that remained was 
triturated repeatedly with ether (4 x 50 ml) the remaining solid was treated slowly and 
carefully with 80 ml of 25% NaOH solution, this was then extracted with ether and the 
combined extracts dried over K2CO3. The solvent was removed slowly at 35 0 C under house 
vacuum. The yellow oil that remained was distilled under vacuum on the Kughlerohr 
instrument at 75 0 C to give a transparent oil which was stored under argon and refrigerated. 
(Yield 0.53 g, 55 %);1H-NMR 400 MHz (DMSO-d6) : δ = 0.45 (9H, s, 3x CH3), 1.88 (12H, s, 
4 x CH3) 
N-acyl hydrazide derivative as rearrangement product using Barton’s base 78 
Synthesis of ethyl 2-(1-acetyl-2-(4-nitrophenyl)hydrazinyl)-2-methylpropanoate 78 
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The substrate azoacetate 215 (702 mg, 2 mmol.) was dissolved in 10 ml of ethanol and the 
reaction vessel flushed with nitrogen. To which was added of Barton’s base (342 mg, 2 
mMol) by syringe through a rubber septum. The reaction was stirred for 1 hour before TLC 
testing showed the consumption of all starting material and the emergence of a new spot. 
After 2 hours 50 ml of DCM was used to dilute the reaction mixture. The entire solution was 
washed with 20 ml of cold 5% HCl and 20 ml of cold water and the organic phase dried and 
the solvent removed under vacuum to give an orange solid. (Yield 0.23 g, 37 %); 
Spectra identical to those from KCN/ethanol procedure 
N-acyl hydrazide derivative as rearrangement product of anilide azoacetate 70f 
Yield  (0.14 g, 16 %); mp 195-197 ºC 1H NMR (400 MHz, DMSO-d6): δ = 1.49 (3H, s, CH3), 
1.53 (3H, s, CH3), 1.92 (3H, s, CH3), 6.96 (1H, s br, ArH),7.07 (1H, t, ArH, J = 7.2), 7.33-
7.26 (3H, m, ArH), 7.61 (2H, d, ArH, J = 7.6), 8.15 (2H, s br, ArH), 9.06 (1H, s br, NH), 
9.48 (1H, s br, NH); 13C NMR (100 MHz, DMSO-d6) 21.7, 22.9, 24.3, 65.6, 110.5 (d, J = 
222), 120.8, 123.5, 126.2 (d, J = 69), 128.3, 138.7, 138.9, 154.2, 171.8, 172.8. IR (KBr) 
3338, 3288, 1647, 1592, 1522, 1329, 1272, 1108, 750, 695 cm-1. 
 
Benzyloxycarbonyl-threonine (Cbz-Threonine) 176 
To a solution of L-threonine 175 (11.91g, 0.1 mol) in 50 mls of 2N NaOH was added 
alternately benzyl chloroformate (14.5 mls. 17.32 g, 0.101 mol) and Na2CO3 (65 mls, 0.13 
mol) in 10 roughly equal aliquots over 30 minutes. The solution was allowed to stir for 4 
hours and then extracted twice with 20 ml portions of ether. The aqueous phase was cooled to 
0o C and conc. HCl was added dropwise to the solution to pH 3-4. The oil that separated was 
transferred to ethyl acetate (50 ml) and the aqueous phase was then saturated with NaCl and 
extracted with a further 50 ml of ethyl acetate. The organic extracts were combined and dried 
over MgSO4. The solvent was removed and a small potion of the oil that remained was 
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removed, cooled and scratched. The solid collected was used to seed the remaining oil, which 
crashed out overnight. (Yield 23.53 g, 93%). M.p. 101-103 
Spectra consistent with sample purchased from sigmaaldrich® 
Z-Threonyl-4-methoxy-anilide, (benzyl-3-hydroxy-1-(4-methoxyphenylamino)-1-oxobutan-
2-ylcarbamate) 177a 
Cbz-L-Threonine 176 (10 g, 0.040 mol), 4-methoxy aniline (4.92 g, 0.040 mol) and 1-
hydroxy-benzotriazole monohydrate (6.12 g, 0.040 mol) were finely ground and dissolved in 
150 ml of dichloromethane. The solution was cooled to 0o C in an ice bath and finely ground 
dicyclohexylcarbodiimide (8.2 g, 0.040 mol) was added. The solution was allowed to stir 
overnight at room temperature and the N,N’-dicyclohexylurea that precipitated was filtered 
from the solution and washed with 50 ml of dichloromethane. The combined organic extracts 
were washed with 50 ml of saturated NaHCO3 solution followed by 50 ml of 10% citric acid 
solution, another 50 ml of saturated NaHCO3 solution, and finally 50 ml of water. The 
organic extracts were dried and passed through a 4 cm silica plug to remove a baseline 
impurity (TLC) and eluted using 70:30 Ethyl acetate: Hexane. The solvent was removed in 
vacuo, and the residue collected. (Yield 9.74 g, 68%) .1H-NMR 400 MHz (DMSO-d6) : δ = 
1.12 (3H, d, CH3, J = 6.0 Hz), 3.72 (3H, s, OCH3), 4.04-4.00 (1H, m, CH), 4.11- 4.09 (1H, m, 
CH), 4.95 (1H, d, OH, J = 6.0 Hz), 5.09 (2H, s, CH2), 6.89 (2H, d, ArH, J = 8.8 Hz), 7.08 
(1H, d, NH, J = 8.4 Hz), 7.32 (5H, m, ArH), 7.54 (2H, d, ArH, J = 8.8 Hz), 9.82 (1H, s, NH). 
13C-NMR 100 MHz (DMSO-d6) : 20.6, 55.5, 61.7, 65.9, 67.2, 114.2, 121.2, 128.0, 128.2, 
128.7, 132.4, 137.3, 155.6, 156.5, 169.1. IR (KBr)    3361, 1683, 1588, 1510, 1239, 1071 cm-
1
. 
Z-Threonyl-4-chloro anilide, (benzyl-1-(4-chlorophenylamino)-3-hydroxy-1-oxobutan-2-
ylcarbamate) 177c  
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This coupling was carried out using the same procedure as that used for Z-Thr-N-Ph-4-OMe, 
except that the aniline used was 4-Chloroaniline 
(Yield 8.69 g, 60%). 
1H-NMR 400 MHz (DMSO-d6) : δ = 1.14 (3H, d, CH3, J = 6.0 Hz), 4.04-4.03 (1H, m, CH), 
4.14-4.11 (1H, m, CH), 4.94 (1H, d, OH, J = 6.0 Hz), 5.07 (2H, s, CH2), 7.14 (1H, d, NH, J = 
8.4 Hz), 7.38-7.33 (7H, m, ArH), 7.66 (2H, d, ArH, J = 8.4 Hz), 10.12 (1H, s, NH), 13C-NMR 
100 MHz (DMSO-d6) : 20.6, 61.8, 66.0, 67.1, 121.2, 127.3, 128.0, 128.2, 128.7, 129.0, 137.3, 
138.2, 156.6, 169.8. IR (KBr) 3280 2360, 1692, 1649, 1536, 1515, 1242, 1037, 696 cm-1. 
Z-Threonyl-3,4-dimethyl anilide, (benzyl-1-(3,4-dimethylphenylamino)-3-hydroxy-1-
oxobutan-2-ylcarbamate) 177d 
This coupling  was carried out using the same procedure as that used for Z-Thr-N-Ph-4-OMe, 
except that the aniline used was 3,4-Dimethylaniline. 
(Yield 8.26 g, 58%). 1H-NMR 400 MHz (DMSO-d6) : δ = 1.12 (3H, d, CH3, J = 5.6 Hz), 2.16 
(3H, s, CH3), 2.18 (3H, s, CH3), 4.02 (1H, s, CH), 4.10-4.08 (1H, m, CH), 4.94 (1H, s br, 
OH), 5.07 (2H, s, CH2), 7.05 (1H, d, ArH, J = 8.0 Hz), 7.10 (1H, d, NH, J = 8.4 Hz), 7.35 
(7H, m, ArH), 9.80 (1H, s, NH). 13C-NMR 100 MHz (DMSO-d6) : 19.1, 20.0, 20.6, 61.7, 
65.9, 67.2, 117.2, 120.9, 128.0, 128.2, 128.7, 129.9, 131.4, 136.6, 137.0, 137.4, 156.5, 169.3. 
IR (KBr) 3281, 2360, 1696, 1654, 1537, 1243, 1040, 696 cm-1. 
Z-Threonyl-anilide (benzyl-3-hydroxy-1-oxo-1-(phenylamino)butan-2-ylcarbamate) 177b 
This coupling was carried out using the same procedure as that used for Z-Thr-N-Ph-4-OMe, 
except that aniline was used. 
(Yield 7.87 g, 60%); 1H-NMR 400 MHz (DMSO-d6) : δ = 1.13 (3H, d, CH3, J = 6.4 Hz), 
4.05-4.01 (1H, m, CH), 4.14-4.11 (1H, m, CH), 4.92 (1H, d, OH, J = 6.0 Hz), 5.08 (2H, s, 
CH2), 7.06-7.04 (1H, m, ArH), 7.10 (1H, d, NH, J = 8.8 Hz), 7.39-7.30 (7H, m, ArH), 7.62 
(2H, d, ArH, J = 7.6 Hz), 9.96 (1H, s, NH); 13C-NMR 100 MHz (DMSO-d6) : 20.2, 61.4, 
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65.6, 66.8, 119.2, 123.3, 127.6, 127.8, 128.3, 128.7, 136.9, 138.8, 156.7, 169.2; IR (KBr) 
3291, 1688, 1650, 1537, 1520, 1240, 1045, 698 cm-1. 
Esters of threonine 
Methyl-2-(benzyloxycarbonylamino)-3-hydroxybutanoate 178a (Z-Thr-OMe) 
To a solution of Z-threonine 176 (5.83 g, 23 mmol) in methanol (100 cm3), was added thionyl 
chloride (2.1 cm3, 28.8 mmol) dropwise over 30 min and the mixture was allowed to stir for 
20 h. After TLC showed consumption of the starting material, the solvent was removed and 
the remaining oil taken up in 30 cm3 of CHCl3. The organic solution was washed alternately 
with saturated NaHCO3 and brine (3 x 10 cm3 each). The solution was dried over MgSO4 and 
the solvent was removed under reduced pressure. The white solid product was dried and 
collected. (Yield 4.43 g 72%); mp 77-79 0C; 1H-NMR 400 MHz (CDCl3) : δ = 1.25 (3H, d, 
CH3, J = 6.4 Hz), 2.72 (1H, s, OH), 3.75 (3H, s, CH), 4.34-4.32 (2H, m, 2 x CH), 5.13 (2H, s, 
CH2), 5.87-5.77 (1H, m, NH), 7.37-7.32 (5H, m, ArH); IR (KBr) 3450, 3314, 1715 cm-1. 
Ethyl-2-(benzyloxycarbonylamino)-3-hydroxybutanoate 178b (Z-Thr-OEt) 
(Yield 3.33 g 51%); mp 29-31 0C; 1H-NMR 400 MHz (CDCl3) : δ = 1.19-1.13 (6H, m, 2 x 
CH3), 2.70 (1H, s, OH), 4.11 (2H, q, CH2, J = 7.2), 4.23-4.20 (2H, m, 2 x CH), 5.03 (2H, s, 
CH2), 5.75-5.72 (1H, m, NH), 7.27-7.19 (5H, m, ArH); IR (KBr) 3401, 1721 cm-1. 
Isopropyl-2-(benzyloxycarbonylamino)-3-hydroxybutanoate 178b (Z-Thr-Oi-Pr) 
(Yield 6.82 g 38%); mp 37-39 0C; 1H-NMR 400 MHz (CDCl3) : δ = 1.21-1.07 (9H, m, 3 x 
CH3), 4.01-3.98 (1H, m, CH), 4.08-4.03 (1H, m, CH), 4.75 (1H, d, OH, J = 6.8), 4.95-4.88 
(1H, m, CH), 5.06 (2H, s, CH2), 7.15 (1H, d, NH, J = 8.4), 7.43-7.31 (5H, m, ArH); IR (KBr) 
3345, 1721 cm-1. 
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Oxidation of Z-Threonyl anilides and esters 
Synthesis of 1-hydroxy-1,2-benziodoxal-3(1H)-one-1-oxide (IBX)  
2-iodobenzoic acid (50g, 0.2 moles) was added to a solution of oxone (181 g, 0.29 moles) in 
650 ml of distilled water. The reaction mixture was carefully and slowly heated to 73 0C (at 
no time was the reaction temperature allowed to leave the 70-75 0C range) and the reaction 
was stirred for 3 hours at this temperature. The solution was allowed to settle and cooled to 0 
0C for 4-5 h; with occasional agitation (No agitation for the last 90 minutes) the solution was 
filtered through a sintered glass funnel and rinsed with (6 x 100 ml) portions of water 
followed by (2 x 100 ml) portions of acetone. The white crystalline product was dried under 
vacuum over three days Yield 85 %. The mother liquor was allowed to sit and filtered for 
solids several times before disposal. All oxidising materials collected were treated with 
NaSO3 and NaOH before disposal. (Yield 47.6 g 85%); 
IBX oxidation of (Z-Thr-N-Ph-OMe 177b) 
Synthesis of benzyl-1-(4-methoxyphenylamino)-1,3-dioxobutan-2-ylcarbamate 187a 
The substrate 177a (0.716 g, 2.0 mmol.) was dissolved in 20 ml of ethyl acetate containing 4 
ml of DMSO, to this was added IBX(1.67 g, 6.0 mmol.). The mixture was refluxed for 3 
hours after which TLC testing showed no remaining starting material. The reaction mixture 
was allowed to cool and the Excess IBX and IBA by-product were filtered off. The filtrate 
was washed with (3 x 20 ml) portions of water and the solvent was removed under vacuum to 
leave a brown/yellow oily residue. The residue was passed through a short column of silica 
eluted with 50:50 ethyl acetate:hexane and the product 187a was recovered as a white solid. 
(Yield 0.43 g, 61%); mp 130-133 ºC; 1H-NMR 400 MHz (DMSO-d6) : δ = 2.23 (3H, s, CH3), 
3.73 (3H, s, OCH3), 5.06 (1H, d, CH, J = 8.0 Hz) 5.10 (2H, s, CH2) 6.91 (1H, d, ArH, J = 8.8 
Hz) 7.37 (5H, m, ArH) 7.51 (2H, d, ArH, J = 9.2 Hz) 7.96 (1H, d, NH, J = 8.4 Hz) 10.28 (1H, 
s, NH)  13C-NMR 100 MHz (DMSO-d6) :27.3, 55.5, 66.1, 66.3, 114.3, 121.3, 128.1, 128.2, 
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128.7, 131.9, 137.1, 156.0, 156.3, 164.6, 202.1; IR (KBr): 3311, 3219, 1701, 1685, 1640, 
1529, 1499, 1238, 1055, 697 cm-1.  -6.6. 
Dess-Martin Periodinane oxidation of (Z-Thr-N-Ph-OMe 177a) Method 1 
Synthesis of benzyl-1-(4-methoxyphenylamino)-1,3-dioxobutan-2-ylcarbamate 187a 
The substrate 177a (0.79 g, 2.23 mmol.)  in 10 mls of DCM was added to a stirred solution of 
Dess-Martin Periodinane (1.05g, 2.47 mmol.) in 10 mls of DCM and 1 ml of pyridine under 
argon. The solution was allowed to stir for 72 hours after which TLC showed the formation 
of some product. The solution was diluted with 50 mls of diethyl ether, filtered to remove any 
solid and washed with (5 x 10 ml) portions of 5% NaOH. 10 ml NaHCO3 and 10 ml water. 
The ether layer was dried and evaporated to a small volume, and then separated by 
chromatography. (Yield 0.38 g, 48%) product 187a and 29% starting material. 
Product had identical spectra to that prepared using IBX 
Dess-Martin Periodinane oxidation of (Z-Thr-N-Ph-OMe 177a) Method 2 
Synthesis of benzyl-1-(4-methoxyphenylamino)-1,3-dioxobutan-2-ylcarbamate 187a 
The substrate 177a (0.79 g, 2.23 mmol.) in DCM (10 mls) was added to a stirred solution of 
Dess-Martin Periodinane (1.05 g, 2.47 mmol.) in DCM (10 mls). The solution was allowed to 
stir for 6 hours while DCM (10 ml pre-shaken with water) was added dropwise. TLC 
monitoring showed the formation of product and consumption of the starting material. The 
solution was diluted with of diethyl ether (50 mls), filtered to remove any solid and washed 
with a (5 x 10 ml portions) of 5% NaOH. 10 ml NaHCO3 and 10 ml water. The ether layer 
was dried and evaporated to a small volume, (Yield 0.51 g, 66%) product 291a recovered. 
Product had identical spectra to that prepared using IBX 
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Generation of dimethyldioxirane  
Into a 500 ml three necked round bottomed flask fitted with a powder addition funnel and 
connected a cooled receiving vessel (Acetone and Liquid N2) with two additional cold traps 
(Acetone and Liquid N2 / Liquid N2) was added  water (35 ml), acetone (27.5ml) and 
NaHCO3 ( 24 g). The system was cooled to 0 0C and placed under vacuum before the addition 
over 30 min of Oxone (2KHSO5.KHSO4.K2SO4) (45g) was commenced. When the addition 
of the Oxone was complete the system was placed under a gentle stream of nitrogen for 1 
hour. The fractions of yellow volatile liquid collected in the receiving vessel and the first cold 
trap were combined and used immediately.  
Dimethyldioxirane oxidation of (Z-Thr-N-Ph-4-OMe 177a) 
Synthesis of benzyl-1-(4-methoxyphenylamino)-1,3-dioxobutan-2-ylcarbamate 187a 
The substrate 177a (0.5 g, 1.4 mMol) were dissolved in the acetone and stirred. The freshly 
prepared dimethyldioxirane solution was added dropwise over 1 hour with the progress of the 
reaction monitored by TLC every 10 minutes. When no more traces of starting material were 
detected the addition of the DMD solution was ceased (17 mls of solution required). The 
reaction was allowed to stir for a further hour before 1 ml of isopropyl alcohol was added to 
the solution to quench any excess DMD (left over DMD solution also quenched with excess 
DMD). The solvent was removed under vacuum and the solid 187a remaining was collected 
(Yield 0.36 g, 73%).  
Product had identical spectra to that prepared using IBX 
 
Moffatt oxidation of (Z-Thr-N-Ph-4-OMe 177a) 
Synthesis of benzyl-1-(4-methoxyphenylamino)-1,3-dioxobutan-2-ylcarbamate 187a 
The substrate 177a (0.358 g, 1 mmol.) was dissolved under nitrogen in 8 ml of anhydrous 
ethyl acetate containing 0.7 ml anhydrous DMSO. To this was added DCC (0.447 g, 2.17 
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mmol.) and H3PO4 (0.078 g, 0.8 mmol., (260µL of a 3.12M solution in ether)). After 2.5 
hours the reaction mixture was treated with 1 ml of water containing two drops of acetic acid 
in order to hydrate the excess DCC. The reaction was allowed to stir overnight under a slow 
stream of nitrogen. The solids (DCU and DCC) were filtered off and the filtrate diluted with 
water and extracted twice with ethyl acetate (10 ml). The extracts were washed with water to 
remove the DMSO, dried over MgSO4, and concentrated to dryness. The product 187a was a 
white solid. (Yield  0.30 g, 88 %). 
Product had identical spectra to that prepared using IBX except  = 0.1. 
 
Preparation of Pyridinium chlorochromate (PCC) 
Concentrated HCl (1.84 ml, 0.022 mole, 12 N) was added to cold pyridine (1.6 ml) with 
constant stirring. The solution was cooled to 0 0C in an ice-bath and added dropwise to 
Chromium trioxide (2 g, 0.02 mol.) with vigorous stirring. The orange Pyridinium 
chlorochromate formed immediately and was filtered from the solution and placed between 
filter papers and dried in a desiccator under vacuum. (Yield 3.65 g, 89%) mp 204-205 0C. 
Pyridinium chlorochromate oxidation of (Z-Thr-N-Ph-4-OMe 177a) 
Synthesis of benzyl-2-(4-methoxyphenylamino)-2-oxoacetylcarbamate 189a 
The substrate (0.716 g, 2 mmol.) was added to a stirred solution of Pyridinium 
chlorochromate (0.43 g, 2 mmol.) in 10 mls of chloroform. The progress of the reaction was 
monitored by TLC, when no starting material remained 10 mls of ether was added to the 
reaction vessel and the entire mixture was passed through a previously prepared short column 
(10 cm x 2 cm) and eluted with 50:50 ethyl acetate:hexane. If no chromium baseline spot 
persisted on TLC the solution was evaporated and the product collected. Occasionally a 
passing through a second short column was necessary. (Yield 0.34, g 55%); 1H-NMR 400 
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MHz (CDCl3): δ = 3.59 (3H, s, CH3), 5.07 (2H, s, CH2), 6.71 (2H, d, ArH, J = 8.8 Hz), 7.25-
7.18 (5H, m, ArH), 7.35 (2H, d, ArH, J = 8.8 Hz), 8.82 (1H, s, NH), 9.35 (1H, s, NH).  
Preparation of Jones reagent 
Jones reagent was prepared by dissolving chromium trioxide (CrO3) (26.72 g, 0.26 Mol)  in 
23 ml of concentrated sulphuric acid, and then diluting the mixture to 100 ml with water.  
Jones oxidation of (Z-Thr-N-Ph-4-OMe 177a) 
Synthesis of benzyl-2-(4-methoxyphenylamino)-2-oxoacetylcarbamate 189a 
The substrate  (1.5 g, 4.1 mMol) was dissolved in 50 ml of acetone, Celite 545 filtering aid 
(diatomaceous earth) was added in order to aid with removal of the reduced Chromium salts 
upon formation. Jones reagent (2.0 ml, 1.1 molar excess) was added dropwise with stirring at 
room temperature. The mixture was allowed to stir overnight after which time the now green 
solution was treated with one ml of isopropyl alcohol, the solution was allowed to stir for a 
further hour. The solution was then gravity filtered through a fresh portion of Celite, this 
process was repeated with the filtrate before the solvent was removed under vacuum. The 
residue was taken up in 20 ml of ethyl acetate and washed with consecutive 20 ml portions of 
10% NaHCO3, and water. The organic portion was dried over MgSO4, and passed through a 
previously prepared short column (10 cm x 2 cm) and eluted with 50:50 ethyl acetate:hexane. 
After the removal of the solvent a waxy solid remained. (Yield 0.63, g 50%) 
Product had identical spectra to that prepared using PCC 
Jones oxidation of (Z-Thr-OMe 178a) 
Methyl-2-(benzyloxycarbonylamino)-3-oxobutanoate 186a 
Z-Thr-OMe 178a (1.02 g, 3.8 mmol) was dissolved in acetone to which was added Celite 545 
filtering agent (0.5 g), and the suspension was cooled to 0 0C. 1 cm3 of Jones reagent 
(prepared as previously described) was added dropwise over 10 min. After 30 min stirring a 
further 2 cm3 portion of Jones reagent was added all at once to the reaction vessel. After 4 h 
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stirring TLC monitoring showed the total consumption of the starting material and the excess 
oxidant was quenched by stirring with excess i-PrOH for 30 min. The solution was then 
gravity filtered through a fresh portion of Celite, this process was repeated with the filtrate 
before the solvent was removed under vacuum. The residue was taken up in 20 ml of ethyl 
acetate and washed consecutive 20 ml portions of 10% NaHCO3, and water. The organic 
portion was dried over MgSO4, and passed through a previously prepared short column (10 
cm x 2 cm) and eluted with 50:50 ethyl acetate:hexane. (Yield 0.78 g 74%); transparent 
yellow oil; 1H-NMR 400 MHz (CDCl3) : δ = 2.37 (3H, s, CH3), 3.81 (3H, s, OCH3), 5.16-
5.12 (3H, m, CH and CH2), 6.12 (1H, d, NH, J = 6.4), 7.38-7.32 (5H, m, ArH);  
Ethyl-2-(benzyloxycarbonylamino)-3-oxobutanoate 186b 
(Yield 0.9 g 84%); transparent pale yellow oil; 1H-NMR 400 MHz (CDCl3) : δ = 1.29 (3H, 
m, CH3), 2.35 (3H, s, CH3), 4.26 (2H, m, CH2), 5.16-5.11 (3H, m, CH and CH2), 6.14 (1H, d, 
NH, J = 6.8), 7.37-7.31 (5H, m, ArH);  
Isopropyl-2-(benzyloxycarbonylamino)-3-oxobutanoate 186c 
(Yield 0.9 g 90%); transparent yellow oil; 1H-NMR 400 MHz (CDCl3) : δ = 1.29-1.24 (6H, 
m, 2 x CH3), 2.36 (3H, s, CH3) 4.01-3.98 (1H, m, CH), 5.11-5.06 (4H, m, 2 x CH and CH2), 
6.09 (1H, d, NH, J = 6.8), 7.36-7.31 (5H, m, ArH);  
 
Hydrazones of oxidised Z-threonyl anilides and esters 
Benzyl-1-(4-methoxyphenylamino)-3-(2-(4-nitrophenyl)hydrazono)-1-oxobutan-2-
ylcarbamate 191a 
The substrate (3.56 g, 10 mmol.) was dissolved 30 ml of methanol. To this was added 4-
nitrophenyl hydrazine (1.68 g, 11 mmol.) dissolved in 5 ml acetic acid with stirring over 30 
minutes. The solution was allowed to stir overnight, and the solid precipitate was filtered off. 
The dried product was used as collected. Yellow solid product, (Yield 2.75 g, 60%). 1H-NMR 
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400 MHz (DMSO-d6) : δ = 1.99 (3H, s, CH3), 3.73 (3H, s, OCH3), 5.01 (1H, d, CH, J = 8.4 
Hz), 5.09 (2H, s, CH2), 6.90 (2H, d, ArH, J = 9.2 Hz), 7.18 (2H, d, ArH, J = 9.2 Hz), 7.40-
7.31 (5H, m, ArH), 7.51 (2H, d, ArH, J = 8.8 Hz), 7.90 (1H, d, NH, J = 8.4 Hz), 8.05 (2H, d, 
ArH, J = 9.2 Hz), 10.06 (1H, s, NH), 10.09 (1H, s, NH); 13C-NMR 100 MHz (DMSO-d6): 
14.0, 55.1, 61.4, 65.7 111.7, 113.8, 120.9, 125.7, 127.7, 127.8, 128.3, 131.8, 136.9, 138.5, 
146.2, 151.3, 155.4, 156.0, 166.6;  
Benzyl-3-(2-(4-nitrophenyl)hydrazono)-1-oxo-1-(phenylamino)butan-2-ylcarbamate 191b 
(Yield 2.96 g, 65%). 1H-NMR 400 MHz (DMSO-d6) : δ = 1.99 (3H, s, CH3), 5.04 (1H, d, 
CH, J = 8.0 Hz), 5.09 (2H, s, CH2), 7.07 (1H, t, ArH, J = 7.2 Hz), 7.16 (2H, d, ArH, J = 9.2 
Hz), 7.37-7.31 (7H, m, ArH), 7.60 (2H, d, ArH, J = 8.0 Hz), 7.93 (1H, d, NH, J = 8.4 Hz), 
8.03 (2H, d, ArH, J = 8.8 Hz), 10.11 (1H, s, NH), 10.20 (1H, s, NH); 13C-NMR 100 MHz 
(DMSO-d6): 14.1, 61.4, 65.7, 111.7, 119.3, 123.6, 125.7, 127.7, 127.8, 128.3, 128.8, 136.8, 
138.5, 138.6, 146.0, 151.2, 156.1, 167.2. 
Benzyl-1-(3,4-dimethylphenylamino)-3-(2-(4-nitrophenyl)hydrazono)-1-oxobutan-2-
ylcarbamate 191d 
(Yield 3.67 g, 75%). 1H-NMR 400 MHz (DMSO-d6) : δ = 1.99 (3H, s, CH3), 2.17 (3H, s, 
CH3), 2.19 (3H, s, CH3), 5.07 (1H, d, CH, J = 8.0 Hz), 5.11 (2H, s, CH2), 7.08 (1H, t, ArH, J 
= 8.0 Hz), 7.22 (2H, d, ArH, J = 9.2 Hz), 7.39-7.31 (7H, m, ArH), 7.91 (1H, d, NH, J = 8.0 
Hz), 8.06 (2H, d, ArH, J = 8.8 Hz), 10.05 (1H, s, NH), 10.10 (1H, s, NH); 13C-NMR 100 
MHz (DMSO-d6): 14.4, 19.1, 19.9, 61.8, 66.1, 112.1, 117.4, 121.1, 126.1, 128.1, 128.2, 
128.7, 130.0, 131.7, 136.7, 136.8, 137.2, 138.9, 146.5, 151.7, 156.4, 167.2. 
Methyl-2-(benzyloxycarbonylamino)-3-(2-(4-nitrophenyl)hydrazono)butanoate 190a 
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Hydrazones 307a-c were prepared using procedures identical to those used for the 
corresponding compounds 308a-d already described. 
(Yield 3.56 g, 95.3 %); mp 163-165; 1H-NMR 400 MHz (CDCl3) : δ = 1.98 (3H, s, CH3), 
3.73 (3H, s, OCH3), 4.99 (1H, d, CH, J = 8.4), 5.10 (2H, s, CH2), 7.17 (2H, d, ArH, J = 9.2), 
7.38-7.31 (5H, m, ArH), 8.12 (2H, d, ArH, J = 9.2), 8.20 (1H, d, NH, J = 8.4),  10.11(1H, s, 
NH). IR (KBr) 3363, 1752, 1499 cm-1. 
 
Ethyl-2-(benzyloxycarbonylamino)-3-(2-(4-nitrophenyl)hydrazono)butanoate 190b 
(Yield 3.13 g, 84 %); mp 138-140; 1H-NMR 400 MHz (CDCl3) : δ = 1.21 (3H, t, CH3, J = 
6.8), 1.97 (3H, s, CH3), 4.18 (2H, m, CH2), 4.92 (1H, d, CH, J = 8.0), 5.09 (2H, s, CH2), 7.17 
(2H, d, ArH, J = 9.2), 7.38-7.33 (5H, m, ArH), 8.11 (2H, d, ArH, J = 9.2), 8.16 (1H, d, NH, J 
= 8.4),  10.11 (1H, s, NH). IR (KBr) 3326, 1721, 1597 cm-1. 
Isopropyl 2-(benzyloxycarbonylamino)-3-(2-(4-nitrophenyl)hydrazono)butanoate 190c 
(Yield 2.14 g, 56 %); mp 120-122; 1H-NMR 400 MHz (CDCl3) : δ = 1.21 (6H, m, CH3), 1.98 
(3H, s, CH3), 4.88 (2H, m, CH2), 4.92 (1H, d, CH, J = 8.0), 5.02 (3H, s, CH and CH2), 7.20 
(2H, d, ArH, J = 8.4), 7.37-7.34 (5H, m, ArH), 8.11 (3H, m, NH and ArH), 10.00 (1H, s, 
NH). IR (KBr) 3413, 1715, 1579 cm-1. 
 
Azoacetates: LTA oxidation of Hydrazones of Z-threonyl anilides and esters 
Azoacetates 193 a-d and 192 a-c were prepared using procedures identical to those used for 
the corresponding compounds 265a already described 0.005 moles of substrate was used in 
each case. 
Methyl-3-acetoxy-2-(benzyloxycarbonylamino)-3-((4-nitrophenyl)diazenyl)butanoate 192a 
(Yield 2.13 g, 94 %); red oil; 1H-NMR 400 MHz (CDCl3) : δ = 1.84 (3H, s, CH3), 2.10 (3H, 
s, CH3), 3.58 (3H, s, OCH3), 4.94-4.92 (1H, m, CH), 5.07-5.04 (2H, m, CH2), 5.65-5.60 (1H, 
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m, NH), 7.30-7.27 (5H, m, ArH), 7.72 (2H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 8.8). IR 
(KBr) 3372, 1741, 1543 cm-1. 
Ethyl-3-acetoxy-2-(benzyloxycarbonylamino)-3-((4-nitrophenyl)diazenyl)butanoate 192b 
(Yield 2.15 g, 91 %); red oil; 1H-NMR 400 MHz (CDCl3) : δ =  1.01 (3H, t, CH3, J =6.8), 
1.84 (3H, s, CH3), 2.08 (3H, s, CH3) 4.02 (3H, q, CH2, J = 6.8), 4.94-4.90 (1H, m, CH), 5.07-
5.02 (2H, m, CH2), 7.29-7.27 (5H, m, ArH), 7.73 (2H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 
8.8); IR (KBr) 3364, 1721, 1523 cm-1. 
3-(benzyloxycarbonylamino)-4-(4-methoxyphenylamino)-2-((4-nitrophenyl)diazenyl)-4-
oxobutan-2-yl acetate 193a 
The azoacetate was synthesised using the procedure described for oxidation of Cyclohexanol-
4-nitrophenyl hydrazone. 
(Yield 2.20 g, 80 %); 1H-NMR 400 MHz (DMSO-d6) : δ = 1.85 (3H, s, CH3), 2.13 (3H, s, 
CH3), 3.76 (3H, s, OCH3), 4.83 (1H, d, CH, J = 8.4 Hz), 4.95 (2H, s, CH2), 6.91 (2H, d, ArH, 
J = 9.2 Hz), 7.31-7.28 (5H, m, ArH), 7.56 (2H, d, ArH, J = 9.2 Hz), 7.73 (2H, d, ArH, J = 9.2 
Hz), 7.97 (1H, d, NH, J = 8.4 Hz), 8.42 (2H, d, ArH, J = 9.2 Hz), 10.28 (1H, s, NH). 
3-(benzyloxycarbonylamino)-2-((4-nitrophenyl)diazenyl)-4-oxo-4-(phenylamino)butan-2-yl 
acetate 193b 
The azoacetate was synthesised using the procedure described for oxidation of Cyclohexanol-
4-nitrophenyl hydrazone 
(Yield 2.02 g, 78 %); 1H-NMR 400 MHz (DMSO-d6) : δ = 1.85 (3H, s, CH3), 2.11 (3H, s, 
CH3), 5.04-4.85 (3H, m, CH and CH2), 7.11-7.07 (1H, m, ArH), 7.35-7.25 (7H, m, ArH), 
7.63 (2H, d, ArH, J = 7.6 Hz), 7.70 (2H, d, ArH, J = 8.8 Hz), 7.93 (1H, d, NH, J = 10.4 Hz), 
8.37 (2H, d, ArH, J = 8.8 Hz), 10.42 (1H, s, NH);  13C-NMR 100 MHz (DMSO-d6): 16.9, 
21.4, 58.2, 65.7, 102.1, 119.5, 123.1, 123.8, 124.9, 127.5, 127.7, 128.2, 128.8, 136.7, 138.4, 
148.4, 154.3, 155.7, 165.3, 168.5. 
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3-(benzyloxycarbonylamino)-4-(3,4-dimethylphenylamino)-2-((4-nitrophenyl)diazenyl)-4-
oxobutan-2-yl acetate 193d 
The azoacetate was synthesised using the procedure described for oxidation of Cyclohexanol-
4-nitrophenyl hydrazone 
(Yield 2.11 g, 77 %); 1H-NMR 400 MHz (DMSO-d6) : δ = 1.88 (3H, s, CH3), 2.12 (3H, s, 
CH3), 2.18 (3H, s, CH3), 2.26 (3H, s, CH3), 5.01-4.91 (3H, m, CH and CH2), 7.08-7.03 (3H, 
m, ArH), 7.31-7.26 (5H, m, ArH), 7.71 (2H, d, ArH, J = 8.8 Hz), 7.93 (1H, d, NH, J = 9.6 
Hz), 8.36 (2H, d, ArH, J = 8.8 Hz), 9.93 (1H, s, NH); 13C-NMR 100 MHz (DMSO-d6): 14.1, 
17.3, 20.1, 21.1, 57.9, 65.6, 102.2, 123.1, 123.8, 124.9, 125.3, 127.5, 127.7, 128.2, 131.8, 
135.5, 136.7, 137.1, 148.4, 154.3, 155.6, 165.5, 168.7. 
Cyclisation of Z-threonyl anilides 
Isolation of N-(4-methoxyphenyl)-5-methyl-2-oxooxazolidine-4-carboxamide 179a and 5-
(1-hydroxyethyl)-3-(4-methoxyphenyl)imidazolidine-2,4-dione 180a 
The substrate (0.716 g, 2 mmol.) was dissolved in acetone and to this was added K2CO3 (1.2 
molar equivalents)
.
 The reaction was then refluxed for 5 hours after which TLC showed the 
consumption of the starting material. The reaction mixture was filtered to remove the 
remaining potassium salts, the solvent was reduced to a small volume and taken up in 20 mls 
of ethyl acetate. The organic phase was washed repeatedly with water until a baseline spot on 
TLC no longer persisted. The organic extracts were dried and the solvent removed under 
vacuum to give a white powder that was separated into its component parts by careful 
chromatography. 
N-(4-methoxyphenyl)-5-methyl-2-oxooxazolidine-4-carboxamide 179a (Yield 0.15 g, 30 %)  
1H NMR (400 MHz, DMSO-d6): δ = 1.40 (3H, d, CH3, J = 6.4), 3.79 (3H, s, OCH3), 3.99 
(1H, d, CH, J = 4.8), 4.58-4.56 (1H, m, CH), 6.91 (2H, d, ArH, J = 4.8), 7.53 (2H, d, ArH, J 
= 4.8), 7.97 (1H, s, NH), 10.05 (1H, s, NH), 13C NMR (100 MHz, DMSO-d6) 21.1, 55.5, 
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61.6, 75.9, 114.3, 121.5, 131.9, 156.0, 158.5, 168.6; Mass Spectrum: C12H14N2O4Na requires 
273.09 [M+Na +] found 273.1.;  +46.8 
5-(1-hydroxyethyl)-3-(4-methoxyphenyl)imidazolidine-2,4-dione 180a 
(Diasteromeric mixture showing duplicate peaks (Bold italic) with roughly 3:2 ratio) 
(Yield 0.14 g, 27%) 1H NMR (400 MHz, DMSO-d6): δ = 1.16 (3H, d, CH3, J = 6.4) 1.21 
(2H, d, 0.7 CH3, J = 6.4 ), 3.78 (5H, s, 1.7 CH3), 4.04 (1H, s, CH), 4.18 (0.7H, s, 0.7 CH),  
5.08, (1H, d, CH, J = 6.0), 5.24, (0.7H, d CH, J = 6.0), 7.00 (3H, m, ArH), 8.20 (3H, m, 
ArH), 8.37 (0.7H, s, NH ), 8.44 (1H, s, NH). 13C NMR (100 MHz, DMSO-d6) 17.9, 20.6, 
55.7, 62.3, 62.8, 65.8, 66.8, 114.2, 114.3, 125.1, 125.3, 128.3, 128.4, 156.8, 157.0, 158.7, 
158.8, 171.8, 171.7. Mass Spectrum: C12H14N2O4Na requires 273.09 [M+Na +] found 273.1. 
 
Cyclisation of azoacetate 193a to Oxazolidinone 196a and Hydantoin 197a 
The azoacetate 193a (0.549 g, 1 mMol) was dissolved in acetone and the reaction vessel 
flushed with nitrogen. To this via a powder addition funnel was added K2CO3 (1.2 molar 
equivalents)
.
 The reaction was allowed to stir for 24 hours and TLC monitoring showed the 
formation of two new spots, and a significant quantity of starting material. The reaction was 
then refluxed for 3 further hours after which TLC showed the consumption of the starting 
material. The reaction mixture was filtered to remove the remaining potassium salts, the 
solvent was reduced to a small volume and taken up in 20 mls of ethyl acetate. The organic 
phase was washed repeatedly with water until a baseline spot on TLC no longer persisted. 
The organic extracts were dried and the solvent removed under vacuum to give an orange oil 
that was separated into its component parts by careful chromatography. 
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N-(4-methoxyphenyl)-5-methyl-5-((4-nitrophenyl)diazenyl)-2-oxooxazolidine-4-
carboxamide 196a 
(Yield 0.06 g, 15%)  1H NMR (400 MHz, DMSO-d6): δ = 1.65 (3H, s, CH3), 3.74 (3H, s, 
OCH3), 4.43 (1H, s, CH), 6.69 (2H, d, ArH, J = 8.8), 7.59 (2H, d, ArH, J = 8.8), 7.97 (2H, d, 
ArH, J = 8.8), 8.26 (1H, s, NH), 8.45 (2H, d, ArH, J = 8.8), 10.41 (1H, s, NH),  
1-(1-(4-methoxyphenyl)-2,5-dioxoimidazolidin-4-yl)-1-((4-nitrophenyl)diazenyl)ethyl 
acetate 197a 
(Yield 0.07 g, 17%)  1H NMR (400 MHz, DMSO-d6): δ = 1.75 (3H, s, CH3), 2.44 (3H, s, 
CH3), 3.74 (3H, s, OCH3), 5.04 (1H, s, CH), 6.95 (2H, d, ArH, J = 9.2), 7.55 (2H, d, ArH, J = 
8.8), 8.00 (2H, d, ArH, J = 9.2), 8.45 (2H, d, ArH, J = 9.2), 10.70 (1H, s, NH) 13C NMR (100 
MHz, DMSO-d6) 23.2, 23.3, 55.1, 65.4, 98.6, 113.9, 120.8, 123.3, 124.8, 130.9, 148.9,  
151.4, 153.7, 155.6, 162.1, 169.6. 
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Isolation and characterisation of azoacetate intermolecular cyclisation 
products 
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4.1 Introduction:   
The base induced cyclisations of azoacetates to azetidinones investigated in chapter 2 also led 
to the isolation of a previously unreported intermolecular cyclisation product involving the 
incorporation of the cyanide ion. Previous researchers investigating the ring closure of the 
azoacetate to the azetidinone had reported the discovery of a rearrangement product formed 
when potassium cyanide was employed in an alcoholic medium. However when alterations 
were made to the reaction stoichiometry, a 2-iminopyrrolidin-5-one (198, scheme 4.2) was 
isolated as the major product. Examples of the cyclisation of 3-cyanopropionamide 
derivatives to form 2-iminopyrrolidin-5-one can be found in the literature (see chapter 1), 
however the cyclisation of our azoacetate substrates 133 in a similar way is quite novel.  
 
 
 
 
 
 
 
 
 
As with the β-lactams in chapter 2 it is essentially an N1-C4 ring closure, however in 
this case a unit of cyanide is bridging this N1-C4 gap. In this case, as with the various other 
syntheses involving azoacetates presented in the previous chapters, we believe that the 
similarity between the reactivity of our azoacetate substrates and more simple propionamides 
is in general a result of their structural similarity.  
 
Scheme 4.1 Cyanide unit bridging the N1-C4 gap in cyclisation 
198f and j f R = H, 
j R = Cl  
 
133f and j 
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4.2 Results and Discussion 
4.2.1  Isolation of 2-iminopyrrolidin-5-ones 
Isolation of the 2-iminopyrrolidin-5-ones bearing the 4-nitrophenylazo functionality 
was achieved as an extension of work carried out by this research group towards the isolation 
of azetidinones from azoacetate precursors 133. It was found at that time that reaction of the 
azoacetate with potassium carbonate in acetone gave the azetidinone 134f. However, when 
the reaction conditions were changed and potassium cyanide was used with propanol, 
rearrangement product 77 could be isolated in addition to the azetidinone (134f, Scheme 4.2). 
 
 
 
 
 
Scheme 4.2 Previously isolated products from reaction of azoacetate with KCN 
However after several repetitions of the reaction using various azoacetates (133, see chapter 
2) it was noted that in some cases small quantities of a further reaction product could be seen 
on TLC. After adjustment of the reaction conditions it was found that an excess of KCN 
could be used in order to increase the ratio of the new material compared to the β-lactam. It 
was found that a twofold excess of base could increase the ratio of the new compound. Any 
further excess of KCN was found to have no further enhancement effect on the product ratio. 
Two substrates in particular showed an affinity for intermolecular reaction and these were 
chosen for further study, these were the azoacetates derived from aryl hydrazones of 
acetoacetanilide 133f and 4-chloro substituted acetoacetanilide 133j. 
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In both cases when the ratio of cyanide added was increased twofold, it was found the trace 
compound, subsequently identified as 2-iminopyrrolidin-5-one, (a cyclised intermolecular 
reaction product), and could be isolated as the major product. It was also noted that the 
increase in the proportion of this product was accompanied by a marked decrease in the 
proportion of β-lactam isolated, whereas the proportion of the rearrangement product found 
remained essentially unchanged (Scheme 4.2). This may be as a consequence of the differing 
reaction mechanisms involved in the production of these compounds. The formation of the β-
lactam, as has been previously discussed, is presumed to occur as a result of the base induced 
abstraction of the relatively acidic amido proton from the substrate azoacetate, followed by 
cyclisation with the acetate group acting as a leaving group. 
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Scheme 4.3 Isolated 2-iminopyrrolidin-5-one 198 from reaction of azoacetate with KCN 
The reason for the increase in 2-iminopyrrolidin-5-one is presumably due to the 
increased concentration of cyanide ions available in solution. The solvent system employed 
for the β-lactam cyclisation while adequate for reactions where the cyanide acts as base, does 
not lend itself well to the nucleophilic substitution process. This is due to the polar alcohol 
providing a source of hydrogen bond formation thus retarding the action of the cyanide ion as 
a nucleophile. Nucleophilic substitution reactions are usually performed in aprotic solvents 
133f and j 
134f and j 
70f and j 
198f and j 
198f R = H, yield 18% 70f, yield 16% 134f yield 12%. 
198j R = Cl yield 23%, 70j yield 17%. 134j, yield 20%  
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where the lone pairs of the solvent can complex the positive ion and enhance the 
nucleophilicity of the negative ion. Therefore it is presumably due to the increased 
concentration of cyanide ions present that allows the cyanide to act as a nucleophile rather 
than as a base, since nucleophilicity is a kinetic property of the ion. Therefore increased 
numbers of interactions lead to a decrease in the effect on the system of solvent polarity. 
4.2.2  Mechanism of formation of 2-iminopyrrolidin-5-ones 
It has already been shown that the acetate group can act as a leaving group although 
not fulfilling the classic criteria for a good leaving group (conjugate base of a strong acid) 
(Chapter 2). Presumably, the mechanism of formation of the intermolecular incorporation of 
the cyanide unit is simply as a result of the competitive reaction between the two 
nucleophiles in solution. If this is the case the mechanism should involve the initial formation 
of a nitrile through nucleophilic displacement of the acetate group by the cyano nucleophile. 
Once again it can be postulated that some anchimeric assistance is provided by the 
neighbouring phenylazo functionality. However in this case it is the cyanide ion that attacks 
at the reaction centre (Scheme 4.3). The subsequent cyclisation through the newly formed 
nitrile is expected due to the proximity of the nucleophilic amide to the polar nitrile in basic 
media. In contrast to what is generally reported about the stability of imines carrying a 
hydrogen on the nitrogen (primary imine),117 this cyclic imino group proved to be stable 
enough to allow for isolation and consequently sent for X-Ray crystal structure 
determination. 
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Scheme 4.4 Proposed mechanism of anchimeric assistance allowing the formation of the 2-
iminopyrrolidin-5-one derivative. 
 
To discount the possibility of a ring expansion of the newly formed β-lactam by attack of the 
cyanide ion had taken place, an isolated sample of β-lactam was reintroduced to refluxing 
propanol containing a two-fold excess of KCN (Scheme 4.4). 
 
 
 
 
Scheme 4.5 Reaction of β-lactam with KCN 
After heating under reflux for 48 hours no change was observed in the starting material. Since 
the isolated 2-iminopyrrolidin-5-ones had formed within 24 hours, it seems clear that this 
reaction pathway was not involved in their formation.  
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4.2.3 1H NMR studies of 2-iminopyrrolidin-5-ones 
Initial attempts to characterize the isolated compound by NMR proved difficult due to 
the similarity between the spectra of the 2-iminopyrrolidin-5-one (198j, figure 4.2b) and the 
β-lactam (134j, figure 4.2a). CDCl3 had been used as the NMR solvent for all of the β-lactam 
molecules synthesized to this point. The new compounds isolated after chromatography from 
the reaction of the azoacetates with excess cyanide were found to dissolve well in this solvent 
and it was therefore initially chosen so that comparisons could be made between the spectra 
of the new compounds and the formerly synthesized β-lactams.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2b 1H NMR spectrum of 2-iminopyrolidin-5-one derivative 198j in CDCl3 
NO N
N N
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Figure 4.2a 1H NMR spectrum of β-lactam derivative 134j in CDCl3 
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Initial results showed the spectra of the two compounds to be remarkably similar, with 
only a slight difference between the chemical shift of the methyl protons of either compound. 
This led to the early assumption that the compound isolated may have been an isomer of the 
β-lactam molecule. It was thought that since the 1H NMR spectra were so similar that such 
minor differences could be attributed to the isolation of the β-lactam in the cis configuration 
(Figure 4.3). This was deemed plausible since in theory the compounds would be separable 
by chromatography and isolation of both configurations of this type of azo-compound is not 
uncommon. 
 
 
 
 
 
 
 
Figure 4.3 Possible isomers of β-lactam 134f 
The trans isomer in most cases, tends to be the predominantly observed isomer due to 
the stability of the system imparted by the lower levels of steric interaction with neighbouring 
groups. The dominance of the trans isomer over the cis was supported by the identification 
by previous researchers of several isolated β-lactams of this type as the trans-isomer using X-
Ray crystallography studies. The hypothesis that the cis isomer had been isolated was soon 
abandoned as further spectral evidence was gathered. This data suggested that the isolated 
compound did not show the characteristic spectral features common to β-lactams. For 
instance the IR spectrum of the compound did not show the characteristic 4-membered 
lactam strong carbonyl stretching vibration common to the other β-lactams (~1750 cm-1).  
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However when the NMR spectra were obtained using DMSO-d6 as solvent, the 
appearance of a broad singlet in the proton spectrum integrating as a one proton could be seen 
at low-field. This indicated the possible presence of a proton attached directly to a 
heteroatom. This was also confirmed using the IR spectrum where the presence of a 
characteristic -NH- stretching vibration was observed. This raised several questions with 
regard to the NMR spectra of the compound in question. Not only was the identification of 
the compound now an issue but the presence and absence of a peak in different NMR 
solvents must be considered. 
 
 
 
 
 
 
 
 
Figure 4.4 1H NMR spectrum of 2-iminopyrrolidin-5-one 198j in DMSO-d6 
There are several potential causes for this type of signal dampening. A commonly observed 
example of this phenomenon in 1H NMR spectra is chemical exchange. In cases where a 
molecule can convert between two configurations in solution, a dynamic equilibrium can 
exist which allows the appearance of a spectrum to change relative to the rate of exchange 
between the two configurations. In this case the flipping of the proton about the imino bond 
would be considered an unsymmetrical two-site exchange. Although the imino moiety is, in 
general terms, a rigid moiety,118 this type of flipping between configurations is conceivable 
because of the unique positioning of the imino group adjacent to the nitrogen lone pair of the 
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amide (Figure 4.5). Resonance stabilization provided by the iminium ion intermediate allows 
flipping from one conformer to the other. 119 
 
 
 
 
Figure 4.5 Mechanism of flipping between configurations of 2-iminopyrrolidin-5-one 198f 
Depending on the rate of population exchange between the two configurations (Figure 4.6a), 
the signals can appear in the spectrum as two peaks (slow exchange), no peak (intermediate 
exchange) or one peak (fast exchange) (Figure 4.6b).  
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Figure 4.7 in “Nuclear Magnetic Resonance”, Oxford chemistry primers. 120 
 
 
Figure 4.6b Graphical representation of line broadening and coalescence related to rate of 
exchange between configurations 
 
Figure 4.6a Configurations of 2-iminopyrrolidin-5-one 198f 
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Essentially what is seen with respect to the rate of exchange between the configurations is 
broadening, coalescence and narrowing of the signal. The rate of exchange of the 
configurations can be affected by a number of factors including temperature, solvent 
viscosity and solvent polarity. It is therefore feasible that the absence of the imino proton in 
spectrum as observed in CDCl3 is as a result of an intermediate rate of transition between the 
two configurations of the molecule. Likewise it is possible that the more polar DMSO-d6 
allows a faster rate of transition through stabilization of the iminium ion, therefore resulting 
in the appearance of the proton signal as a single peak.  
Another possible reason for the absence of the imino- proton in the CDCl3 spectrum 
could be line broadening as a result of the spin-lattice relaxation process. However this type 
of line broadening tends to affect an entire spectrum rather than exerting a localized effect on 
a single nucleus or group of equivalent nuclei. This phenomenon was explored somewhat 
further in the case of anomalies observed in the carbon spectrum of this compound and is 
discussed in more detail in the next section. 
 
4.2.3 13C NMR studies of 2-iminopyrrolidin-5-ones 
The 13C NMR spectrum of the 2-iminopyrrolidin-5-ones when obtained using CDCl3 
as solvent also had some interesting features. The carbon peaks associated with the three 
methyl groups were of particular interest (Figure 4.7). Their appearance showed significant 
line broadening making them barely distinguishable from the baseline. This unusual 
phenomenon was investigated further, three possibilities for the cause of the line broadening 
were considered: 
an effect caused by the instrument. 
an effect inherent to the solvent. 
an effect inherent to the compound. 
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Initially it was suspected that the appearance of the peaks may have been due to an 
effect caused by a problem with the decoupling of the carbon signals. The experiment was 
rerun with the decoupler turned off in order to assess whether the decoupled spectrum would 
be affected. Although the signal strength would be expected to diminish significantly due to 
the lack of Nuclear Overhauser Enhancement (NOE) it was hoped that a weaker but clearly 
defined spectrum would point to a problem experienced during the decoupling process. 
However when the decoupler was turned off the reduction in the signal strength meant that 
the broadened peaks were diminished to the point where they were indistinguishable from the 
baseline noise. Increasing the number of scans was briefly investigated but as expected the 
signal definition improved but this had no effect on the intensity of the signal. The next 
approach was an investigation of the effect of the relaxation time on the signal. A series of 
experiments with gradually increased relaxation time were set up with relaxation times 
ranging from 1 second to 60 seconds, run with 512 scans. This technique did produce the 
desired enhancement of the line broadened peaks, with an improvement in both the signal 
definition and signal strength for all peaks. However the signal enhancement of the peaks of 
interest was found to be relatively low. 
 
 
 
 
 
 
 
Figure 4.7 13C NMR spectrum of 2-iminopyrrolidinone 198j in CDCl3 using standard NMR 
settings (1024 scans, 1 second relaxation delay) 
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The enhancement of the signal observed by extending the relaxation delay as expected, was 
greatest at the longest delay time (60 seconds, Figure 4.8a). The enhancement of the signal in 
this manner is a function of the spin-lattice relaxation time. Spin-lattice relaxation is caused 
by variable local fields which stimulate nuclei to flip amongst their accessible spin states. As 
the nuclei approach equilibrium the energy released is dispersed to the surroundings. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.8b 13C NMR spectrum of 2-iminopyrrolidin-5-one 198j in DMSO-d6 1028 scans 
with a relaxation delay of 1 second. 
Figure 4.8a 13C NMR spectrum of 2-iminopyrrolidinone derivative 198j in CDCl3 512 
scans with a relaxation delay of 60 seconds 
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These variances in populations are typified by T1 the spin-lattice relaxation time. For a 
collection of spin -½ nuclei, assuming exponential relaxation, there is a disparity in the 
number of m = + ½ and m = - ½  spins. For this reason it is favourable to wait a long time 
after T1 has elapsed before recording a spectrum. The extended relaxation time in this case 
can be seen to have an enhancement effect on the signals in the entire spectrum as compared 
to the spectrum run with standard 1 second relaxation delay (Figure 4.8a). This increased 
enhancement did allow the positive identification of the product however it remains unclear 
why the localized line broadening effect is experienced by the carbon nuclei of the methyl 
groups in such a dramatic way. Also, as with the proton spectrum these effects were solvent 
dependant, the spectrum obtained in DMSO-d6 showed a clearly defined spectrum without 
line broadening (Figure 4.8b). 
The overall outcome of these results suggests that the observed line broadening, is not 
likely to be a result of a localized effect caused by the spin-lattice relaxation process. There 
are many relaxation processes that can have an effect on NMR line broadening. (Spin-spin 
relaxation, modulation of the anisotropic chemical shift interaction by molecular tumbling, 
modulation of scalar coupling internal motion, and interaction with the strong fields 
generated by unpaired electrons in a paramagnetic molecule). Unfortunately it is difficult to 
pinpoint with any degree of certainty which of the many possible mechanisms results in the 
anomalous line broadening observed in the spectra presented here. It is most likely a 
combination of effects involving the molecule and the solvent in a similar manner to that 
described for the proton spectrum. Further evidence to suggest that the presence of the imino 
group adjacent to the amine in the ring plays a role was investigated by synthesising a similar 
molecule (pyrrolidine-2,5-dione derivative) whereby flipping was not a possibility. The 
results of this are discussed in section 4.3. 
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4.2.4 HMQC and HMBC studies of 2-iminopyrrolidin-5-ones 
Full characterization of the isolated product required collaborative analysis of all of 
the all available spectra. The presence of the -NH- moiety was confirmed from the 1H NMR 
and IR spectra, and the presence of a previously unaccounted for quaternary carbon from the 
13C and DEPT spectra. However the factor that proved crucial to the eventual full 
characterization of the 2-iminopyrrolidin-5-ones was the simultaneous analysis of the HMQC 
and HMBC spectra of these compounds. HMQC (Heteronuclear Multiple Quantum 
Correlation) is a 2D NMR spectroscopic technique which correlates the carbon and proton 
spectra. The technique shows through bond interactions of the proton with the carbon nucleus 
immediately attached to that proton. This allows the identification of the carbon atom to 
which a particular proton or group of equivalent protons are directly attached (i.e. a carbon-
hydrogen correlation over 1 bond length). HMBC (Heteronuclear Multiple Bond Correlation) 
on the other hand shows interaction of the proton with neighbouring carbon nuclei and 
excludes information on the carbon nucleus immediately attached to the proton. (i.e. a 
carbon-hydrogen correlation over 2 to 3 bond lengths).  
The information provided by these two spectra removes the ambiguity surrounding 
the identification of specific sites within the molecule. HMBC is particularly useful in the 
assignment of quaternary carbon signals. For instance in the case of quaternary carbon sites 5 
and 7 (Table 4.1), examination of the 13C, DEPT and HMQC spectra allow a reasonable 
evaluation to be made of the position of each signal on the carbon spectrum. Estimations can 
be made on the expected chemical shift experienced by the nuclei based on the effects of the 
surrounding groups. This process of site identification is satisfactory when the structure of the 
compound has already been elucidated. However when the structure is unknown, as in this 
case, the additional information provided by the HMBC allows the structure of the compound 
to be identified conclusively.  
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The correlation between the proton attached to nitrogen site 16 and carbons 15 and 5 in 
conjunction with the correlation between the protons attached to carbon 6 and carbons 5 and 
15 showed the position of the newly incorporated cyanide unit. Simply put, because the 
protons at sites 16 and 6 can both “see” the quaternary carbon sites 5 and 15 they must be 
beside each other. 
 
 
 
 
 
Site 1H 13C HMQC HMBC HMBC HMBC HMBC 
1  154.0      
2 7.88-7.91  123.2 125.1 154.0   
3 8.38-8.41  125.1 123.2 148.7   
4  148.7      
5  48.5      
6 1.60  13.8  48.5 81.6 165.3 
7  81.6      
8a 1.07  17.9 22.9 48.5 81.6 179.1 
9a 1.34  22.9 17.9 48.5 81.6 179.1 
10  179.1      
11  132.8      
12 7.37-7.39  128.8 129.3 132.8   
13 7.31-7.33  129.3 128.8 132.3   
14  132.3      
15  165.3      
16 9.09    48.5  165.3 
 
Table 4.1 Correlation table of 1H, 13C, HMQC and HMBC data for 2-iminopyrrolidin-5-one 
198j. 
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Figure 4.9 Relevant portions of HMBC spectrum of 2-iminopyrrolidin-5-one 198j 
It should be noted that the examination of the HMBC (Figure 4.9) established that a 
unit comprising of a quaternary carbon, attached to a heteroatom bearing a single hydrogen, 
was incorporated into the system adjacent to carbon site 5. However, with this knowledge, it 
was possible to go back and examine the reaction conditions for the source of this new 
moiety and postulate the likely structure of the molecule. Considering the entities present in 
the reaction solution the structure including the incorporation of the cyanide unit resulting in 
the formation of the 2-iminopyrrolidin-5-one seemed the only viable candidate. At this point 
comparison of the proposed structure with the available spectra confirmed that the structure 
was correct. 
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In the case of this molecule it was possible not only to identify the structure but 
accurately assign the position of every carbon within the system. It should be noted that 
positions 8 and 9 (Table 4.1) have been assigned arbitrarily, although it is possible to 
distinguish the signals from each other, identification of the precise position of the carbon 
centers in relation to the adjacent chiral centre is not possible using the spectral techniques 
used here. It is possible to hypothesize the most likely position of either group on the 1H and 
13C spectra based on the electronic effects experienced by the groups when in a position cis or 
trans to the large adjacent phenylazo group. However the information available from the 
spectra does not allow the same level of unambiguous assignment as with all of the other 
carbons within the spectrum.  
 
4.2.5 IR studies of 2-iminopyrrolidin-5-one 
As has been previously mentioned the IR spectrum proved a useful tool in the identification 
of the 2-iminopyrrolidin-5-one  
 
 
 
 
 
 
 
 
 
 
Figure 4.11 IR spectrum of 2-iminopyrrolidin-5-one 198j 
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The presence of a strong stretching vibration at 3300 cm-1 is indicative of the presence of a 
secondary amine roughly in the region where it might be expected to find the imino =N-H 
stretch (3350–3320). Although the vibration falls outside the quoted literature rangethis is not 
uncommon in IR spectroscopy and can be attributed to several factors including the 
influences of other functional groups within a molecule,121 the impact of preferred spatial 
orientations, and environmental effects (chemical and physical interactions) on the molecule. 
The other feature of the IR that proved most useful in characterizing of these compound was 
the carbonyl stretch, it was this feature that ruled out the possibility that a β-lactam may have 
been isolated.  Lactams have a characteristic range of carbonyl stretches, the greater the ring 
stress, the higher is the carbonyl absorption frequency. In the case of β-lactams the high level 
of ring stress imparted by the highly constrained ring results in the appearance of the 
carbonyl stretch in the 1750 cm-1 region of the spectrum making it easily identifiable. The 
carbonyl band seen in the spectrum appears at 1660 cm-1 and is indicative of an amide.  
 
4.2.6 Structural studies of 2-iminopyrrolidin-5-one 
Crystals suitable for single crystal X-ray crystallographic determination of the 2-
iminopyrrolidin-5-one 198f were grown from a saturated solution of ethyl acetate : hexane 85 
: 15. The substrate molecule was dissolved in the solvent mixture and allowed to stand for 20 
days undisturbed; slow evaporation was controlled by covering the vessel (clean new test 
tube) with perforated foil. The resulting crystals were orange block-like clusters. The 2-
iminopyrrolidin-5-one 198f crystallized in the triclinic system with P1 space group with a 
single molecule per asymmetric unit. Some of the main features of interest within this 
molecule include the imine, N-H bond distance is 0.88(3) Å. The imine C=N bond distance is 
1.267(2) Å. The bond angle across these two bonds is C(9)-N(4)-H(1N4) 108.6(18). These 
values compare well to the values for this moiety as quoted in the mainstream literature.122 
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The bond lengths and angles associated with the phenylazo group were also as expected. The 
slight disparity between the values for C(7)-N(3) and C(6)-N(2) bond distances is a reflection 
of the proximity of N(2) to the aromatic ring. The double bond character of this system would 
be expected to result in a slight reduction of the C(6)-N(2) bond length due to the sp2 
hybridized C(6) electrons being more tightly bound than the sp hybridized electrons 
associated with C(7). Similarly inconsistency between the bond angles through these bonds 
can be seen, however in the case of the bond angles other factors, not as easily quantifiable 
may have an effect. Steric effects from neighbouring groups as well as intermolecular 
interactions within the crystal lattice all have contributory effects on the orientation of these 
groups.  The carbonyl C=O distance for this molecule is 1.211(2) Å, which is consistent with 
literature values. The O-N-O nitro bond distances 1.220(2) and 1.223(2) fall between the 
characteristic N-O single bond value (1.36 Å) and characteristic N=O double bond value 
(1.18 Å). The resonance possibilities allowed by this group results in both bonds having some 
single bond and double bond character.  
 
 
 
 
 
 
 
 
 
Figure 4.12 X-Ray crystal structure of 2-iminopyrrolidin-5-one 198f 
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Table 4.2 Selected bond distances (Å) and angles (O) for 2-iminopyrrolidin-5-one 198f with 
estimated standard deviations 
Bond distances (Å) 
N(5) - C(10) 1.435(2) 
N(3) - C(7) 1.478(2) 
C(9) - N(4) 1.402(2) 
N(2) - N(3) 1.251(2) 
C(3) - N(1) 1.470(2) 
N(1) - O(1) 1.220(2) 
N(1) - O(2) 1.223(2) 
Bond angles (O) 
C(9)-N(4)-H(1N4) 108.6(18) 
N(2)-N(3)-C(7) 110.96(13) 
N(3)-N(2)-C(6) 113.78(14) 
C(16)-N(5)-C(10) 122.55(13) 
O(1)-N(1)-C(3) 118.68(14) 
 
 
 
Figure 4.13 ORTEP view of 2-iminopyrrolidin-5-one 198f showing packing relative to the 
unit cell 
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Table 4.3 Crystal data and structure refinement for 2-iminopyrrolidin-5-one 198f 
Quantity Measurement 
Empirical formula  C19 H19 N5 O3 
Formula weight  365.39 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 (#1) 
Unit cell dimensions a = 6.1179(9) Å α= 72.868(3)°. 
 b = 7.7340(12) Å β= 79.475(3)°. 
 c = 9.9532(15) Å γ = 81.828(3)°. 
Volume 440.52(12) Å3 
Z 1 
Density (calculated) 1.377 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 192 
Crystal size 1.00 x 0.40 x 0.30 mm3 
Theta range for data 2.17 to 30.50°. 
Index ranges -8<=h<=8, -11<=k<=11, -14<=l<=14 
Reflections collected 10436 
Independent reflections 2668 [R(int) = 0.0378] 
Completeness to theta = 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9716 and 0.8046 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2668 / 3 / 251 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0375, wR2 = 0.0955 
R indices (all data) R1 = 0.0394, wR2 = 0.0972 
Largest diff. peak and hole 0.374 and -0.229 e.Å-3 
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Figure 4.14 Mercury view of 2-iminopyrrolidin-5-one 198f showing intermolecular 
hydrogen bonding interactions through the phenylazo group. 
 
 
 
 
 
 
 
 
Figure 4.15 Mercury view of 2-iminopyrrolidin-5-one 198f showing intermolecular 
hydrogen bonding interactions through the imine group. 
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Figure 4.16 Mercury view of 2-iminopyrrolidin-5-one 198f showing intermolecular 
hydrogen bonding interactions through the nitro group and the carbonyl. 
Solid crystals are made up of a rigid lattice of molecules, atoms or ions, the locations 
of which are characteristic of the substance. The homogeny of the interior of this solid body 
results in the crystal having a distinctive form; a regular shape to the facade develops as a 
crystal grows. The molecules and indeed the groups within the molecules, become organized 
into regular repeating patterns and this determines the possible nonbonding interactions 
between functional groups. The hydrogen bonding interactions shown in Figures 4.14 - 4.16 
have been generated from calculated values. The “Mercury 1.4.2” crystal viewing package 
has the ability to identify all contacts between atoms of any type that are shorter than a 
specified van der Waals corrected distance. In this way it can be used to predict likely 
intermolecular hydrogen bond interactions and insert representations of these predicted bonds 
into the crystal structure diagrams. The visualization of these interactions is helpful to the 
understanding of the spacial arrangement of the molecules in the solid phase.   
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4.3 Synthesis and characterization of pyrrolidine-2,5-dione (succinimide) derivative. 
Many syntheses of pyrrolidine-2,5-diones (succinimide) molecules have been 
reported, the molecules are not only a valuable medicinal structures but a valuable synthetic 
intermediate.  The synthesis of the pyrrolidine-2,5-dione derivatives 201 was completed by 
refluxing the substrate 2-iminopyrrolidin-5-ones 198 in aqueous acetic acid for 4 hours.  
 
 
 
 
 
 
 
 
 
 
 
201f R = H or 201j R = Cl 
Scheme 4.6 Mechanism of formation of pyrrolidine-2,5-dione derivatives 
It was decided to use the 2-iminopyrrolidin-5-one 198f discussed in the previous 
section in the synthesis of the pyrrolidine-2,5-dione (201, Scheme 4.6). It was hoped that a 
successful synthesis would not only produce another novel molecule but also perhaps shed 
some further light on the anomalous spectral issues arising from the synthesis of the parent 
compound. The line broadening observed in the 13C spectrum of the 2-iminopyrrolidin-5-one 
was of particular interest. The synthesis was successfully achieved using acetic acid to effect 
the desired transformation. 
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It had previously been noticed that when a pure crystalline sample of the 2-
iminopyrrolidin-5-one 198f was left standing in air for a period of several days the TLC 
showed the development of  trace amounts of a new spot. TLC comparison of the pyrrolidine-
2,5-dione with the decomposing sample of  2-iminopyrrolidin-5-one showed the pyrrolidine-
2,5-dione to have an identical Rf value to the unknown compound. Attempts to isolate enough 
of this compound for further analysis by chromatography failed. However when the 
decomposing sample was reacted with aqueous acetic acid TLC monitoring of the reaction 
showed development of a single product corresponding to the unknown compound and this 
was confirmed to be the pyrrolidine-2,5-dione derivative. This suggests that the substrate 2-
iminopyrrolidin-5-one is prone to hydrolysis on contact with atmospheric moisture over time.  
   The spot in lane 1 represents a pure sample of 2-iminopyrrolidin-5-one 
   The spot in lane 2 represents a pure sample of pyrrolidine-2,5-dione 
The spots in lane 3 represent a partially decomposed sample of 2-
iminopyrrolidin-5-one left open to the atmosphere for 4 days. 
The spot in lane 4 represents the reaction product (also pyrrolidine-2,5-
dione) of the degraded sample after reflux with acetic acid for 4 hours 
Figure 4.17 Representation of TLC (EtOAc:Hex 30:70) showing transformation of degraded 
2-iminopyrrolidin-5-one 198f to pyrrolidine-2,5-dione 201f using acetic acid  
4.3.1 NMR studies of pyrrolidine-2,5-dione derivative. 
In the proton spectrum of the 2-iminopyrrolidin-5-one observed broadening could be 
rationalized in terms of the chemical exchange experienced by the cyclic imino functionality. 
However in the 13C spectrum the line broadening not only affected the imino carbon but also 
had a drastic effect on the three methyl carbons attached to two different ring positions within 
the molecule. The synthesis of the pyrrolidine-2,5-dione offered an opportunity to alter a 
single functionality within the molecule and observe what the effect of that change would 
 
1 2 3 4 
Rf = 0.81 
Rf = 0.60 
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have on the NMR spectra of the new compound. Since it was suspected that the line 
broadening was somehow caused by the presence of the imino group, the synthesis of the 
pyrrolidine-2,5-dione allowed this to be investgated without altering any other moiety within 
the system. When the 13C spectrum of the pyrrolidine-2,5-dione was obtained using CDCl3 as 
solvent, no line broadening akin to what had been observed for the 2-iminopyrrolidin-5-one 
could be detected (Figure 4.18). Again this evidence lends credence to the assertion that it is 
the presence of the imino group that causes this drastic effect on the spectra run in CDCl3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Comparison of the 13C NMR spectra of the 2-iminopyrrolidin-5-one 198j and the 
structurally similar pyrrolidine-2,5-dione derivative 201j both in CDCl3. 
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4.4 Pyrazole formation 
Due to their wide ranging applications in medicinal and agrochemical roles new synthetic 
routes to pyrazoles have received much attention. Thus far, the full potential of these 
compounds has not been exploited due to the limited number of synthetic procedures 
available for their synthesis.  
Currently the most common method of obtaining pyrazoles is through the reaction of 
1,3-diketones 202 with hydrazine or its derivatives 203.123 However a commonly encountered 
problem with this route is to maintain regioselectivity in the product. To date this problem 
remains the greatest challenge within the field.  The method often produces a mixture of 
regioisomers (e.g. 204 and 205 Scheme 4.7) if the reactivity of the two carbonyl groups is not 
significantly different, a problem that has obvious repercussions on the scope of the 
procedure 
 
 
 
 
 
Scheme 4.7 General scheme for the formation of pyrazoles via diketones and hydrazines 
This problem is compounded by the difficulties arising from the synthesis of pure 1,3-
diketones 202 as starting material. Methods for producing this entity often return complex 
mixtures of condensation products not easily separated from the desired product. In light of 
these issues, the formation of the pyrazole through incorporation of the cyanide ion into a 
parent azoacetate is an interesting example. This setup ensures regioselectivity in the finished 
product, and has the added advantage of introducing exocyclic functional groups that provide 
the opportunity for further fuctionalization and diversification within the product. 
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a,Y = OEt, b, Y = NH-phenyl,  
Scheme  4.8 Transformation of α,α-unsubstituted azoacetate to pyrazole. 
The presence of an extra nitrogen atom in the product suggests that a cyanide unit has 
also been incorporated into the molecule. The initial formation of a nitrile seems the most 
likely route towards the cyclisation to the pyrazole, however a direct substitution seems 
unlikely. This seems counterintuitive from several standpoints. Firstly, attack of a nucleophile 
such as the cyanide ion at an unsubstituted α- carbon at first glance seems an unlikely 
reaction; and secondly it has just been shown in the previous sections that in the case of the 
di-methylated analogue under similar conditions the cyanide ion reacts readily to displace the 
acetate moiety followed by cyclisation to the 2-iminopyrrolidin-5-one ring. There is some 
theoretical support for this direct attack at the α-carbon. In order to best rationalize how these 
groups might interact to give the product in question the HASB (Hard Acid Soft Base) 
approach to the reactive species can be applied. This is not a scientific theory in the true sense 
of the term, but a set of principles based on experimental observations used to explain 
atypical reaction results. The system, introduced by Pearson and Songstad, is based on a 
proposed affinity of similar groups for reaction with each other124. Although empirical in 
nature, the principles have been used to predict the behaviour of many organic reactions that 
are not easily explained by other means. The principles work by sorting organic functional 
groups based on the similarities in their experimental properties. The properties attributed to 
the groups under the HASB principles is given in Table 4.4.125 
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Table 4.4 Summary table of properties of acids and bases under the HASB system 
 Hard Acid Hard Base Soft Acid Soft Base 
Reaction Role electrophiles nucleophiles electrophiles nucleophiles 
Bonding Orbital high LUMO low HOMO low LUMO high HOMO 
Polarizability low low high high 
Valence electrons None unshared Tightly held unshared Loosely held 
Examples H+,  Li+ ,   Na+, 
K+,  Mg2+ , 
Ca2+, Al3+, 
Cr2+, Fe3+ 
H2O, -OH, F-, 
AcO-, SO42-, 
Cl-, CO32- ,  
NO3,  ROH 
Cu+, Ag+, Pd2+, 
I2  Pt2+, Hg2+, 
BH3, CH2, 
carbenes, Br2 
RS,  I-, CN-, CO, 
(RO)3P, RCN, 
C2H4, C6H6, H- ,R- 
Bond Type Ionic Covalent 
 
Both reaction centers can be thought of as ambident in nature, and as such, can react either 
through the carbon or the heteroatom; however the position of the carbon and nitrogen in the 
final isolated product suggests that a nitrile was formed at some point. This would strongly 
suggest that the initial step is that of carbon-carbon bond formation. 
 
 
 
 
Figure 4.19 Ambident cyanide ion and β-keto compound shown in both forms 
Since the cyanide ion falls under the category of a soft base and a -CH2- can be categorized as 
a soft acid (highlighted in Table 4.4), direct reaction between the two groups can be 
rationalized. However the -CH2- unit in question is part of a β-keto system and must be 
considered as such. 
C N C N
R
O
Y
O
Y
R 
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The most likely scenario is an initial base induced abstraction of one of the highly acidic 
alpha-hydrogen atoms followed by elimination. This type of competing elimination reaction 
is commonly found in systems where the substrate has a hydrogen atom that can be easily 
removed and the base chosen can act as a base or a nucleophile. Often in such cases the base 
induced enolate formation is the result of resonance stabilization offered by this 
conformation. However, in this case, due to the presence of the azoacetate group, it is feasible 
that loss of the acetate moiety produces a more favorable conformation due to the 
stabilization provided by conjugation within the system (Scheme 4.9). If the formation of the 
enolate is assumed to take place the subsequent degradation to the more conjugated system 
with loss of the acetate group is also a likely outcome. 
 
 
 
 
 
 
 
Y = OEt or NH-phenyl,  
Scheme 4.9 Base induced elimination of acetate group from azoacetate 
If this hypothesis is accepted then reasonable assumptions can be made as to the mechanism 
of formation of the pyrazole. Firstly the configuration of this proposed intermediate is such 
that it is a typical substrate for nucleophilic addition. The additions across the carbon-carbon 
double bonds of these enone type substrates are quite well known. However in these cases the 
attacking nucleophile almost exclusively adds to the carbon furthest from the carbonyl 
(Scheme 4.10). 
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Y = OEt or NH-phenyl,  
Scheme 4.10 Mechanism for nucleophilic attack by cyanide ion at a position β to the 
carbonyl. 
The reason that this configuration is usually preferred is once again the resonance 
stabilization provided by the formation of the enolate intermediate (209, Scheme 4.10). 
Protonation of the more negative oxygen usually occurs to give the enol which tautomerizes 
to give the carbonyl. But, in the case of the proposed intermediate there is an alternative to 
the enolate formation through azo/hydrazone tautomerisation that offers equal if not greater 
stability through attack α to the carbonyl. 
 
 
 
 
 
Y = OEt or NH-phenyl,  
Scheme 4.11 Mechanism for nucleophilic attack by cyanide ion at a position α to the 
carbonyl. 
The formation of, and subsequent cyclisation of this compound 211 has been previously 
reported.67 In that case the reaction between hydrazidic halides with cyanoacetic acid 
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derivatives were investigated (Scheme 1.17). This is essentially condensation of the two 
molecules to the hydrazone with the cyano group already in place followed by cyclisation to 
the pyrazole in a manner identical to that proposed here (See chapter 1). Although the 
products are the same there are some differences in the experimental procedures and 
fundamental reaction sequences being explored.  
 
 
 
 
Scheme 4.12 Mechanism of cyclisation to form the pyrazole. 
Structural study of Pyrazole  
Crystals suitable for single crystal X-Ray crystallographic determination of the pyrazole were 
grown in acetonitrile/methanol using the slow cooling technique. This involved dissolving the 
substrate molecule in hot acetonitrile/methanol and cooling the solution to room temperature 
over 10 days. Evaporation was minimized by covering the cooling vessel (clean new test 
tube) with foil. The resulting crystals were colourless and needle-like in appearance.  
 
 
 
 
 
 
 
Figure 4.20 Crystal structure of pyrazole 207b 
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The pyrazole 207b crystallizes in the monoclinic space group P21/n (#14) with four 
molecules per asymmetric unit.  Some of the main features of interest within this molecule 
include the free amine, C-N bond distance is 1.350(2) Å. The observed bond angles and 
internal torsional angles within the 5 membered ring are indicative of a planar system. This 
would be expected for a small aromatic system. 
 
Table 4.5 Selected bond distances (Å) and angles (O) for pyrazole 207b  with estimated 
standard deviations 
Bond distances (Å) 
C(7)–N(4) 1.350(2) 
N(2)–C(7) 1.363(2) 
N(3)–C(16) 1.320(2) 
N(2)–N(3) 1.393(2) 
C(9)–O(4) 1.243(2) 
N(1)–O(2) 1.227(2) 
N(1)–O(1) 1.229(2) 
Bond angles (O) 
C(7)–N(2)–N(3) 111.61(15) 
N(2)-N(3)-C(7) 110.96(13) 
N(3)-N(2)-C(6) 113.78(14) 
C(16)-N(5)-C(10) 122.55(13) 
O(1)-N(1)-C(3) 118.68(14) 
Torsional angles (O) 
C(7)–N(2)–N(3)–C(16) 1.6(2) 
N(3)–N(2)–C(7)–C(8) –1.7(2) 
N(2)–C(7)–C(8)–C(16) 1.0(2) 
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Figure 4.21 ORTEP view of pyrazole 207b showing packing relative to the unit cell 
 
 
 
Figure 4.22 Mercury view of pyrazole 207b depicting the hydrogen bonding interactions, 
including interactions with acetonitrile solvent molecule. 
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Figure 4.23 Mercury view of pyrazole 207b depicting all intermolecular interactions, 
including interactions with solvent molecules (methanol and acetonitrile). 
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Table 4.4 Crystal data and structure refinement for pyrazole 207b 
Quantity Measurement 
Empirical formula C18.625 H17.75 N5.75 O3.125 
Molecular formula C17 H15 N5 O3 x 0.75 (C2 H3 N) x 0.125 (C H4 
Formula weight 372.29 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21/n (#14) 
Unit cell dimensions a = 13.394(2) Å  α= 90°. 
 b = 3.8267(6) Å  β= 92.688(3)°. 
 c = 33.470(5) Å  γ = 90°. 
Volume 1713.6(5) Å3 
Z 4 
Density (calculated) 1.443 Mg/m3 
Absorption coefficient 0.103 mm–1 
F(000) 779 
Crystal size 1.00 x 0.10 x 0.05 mm3 
Theta range for data 1.67 to 28.35°. 
Index ranges –17<=h<=17, –5<=k<=5, –44<=l<=44 
Reflections collected 16121 
Independent reflections 4230 [R(int) = 0.0280] 
Completeness to theta = 99.1 % 
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9948 and 0.8070 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 4230 / 0 / 323 
Goodness–of–fit on F2 1.124 
Final R indices [I>2sigma(I)] R1 = 0.0653, wR2 = 0.1581 
R indices (all data) R1 = 0.0716, wR2 = 0.1617 
Largest diff. peak and hole 0.712 and –0.389 e.Å–3 
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4.5 Conclusion: 
It has been shown that the substrate azoacetates discussed in this chapter provide a facile 
route to a selection of heterocyclic systems through incorporation of a cyanide unit. It has 
also been shown that the azo moiety can be assimilated in an endocyclic (pyrazole) or 
exocyclic (iminopyrrolidin-5-one) position depending on the substitution of these 
azoacetates. The isolation of the 2-iminopyrrolidin-5-one derivatives had not been reported 
by the original researchers, However once it had been isolated, it was found that with minor 
modifications to the reaction stoichiometry the 2-iminopyrrolidin-5-one can be isolated as the 
major product.  
Additionally this structure was easily modified to produce a pyrrolidine-2,5-dione derivative 
upon reaction with aqueous acetic acid.  Pyrrolidine-2,5-dione derivatives have been widely 
employed in a range of roles within the medicinal and synthetic chemistry fields. Initial 
characterization of the 2-iminopyrrolidin-5-ones proved difficult due to some unusual effects 
observed in the 1H and 13C spectra of these compounds when CDCl3 was employed as 
solvent. The high level of structural similarity between the pyrrolidine-2,5-dione and the 2-
iminopyrrolidin-5-one (different only by a cyclic C==O versus C==NH unit) provided a 
unique opportunity to study an unusual NMR phenomenon. The solvent specific line 
broadening of 2-iminopyrrolidin-5-one investigated here is not often observed. The details of 
these syntheses have recently been accepted for publication as a full paper in “Heterocycles” 
(see Appendix IV). 
Overall, it has been shown that the azoacetates chosen for study in this thesis provide access 
to a variety of phenylazo substituted heterocycles and important information has been 
gathered concerning the construction of heterocycles directly attached to the phenylazo group 
via azoacetates. 
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4.6 Experimental: 
Ethyl acetoacetate and substituted acetoacetanilides were purchased from the Sigma Aldrich 
chemical company and were used as received. All solvents were dried or distilled prior to 
use. Melting points were determined using a Griffin melting point apparatus and are 
uncorrected. Infrared spectra were recorded on a Perkin-Elmer 2000FT-IR spectrometer. 
NMR spectra were recorded using a Bruker AC 400 NMR spectrometer operating at 400 
MHz for 1H NMR and at 100 MHz for 13C NMR. The 1H and 13C NMR chemical shifts 
(ppm) are relative to TMS and all coupling constants (J) are in Hertz (Hz).  
Synthesis of 2-iminopyrrolidin-5-ones (198f and 198j) 
5-imino-3,3,4-trimethyl-4-((4-nitrophenyl)diazenyl)-1-phenylpyrrolidin-2-one 198f 
The azoacetate (133f) (1g, 2.1 mmol) was dissolved in hot propanol (40 ml) to which 
potassium cyanide (0.30 g, 4.6 mmol) was added. The solution was allowed to reflux for 30 
min, after which TLC showed development of product spots and total consumption of the 
starting material, this was evaporated to dryness. Water (100 ml) was added to the reaction 
vessel and this was extracted with EtOAc (2 x 25 ml) followed by CH2Cl2 (2 x 25 ml). The 
combined extracts were dried over magnesium sulfate and upon evaporation to dryness an 
orange oil was collected. The product was isolated after column chromatography. 
198f, Yield  (0.17 g, 18 %); mp 142-145 ºC 1H NMR (400 MHz, DMSO-d6): δ = 1.19 (3H, s, 
CH3), 1.42 (3H, s, CH3), 1.61 (3H, s, CH3), 7.34-7.28 (2H, m, ArH), 7.41-7.39 (1H, m, ArH), 
7.52-7.47 (2H, m, ArH, ), 7.76 (2H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 9.2); 9.00 (1H, s 
NH); 13C NMR (100 MHz, DMSO-d6) 13.3, 17.9, 24.4, 49.3, 83.1, 123.4, 124.8, 126.3, 
128.7, 129.2, 131.9, 149.3, 153.9, 174.3, 180.5; IR (KBr) 1661, 1528, 1377 cm-1 
(134f) Yield (0.10 g, 12 %). Spectra identical to those reported in chapter 2 
(77f) Yield  (0.14 g, 16 %); mp 195-197 ºC 1H NMR (400MHz, DMSO-d6): δ = 1.49 (3H, s, 
CH3), 1.53 (3H, s, CH3), 1.92 (3H, s, CH3), 6.96 (1H, s br, ArH),7.07 (1H, t, ArH, J = 7.2), 
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7.33-7.26 (3H, m, ArH), 7.61 (2H, d, ArH, J = 7.6), 8.15 (2H, s br, ArH), 9.06 (1H, s br, 
NH), 9.48 (1H, s br, NH); 13C NMR (100MHz, DMSO-d6) 21.7, 22.9, 24.3, 65.6, 110.5 (d, J 
= 222), 120.8, 123.5, 126.2 (d, J = 69), 128.3, 138.7, 138.9, 154.2, 171.8, 172.8. IR (KBr) 
3338, 3288, 1647, 1592, 1522, 1329, 1272, 1108, 750, 695 cm-1. 
 
1-(4-chlorophenyl)-5-imino-3,3,4-trimethyl-4-((4-nitrophenyl)diazenyl)pyrrolidin-2-one 
198j 
Yield  (0.21 g, 23%); mp 201-203 ºC; 1H NMR (400 MHz, DMSO-d6): δ = 1.07 (3H, s, CH3), 
1.34 (3H, s, CH3), 1.60 (3H, s, CH3), 7.32 (2H, d, ArH, J =8.4), 7.38 (2H, d, ArH, J =8.4), 
7.89 (2H, d, ArH, J = 9.2), 8.40 (2H, d, ArH, J = 9.2), 9.08 (1H, s, NH); 13C NMR (100 
MHz, DMSO-d6) 13.8, 17.9, 22.9, 48.5, 81.6, 123.2, 125.1, 128.8, 129.3, 132.3, 132.8, 148.7, 
154.0, 165.3, 179.1. IR (KBr) 3300, 1742, 1661, 1492 cm-1. 
Synthesis of succinimide (201f) 
Synthesis of 3,3,4-trimethyl-4-((4-nitrophenyl)diazenyl)-1-phenylpyrrolidine-2,5-dione 
(201f) 
The 2-iminopyrrolidin-5-one 198f (200 mg, 0.54 mmol) was dissolved in 10 ml of aqueous 
acetic acid. The solution was heated to 50 oC for 24 h, 100 oC for a further 24 h and finally 
allowed to reflux for 4 h after which TLC showed total consumption of the starting material. 
The solution was allowed to cool and added to ice-water (100 ml) which induced 
precipitation of a pale yellow solid that was filtered from solution. Yield (153 mg, 78 %); 
product decomposed in air over 24 h; 1H NMR (400 MHz, CDCl3): δ = 1.19 (3H, s, CH3), 
1.42 (3H, s, CH3), 1.61 (3H, s, CH3), 7.30-7.25 (2H, m, ArH), 7.35-7.32 (1H, m, ArH), 7.43-
7.37 (2H, m, ArH), 7.76 (2H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 9.2); 13C NMR (100 
MHz, CDCl3) 13.3, 17.9, 24.4, 49.3, 83.1, 123.4, 124.8, 126.3, 128.7, 129.2, 131.9, 149.3, 
153.9, 174.3, 180.5; IR (KBr) 1719, 1529, 1396, 1346 cm-1. 
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Synthesis of pyrazoles (207a and 207b) 
Synthesis of 5-amino-3-methyl-1-(4-nitrophenyl)-N-phenyl-1H-pyrazole-4-carboxamide 
(207a) 
The substrate azoacetate 206a (1 g, 3.1 mmol) was dissolved in hot n-PrOH (40 ml) to which 
potassium cyanide (0.3 g, 4.6 mmol) was added. The solution was allowed to reflux for 4 h, 
before being evaporated to dryness. Water (100 ml) was added to the reaction vessel and this 
was extracted with CH2Cl2 (15:85). The combined extracts were dried over magnesium 
sulfate and upon evaporation to a reduced volume a pale brown solid precipitated. The 
precipitate was filtered off and washed with petroleum ether and the product isolated after 
flash chromatography. Yield (0.13 g, 15 %) mp 210-212 ºC; 1H NMR (400 MHz, DMSO-d6): 
δ = 1.27 (3H, t, CH3, J = 7.2), 2.26 (3H, s, CH3), 4.20 (2H, q, CH2, J = 7.2), 6.64 (2H, s br, 
CH2), 7.81 (2H, d, ArH , J = 7.2), 8.32 (2H, d, ArH, J = 7.2); 13C NMR (100 MHz, DMSO-
d6) 14.3, 14.4, 59.1, 93.9, 123.0, 124.9, 143.1, 144.9, 150.6, 151.2, 164.0; IR (KBr) 3349, 
1676, 1548, 1344 cm-1. Mass Spectrum: [M+H]+ found 291.5, C13H15N4O4 requires 291.1. 
Ethyl 5-amino-3-methyl-1-(4-nitrophenyl)-1H-pyrazole-4-carboxylate 207b 
207b synthesized using an identical procedure to 207b using 206a as substrate 
Yield (0.12 g, 15 %); mp 181-183 ºC; 1H NMR (400 MHz, DMSO-d6): δ = 2.94 (3H, s, CH3), 
6.60 (2H, s br, CH2), 7.06 (1H, t, ArH , J = 7.6), 7.32 (2H, t, ArH, J = 7.6), 7.63 (2H, d, ArH 
, J = 7.6), 7.88 (2H, d, ArH
 
, J = 9.2), 8.35 (2H, d, ArH, J = 9.2), 8.85 (1H, s, NH,); 13C 
NMR (100 MHz, DMSO-d6) 14.2, 98.4, 120.4, 122.6, 123.3, 124.9, 128.5, 138.8, 143.3, 
144.7, 148.2, 150.7, 163.3; IR (KBr) 3455, 3429, 3313, 1650, 1599, 1543, 1495 cm-1. Mass 
Spectrum: [M+Na]+ found 360.4, C17H15N5NaO3 requires 360.1. 
  
  
 
 
 
 
 
 
 
 
 
Appendix I 
(Crystal structure and supporting data for N-acyl hydrazide derivative 79) 
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 Crystal structure and supporting data for N-acyl hydrazide derivative 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 molecule; thermal ellipsoids are drawn on the 50% probability level 
 Table 1.  Crystal data and structure refinement for 72. 
 
Identification code  72 
Empirical formula  C14 H19 N3 O5 
Formula weight  309.32 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 (#19) 
Unit cell dimensions a = 10.6723(6) Å  α= 90°. 
 b = 11.7713(7) Å  β= 90°. 
 c = 12.3081(7) Å  γ = 90°. 
Volume 1546.23(15) Å3 
Z 4 
Density (calculated) 1.329 Mg/m3 
Absorption coefficient 0.102 mm–1 
F(000) 656 
Crystal size 1.00 x 1.00 x 0.90 mm3 
Theta range for data collection 2.39 to 30.50°. 
C10
C11
C9
N2
O4
N3
C12
C5 C6
C7 O3
C4
O5
C8
C1
C3 C13C2
O1 N1
C14
O2
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Index ranges –15<=h<=15, –16<=k<=16, –17<=l<=17 
Reflections collected 36459 
Independent reflections 2661 [R(int) = 0.0293] 
Completeness to theta = 30.50° 99.7 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9138 and 0.8407 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 2661 / 0 / 275 
Goodness–of–fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0350, wR2 = 0.0892 
R indices (all data) R1 = 0.0360, wR2 = 0.0899 
Largest diff. peak and hole 0.443 and –0.150 e.Å–3 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 72.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________  
Atom x y z U(eq) 
______________________________________________________________________   
C(1) 4928(1) 3245(1) 8056(1) 16(1) 
C(2) 5010(1) 3283(1) 9182(1) 16(1) 
C(3) 6152(1) 3078(1) 9680(1) 15(1) 
N(1) 6218(1) 3047(1) 10862(1) 20(1) 
O(1) 7256(1) 3016(1) 11296(1) 28(1) 
O(2) 5223(1) 3039(1) 11374(1) 31(1) 
C(4) 7234(1) 2875(1) 9080(1) 18(1) 
C(5) 7157(1) 2831(1) 7956(1) 18(1) 
C(6) 5997(1) 2991(1) 7438(1) 15(1) 
N(2) 5945(1) 2853(1) 6330(1) 19(1) 
N(3) 4880(1) 3121(1) 5742(1) 15(1) 
C(7) 3999(1) 2309(1) 5545(1) 19(1) 
O(3) 3113(1) 2529(1) 4943(1) 24(1) 
C(8) 4117(2) 1188(1) 6127(1) 30(1) 
C(9) 4772(1) 4252(1) 5210(1) 16(1) 
C(10) 5124(1) 4166(1) 4010(1) 23(1) 
C(11) 5630(1) 5103(1) 5785(1) 24(1) 
C(12) 3426(1) 4693(1) 5356(1) 18(1) 
O(4) 2849(1) 5201(1) 4668(1) 28(1) 
O(5) 3055(1) 4539(1) 6384(1) 19(1) 
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C(13) 1807(1) 4925(1) 6680(1) 22(1) 
C(14) 863(2) 4008(2) 6483(2) 35(1) 
______________________________________________________________________  
 Table 3.   Bond lengths [Å] and angles [°] for  72. 
______________________________________  
C(1)–C(2)  1.3897(17) 
C(1)–C(6)  1.4033(16) 
C(1)–H(1)  0.930(18) 
C(2)–C(3)  1.3850(16) 
C(2)–H(2)  0.95(2) 
C(3)–C(4)  1.3912(17) 
C(3)–N(1)  1.4572(15) 
N(1)–O(1)  1.2301(15) 
N(1)–O(2)  1.2359(15) 
C(4)–C(5)  1.3872(17) 
C(4)–H(4)  0.91(2) 
C(5)–C(6)  1.4050(16) 
C(5)–H(5)  0.93(2) 
C(6)–N(2)  1.3750(15) 
N(2)–N(3)  1.3838(14) 
N(2)–H(1N2)  0.867(19) 
N(3)–C(7)  1.3627(16) 
N(3)–C(9)  1.4879(16) 
C(7)–O(3)  1.2284(16) 
C(7)–C(8)  1.5069(19) 
C(8)–H(8A)  0.91(3) 
C(8)–H(8B)  0.98(3) 
C(8)–H(8C)  0.98(3) 
C(9)–C(10)  1.5280(17) 
C(9)–C(11)  1.5305(18) 
C(9)–C(12)  1.5386(17) 
C(10)–H(10A)  0.97(2) 
C(10)–H(10B)  0.92(2) 
C(10)–H(10C)  1.00(2) 
C(11)–H(11A)  0.937(19) 
C(11)–H(11B)  0.97(2) 
C(11)–H(11C)  0.97(2) 
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C(12)–O(4)  1.2050(16) 
C(12)–O(5)  1.3381(16) 
O(5)–C(13)  1.4539(16) 
C(13)–C(14)  1.497(2) 
C(13)–H(13A)  0.96(2) 
C(13)–H(13B)  1.00(2) 
C(14)–H(14A)  0.96(2) 
C(14)–H(14B)  0.99(2) 
C(14)–H(14C)  0.94(3) 
  
C(2)–C(1)–C(6) 119.77(11) 
C(2)–C(1)–H(1) 119.3(11) 
C(6)–C(1)–H(1) 120.9(11) 
C(3)–C(2)–C(1) 119.37(11) 
C(3)–C(2)–H(2) 120.5(13) 
C(1)–C(2)–H(2) 120.0(13) 
C(2)–C(3)–C(4) 121.76(10) 
C(2)–C(3)–N(1) 119.22(11) 
C(4)–C(3)–N(1) 119.01(11) 
O(1)–N(1)–O(2) 123.49(10) 
O(1)–N(1)–C(3) 118.59(11) 
O(2)–N(1)–C(3) 117.92(11) 
C(5)–C(4)–C(3) 119.05(11) 
C(5)–C(4)–H(4) 122.9(13) 
C(3)–C(4)–H(4) 118.0(13) 
C(4)–C(5)–C(6) 120.02(11) 
C(4)–C(5)–H(5) 117.2(13) 
C(6)–C(5)–H(5) 122.6(13) 
N(2)–C(6)–C(1) 122.06(11) 
N(2)–C(6)–C(5) 118.00(11) 
C(1)–C(6)–C(5) 119.91(10) 
C(6)–N(2)–N(3) 121.60(10) 
C(6)–N(2)–H(1N2) 121.6(12) 
N(3)–N(2)–H(1N2) 114.6(12) 
C(7)–N(3)–N(2) 120.04(11) 
C(7)–N(3)–C(9) 119.73(10) 
N(2)–N(3)–C(9) 119.79(10) 
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O(3)–C(7)–N(3) 119.40(12) 
O(3)–C(7)–C(8) 122.39(13) 
N(3)–C(7)–C(8) 118.13(12) 
C(7)–C(8)–H(8A) 111.0(17) 
C(7)–C(8)–H(8B) 106.3(15) 
H(8A)–C(8)–H(8B) 111(2) 
C(7)–C(8)–H(8C) 106.6(17) 
H(8A)–C(8)–H(8C) 110(2) 
H(8B)–C(8)–H(8C) 112(2) 
N(3)–C(9)–C(10) 110.33(10) 
N(3)–C(9)–C(11) 109.66(10) 
C(10)–C(9)–C(11) 110.10(11) 
N(3)–C(9)–C(12) 108.82(10) 
C(10)–C(9)–C(12) 111.34(10) 
C(11)–C(9)–C(12) 106.50(10) 
C(9)–C(10)–H(10A) 107.3(13) 
C(9)–C(10)–H(10B) 111.7(13) 
H(10A)–C(10)–H(10B) 109.9(19) 
C(9)–C(10)–H(10C) 108.9(13) 
H(10A)–C(10)–H(10C) 108.4(19) 
H(10B)–C(10)–H(10C) 110.6(18) 
C(9)–C(11)–H(11A) 111.9(12) 
C(9)–C(11)–H(11B) 105.4(15) 
H(11A)–C(11)–H(11B) 105.6(18) 
C(9)–C(11)–H(11C) 110.8(14) 
H(11A)–C(11)–H(11C) 108.8(19) 
H(11B)–C(11)–H(11C) 114(2) 
O(4)–C(12)–O(5) 125.48(12) 
O(4)–C(12)–C(9) 124.24(12) 
O(5)–C(12)–C(9) 109.90(10) 
C(12)–O(5)–C(13) 117.76(10) 
O(5)–C(13)–C(14) 110.51(12) 
O(5)–C(13)–H(13A) 108.8(13) 
C(14)–C(13)–H(13A) 110.2(13) 
O(5)–C(13)–H(13B) 106.5(12) 
C(14)–C(13)–H(13B) 107.6(12) 
H(13A)–C(13)–H(13B) 113.1(18) 
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C(13)–C(14)–H(14A) 109.6(14) 
C(13)–C(14)–H(14B) 112.2(14) 
H(14A)–C(14)–H(14B) 108.8(19) 
C(13)–C(14)–H(14C) 116.4(17) 
H(14A)–C(14)–H(14C) 105(2) 
H(14B)–C(14)–H(14C) 105(2) 
  
______________________________________  
Symmetry transformations used to generate equivalent atoms:  
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for 72.  The anisotropic 
displacement factor exponent takes the form:  –2pi2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
_________________________________________________________________________________  
Atom U11 U22  U33 U23 U13 U12 
_________________________________________________________________________________  
C(1) 12(1)  19(1) 16(1)  1(1) –2(1)  1(1) 
C(2) 14(1)  17(1) 16(1)  2(1) 0(1)  1(1) 
C(3) 17(1)  16(1) 13(1)  1(1) –2(1)  0(1) 
N(1) 22(1)  22(1) 15(1)  0(1) –2(1)  2(1) 
O(1) 23(1)  41(1) 20(1)  2(1) –8(1)  –3(1) 
O(2) 24(1)  53(1) 17(1)  3(1) 2(1)  11(1) 
C(4) 13(1)  22(1) 18(1)  2(1) –3(1)  2(1) 
C(5) 13(1)  24(1) 17(1)  1(1) –1(1)  3(1) 
C(6) 13(1)  17(1) 14(1)  1(1) –1(1)  2(1) 
N(2) 13(1)  29(1) 13(1)  0(1) –1(1)  6(1) 
N(3) 14(1)  17(1) 14(1)  0(1) –3(1)  2(1) 
C(7) 21(1)  17(1) 18(1)  –4(1) 0(1)  0(1) 
O(3) 21(1)  26(1) 25(1)  –6(1) –7(1)  –2(1) 
C(8) 39(1)  17(1) 34(1)  2(1) –3(1)  –2(1) 
C(9) 17(1)  17(1) 14(1)  1(1) –1(1)  1(1) 
C(10) 25(1)  29(1) 14(1)  3(1) 2(1)  4(1) 
C(11) 25(1)  21(1) 26(1)  –2(1) –1(1)  –6(1) 
C(12) 20(1)  18(1) 17(1)  –1(1) –1(1)  4(1) 
O(4) 30(1)  32(1) 23(1)  6(1) –1(1)  13(1) 
O(5) 18(1)  22(1) 18(1)  –1(1) 2(1)  5(1) 
C(13) 19(1)  22(1) 25(1)  –3(1) 3(1)  5(1) 
C(14) 27(1)  39(1) 39(1)  –11(1) 6(1)  –7(1) 
_________________________________________________________________________________ 
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 72. 
______________________________________________________________________  
Atom x  y  z  U(eq) 
______________________________________________________________________  
H(1) 4160(17) 3380(16) 7723(15) 18(4) 
H(2) 4300(20) 3491(18) 9602(18) 31(5) 
H(4) 7965(19) 2775(18) 9449(16) 28(5) 
H(5) 7884(19) 2642(19) 7577(17) 27(5) 
H(1N2) 6619(17) 2782(17) 5942(16) 21(4) 
H(8A) 4930(20) 960(20) 6150(20) 44(6) 
H(8B) 3790(20) 1310(20) 6860(20) 47(7) 
H(8C) 3610(30) 640(20) 5720(20) 53(7) 
H(10A) 5980(20) 3893(19) 3973(17) 28(5) 
H(10B) 4600(20) 3675(18) 3641(17) 25(5) 
H(10C) 5090(20) 4941(19) 3680(18) 33(6) 
H(11A) 5456(18) 5153(16) 6529(16) 19(4) 
H(11B) 5410(20) 5840(20) 5486(19) 37(6) 
H(11C) 6500(20) 4900(20) 5692(18) 33(5) 
H(13A) 1600(20) 5586(19) 6257(17) 30(5) 
H(13B) 1826(19) 5078(17) 7480(17) 27(5) 
H(14A) 900(20) 3780(20) 5730(20) 35(6) 
H(14B) 0(20) 4260(20) 6655(19) 35(6) 
H(14C) 970(30) 3330(30) 6880(20) 54(7) 
______________________________________________________________________  
 Table 6.  Torsion angles [°] for 72. 
____________________________________________  
C(6)–C(1)–C(2)–C(3) 0.41(19) 
C(1)–C(2)–C(3)–C(4) 2.48(19) 
C(1)–C(2)–C(3)–N(1) –176.10(11) 
C(2)–C(3)–N(1)–O(1) –170.44(12) 
C(4)–C(3)–N(1)–O(1) 10.93(19) 
C(2)–C(3)–N(1)–O(2) 10.50(18) 
C(4)–C(3)–N(1)–O(2) –168.12(12) 
C(2)–C(3)–C(4)–C(5) –2.7(2) 
N(1)–C(3)–C(4)–C(5) 175.88(12) 
C(3)–C(4)–C(5)–C(6) 0.0(2) 
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C(2)–C(1)–C(6)–N(2) 174.71(12) 
C(2)–C(1)–C(6)–C(5) –3.01(19) 
C(4)–C(5)–C(6)–N(2) –175.03(12) 
C(4)–C(5)–C(6)–C(1) 2.78(19) 
C(1)–C(6)–N(2)–N(3) 9.78(19) 
C(5)–C(6)–N(2)–N(3) –172.46(11) 
C(6)–N(2)–N(3)–C(7) –91.96(15) 
C(6)–N(2)–N(3)–C(9) 95.72(14) 
N(2)–N(3)–C(7)–O(3) –173.61(11) 
C(9)–N(3)–C(7)–O(3) –1.28(18) 
N(2)–N(3)–C(7)–C(8) 9.64(18) 
C(9)–N(3)–C(7)–C(8) –178.03(12) 
C(7)–N(3)–C(9)–C(10) –74.17(14) 
N(2)–N(3)–C(9)–C(10) 98.18(13) 
C(7)–N(3)–C(9)–C(11) 164.40(12) 
N(2)–N(3)–C(9)–C(11) –23.25(15) 
C(7)–N(3)–C(9)–C(12) 48.27(14) 
N(2)–N(3)–C(9)–C(12) –139.39(10) 
N(3)–C(9)–C(12)–O(4) –141.30(14) 
C(10)–C(9)–C(12)–O(4) –19.48(19) 
C(11)–C(9)–C(12)–O(4) 100.56(15) 
N(3)–C(9)–C(12)–O(5) 45.46(13) 
C(10)–C(9)–C(12)–O(5) 167.28(11) 
C(11)–C(9)–C(12)–O(5) –72.69(13) 
O(4)–C(12)–O(5)–C(13) 5.8(2) 
C(9)–C(12)–O(5)–C(13) 178.94(10) 
C(12)–O(5)–C(13)–C(14) 88.59(16) 
____________________________________________  
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Crystal structure and supporting data for 2-iminopyrrolidin-5-one derivative 198f 
 
O2
N1
O1
C4
C3
C5
C2
C18
C6
C1
N2
C19
C17
N3
O3
C16
C7
N5
C9
C15 N4
C10
C14
C8
C13
C11C12
 jam01, molecule; thermal ellipsoids are drawn on the 50% probability level 
 
Table 1.  Crystal data and structure refinement for 198f. 
 
Identification code  198f 
Empirical formula  C19 H19 N5 O3 
Formula weight  365.39 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 (#1) 
Unit cell dimensions a = 6.1179(9) Å  α= 72.868(3)°. 
 b = 7.7340(12) Å β= 79.475(3)°. 
 c = 9.9532(15) Å γ = 81.828(3)°. 
Volume 440.52(12) Å3 
Z 1 
Density (calculated) 1.377 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 192 
Crystal size 1.00 x 0.40 x 0.30 mm3 
Theta range for data collection 2.17 to 30.50°. 
Index ranges -8<=h<=8, -11<=k<=11, -14<=l<=14 
Reflections collected 10436 
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Independent reflections 2668 [R(int) = 0.0378] 
Completeness to theta = 30.50° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9716 and 0.8046 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2668 / 3 / 251 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0375, wR2 = 0.0955 
R indices (all data) R1 = 0.0394, wR2 = 0.0972 
Largest diff. peak and hole 0.374 and -0.229 e.Å-3 
 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 198f.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________  
Atom x y z U(eq) 
______________________________________________________________________   
C(1) 4850(3) 4705(2) 5165(2) 15(1) 
C(2) 6312(3) 5961(2) 4357(2) 15(1) 
C(3) 6023(3) 6809(2) 2948(2) 13(1) 
N(1) 7535(2) 8183(2) 2104(2) 16(1) 
O(1) 9093(2) 8411(2) 2625(2) 26(1) 
O(2) 7152(3) 9049(2) 915(2) 38(1) 
C(4) 4354(3) 6465(2) 2317(2) 15(1) 
C(5) 2919(3) 5179(2) 3138(2) 15(1) 
C(6) 3190(3) 4298(2) 4546(2) 14(1) 
N(2) 1641(2) 2977(2) 5288(2) 15(1) 
N(3) 2280(2) 1855(2) 6366(2) 13(1) 
C(7) 625(3) 525(2) 7068(2) 12(1) 
C(8) -1350(3) 1494(2) 7845(2) 16(1) 
C(9) 1713(3) -1023(2) 8168(2) 14(1) 
N(4) 3102(3) -1005(2) 8964(2) 18(1) 
N(5) 807(2) -2610(2) 8214(2) 15(1) 
C(10) 1227(3) -4349(2) 9204(2) 14(1) 
C(11) -558(3) -5196(2) 10109(2) 18(1) 
C(12) -170(3) -6941(2) 10999(2) 21(1) 
C(13) 1972(3) -7811(2) 10984(2) 22(1) 
C(14) 3747(3) -6928(2) 10093(2) 20(1) 
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C(15) 3392(3) -5190(2) 9190(2) 18(1) 
C(16) -404(3) -2367(2) 7112(2) 15(1) 
O(3) -1428(2) -3512(2) 6965(1) 22(1) 
C(17) -73(3) -479(2) 6089(2) 13(1) 
C(18) 1902(3) -799(2) 4953(2) 16(1) 
C(19) -2155(3) 348(2) 5404(2) 17(1) 
______________________________________________________________________  
Table 3.   Bond lengths [Å] and angles [°] for  198f. 
______________________________________  
C(1)-C(2)  1.384(2) 
C(1)-C(6)  1.395(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.394(2) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.386(2) 
C(3)-N(1)  1.470(2) 
N(1)-O(1)  1.220(2) 
N(1)-O(2)  1.223(2) 
C(4)-C(5)  1.391(2) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.394(2) 
C(5)-H(5)  0.9500 
C(6)-N(2)  1.436(2) 
N(2)-N(3)  1.251(2) 
N(3)-C(7)  1.478(2) 
C(7)-C(9)  1.531(2) 
C(7)-C(8)  1.537(2) 
C(7)-C(17)  1.557(2) 
C(8)-H(8A)  0.9800 
C(8)-H(8B)  0.9800 
C(8)-H(8C)  0.9800 
C(9)-N(4)  1.267(2) 
C(9)-N(5)  1.402(2) 
N(4)-H(1N4)  0.88(3) 
N(5)-C(16)  1.386(2) 
N(5)-C(10)  1.435(2) 
C(10)-C(11)  1.389(2) 
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C(10)-C(15)  1.390(2) 
C(11)-C(12)  1.394(2) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.385(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.391(3) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.392(2) 
C(14)-H(14)  0.9500 
C(15)-H(15)  0.9500 
C(16)-O(3)  1.211(2) 
C(16)-C(17)  1.530(2) 
C(17)-C(19)  1.525(2) 
C(17)-C(18)  1.543(2) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
  
C(2)-C(1)-C(6) 119.54(15) 
C(2)-C(1)-H(1) 120.2 
C(6)-C(1)-H(1) 120.2 
C(1)-C(2)-C(3) 118.02(15) 
C(1)-C(2)-H(2) 121.0 
C(3)-C(2)-H(2) 121.0 
C(4)-C(3)-C(2) 123.62(15) 
C(4)-C(3)-N(1) 118.43(14) 
C(2)-C(3)-N(1) 117.92(14) 
O(1)-N(1)-O(2) 123.40(16) 
O(1)-N(1)-C(3) 118.68(14) 
O(2)-N(1)-C(3) 117.91(15) 
C(3)-C(4)-C(5) 117.60(14) 
C(3)-C(4)-H(4) 121.2 
C(5)-C(4)-H(4) 121.2 
C(4)-C(5)-C(6) 119.80(15) 
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C(4)-C(5)-H(5) 120.1 
C(6)-C(5)-H(5) 120.1 
C(5)-C(6)-C(1) 121.36(15) 
C(5)-C(6)-N(2) 115.15(14) 
C(1)-C(6)-N(2) 123.48(14) 
N(3)-N(2)-C(6) 113.78(14) 
N(2)-N(3)-C(7) 110.96(13) 
N(3)-C(7)-C(9) 108.05(13) 
N(3)-C(7)-C(8) 107.52(13) 
C(9)-C(7)-C(8) 108.76(13) 
N(3)-C(7)-C(17) 115.37(13) 
C(9)-C(7)-C(17) 102.90(13) 
C(8)-C(7)-C(17) 113.88(13) 
C(7)-C(8)-H(8A) 109.5 
C(7)-C(8)-H(8B) 109.5 
H(8A)-C(8)-H(8B) 109.5 
C(7)-C(8)-H(8C) 109.5 
H(8A)-C(8)-H(8C) 109.5 
H(8B)-C(8)-H(8C) 109.5 
N(4)-C(9)-N(5) 122.70(15) 
N(4)-C(9)-C(7) 130.71(15) 
N(5)-C(9)-C(7) 106.55(13) 
C(9)-N(4)-H(1N4) 108.6(18) 
C(16)-N(5)-C(9) 112.61(13) 
C(16)-N(5)-C(10) 122.55(13) 
C(9)-N(5)-C(10) 124.62(14) 
C(11)-C(10)-C(15) 121.36(15) 
C(11)-C(10)-N(5) 119.17(14) 
C(15)-C(10)-N(5) 119.40(14) 
C(10)-C(11)-C(12) 119.14(16) 
C(10)-C(11)-H(11) 120.4 
C(12)-C(11)-H(11) 120.4 
C(13)-C(12)-C(11) 120.28(16) 
C(13)-C(12)-H(12) 119.9 
C(11)-C(12)-H(12) 119.9 
C(12)-C(13)-C(14) 119.82(16) 
C(12)-C(13)-H(13) 120.1 
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C(14)-C(13)-H(13) 120.1 
C(13)-C(14)-C(15) 120.75(17) 
C(13)-C(14)-H(14) 119.6 
C(15)-C(14)-H(14) 119.6 
C(10)-C(15)-C(14) 118.63(16) 
C(10)-C(15)-H(15) 120.7 
C(14)-C(15)-H(15) 120.7 
O(3)-C(16)-N(5) 124.76(15) 
O(3)-C(16)-C(17) 126.92(15) 
N(5)-C(16)-C(17) 108.19(13) 
C(19)-C(17)-C(16) 111.40(13) 
C(19)-C(17)-C(18) 110.44(13) 
C(16)-C(17)-C(18) 104.73(13) 
C(19)-C(17)-C(7) 116.64(13) 
C(16)-C(17)-C(7) 101.68(13) 
C(18)-C(17)-C(7) 111.02(13) 
C(17)-C(18)-H(18A) 109.5 
C(17)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
C(17)-C(19)-H(19A) 109.5 
C(17)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 
C(17)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 
H(19B)-C(19)-H(19C) 109.5 
______________________________________  
Symmetry transformations used to generate equivalent atoms: 
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for jam01.  The anisotropic 
displacement factor exponent takes the form:  -2pi2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
_________________________________________________________________________________  
Atom U11 U22  U33 U23 U13 U12 
_________________________________________________________________________________  
C(1) 17(1)  13(1) 13(1)  -1(1) -3(1)  -3(1) 
C(2) 15(1)  14(1) 16(1)  -3(1) -4(1)  -2(1) 
C(3) 14(1)  11(1) 14(1)  -2(1) 0(1)  -3(1) 
N(1) 17(1)  15(1) 15(1)  -2(1) 0(1)  -5(1) 
O(1) 24(1)  28(1) 24(1)  -1(1) -5(1)  -13(1) 
O(2) 42(1)  42(1) 24(1)  14(1) -13(1)  -25(1) 
C(4) 19(1)  14(1) 13(1)  -2(1) -3(1)  -3(1) 
C(5) 16(1)  15(1) 15(1)  -3(1) -4(1)  -4(1) 
C(6) 15(1)  10(1) 15(1)  -2(1) -3(1)  -3(1) 
N(2) 16(1)  13(1) 15(1)  -1(1) -2(1)  -4(1) 
N(3) 14(1)  12(1) 14(1)  -3(1) 0(1)  -2(1) 
C(7) 13(1)  12(1) 11(1)  -2(1) -1(1)  -3(1) 
C(8) 15(1)  18(1) 15(1)  -6(1) 0(1)  0(1) 
C(9) 14(1)  12(1) 13(1)  -2(1) 0(1)  -3(1) 
N(4) 22(1)  14(1) 19(1)  -2(1) -6(1)  -4(1) 
N(5) 17(1)  11(1) 15(1)  0(1) -5(1)  -5(1) 
C(10) 19(1)  11(1) 12(1)  -1(1) -3(1)  -4(1) 
C(11) 19(1)  18(1) 16(1)  -4(1) -2(1)  -6(1) 
C(12) 29(1)  19(1) 16(1)  0(1) -2(1)  -13(1) 
C(13) 36(1)  14(1) 15(1)  -1(1) -6(1)  -5(1) 
C(14) 26(1)  17(1) 17(1)  -5(1) -6(1)  1(1) 
C(15) 20(1)  17(1) 16(1)  -3(1) -2(1)  -3(1) 
C(16) 17(1)  15(1) 13(1)  -3(1) -2(1)  -3(1) 
O(3) 28(1)  19(1) 21(1)  -2(1) -8(1)  -10(1) 
C(17) 13(1)  14(1) 11(1)  -3(1) -3(1)  -3(1) 
C(18) 17(1)  17(1) 16(1)  -6(1) -1(1)  -1(1) 
C(19) 14(1)  18(1) 18(1)  -5(1) -6(1)  -1(1) 
_________________________________________________________________________________ 
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 198f. 
______________________________________________________________________  
Atom x  y  z  U(eq) 
______________________________________________________________________  
H(1) 4976 4125 6136 18 
H(2) 7479 6237 4750 18 
H(4) 4194 7085 1357 18 
H(5) 1757 4901 2742 18 
H(8A) -820 1934 8545 25 
H(8B) -2473 642 8329 25 
H(8C) -2015 2526 7155 25 
H(1N4) 3460(50) 120(40) 8770(30) 28(7) 
H(11) -2025 -4594 10121 21 
H(12) -1379 -7536 11619 26 
H(13) 2228 -9008 11580 26 
H(14) 5219 -7517 10100 24 
H(15) 4604 -4592 8577 21 
H(18A) 1570 -1711 4532 25 
H(18B) 3256 -1231 5396 25 
H(18C) 2133 343 4209 25 
H(19A) -2471 -423 4852 25 
H(19B) -1905 1565 4774 25 
H(19C) -3427 435 6146 25 
______________________________________________________________________  
 
Table 6.  Torsion angles [°] for 198f. 
____________________________________________  
C(6)-C(1)-C(2)-C(3) 1.6(2) 
C(1)-C(2)-C(3)-C(4) 0.1(2) 
C(1)-C(2)-C(3)-N(1) 178.16(14) 
C(4)-C(3)-N(1)-O(1) -175.49(16) 
C(2)-C(3)-N(1)-O(1) 6.3(2) 
C(4)-C(3)-N(1)-O(2) 5.0(2) 
C(2)-C(3)-N(1)-O(2) -173.17(18) 
C(2)-C(3)-C(4)-C(5) -1.0(2) 
N(1)-C(3)-C(4)-C(5) -179.10(14) 
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C(3)-C(4)-C(5)-C(6) 0.3(2) 
C(4)-C(5)-C(6)-C(1) 1.4(2) 
C(4)-C(5)-C(6)-N(2) -179.06(14) 
C(2)-C(1)-C(6)-C(5) -2.3(2) 
C(2)-C(1)-C(6)-N(2) 178.14(14) 
C(5)-C(6)-N(2)-N(3) 160.32(14) 
C(1)-C(6)-N(2)-N(3) -20.1(2) 
C(6)-N(2)-N(3)-C(7) -179.31(12) 
N(2)-N(3)-C(7)-C(9) 168.07(13) 
N(2)-N(3)-C(7)-C(8) -74.70(16) 
N(2)-N(3)-C(7)-C(17) 53.59(17) 
N(3)-C(7)-C(9)-N(4) 35.4(2) 
C(8)-C(7)-C(9)-N(4) -81.1(2) 
C(17)-C(7)-C(9)-N(4) 157.83(17) 
N(3)-C(7)-C(9)-N(5) -147.02(13) 
C(8)-C(7)-C(9)-N(5) 96.56(15) 
C(17)-C(7)-C(9)-N(5) -24.54(16) 
N(4)-C(9)-N(5)-C(16) -170.87(16) 
C(7)-C(9)-N(5)-C(16) 11.26(18) 
N(4)-C(9)-N(5)-C(10) 3.8(2) 
C(7)-C(9)-N(5)-C(10) -174.05(14) 
C(16)-N(5)-C(10)-C(11) -64.9(2) 
C(9)-N(5)-C(10)-C(11) 120.88(18) 
C(16)-N(5)-C(10)-C(15) 111.97(18) 
C(9)-N(5)-C(10)-C(15) -62.2(2) 
C(15)-C(10)-C(11)-C(12) -1.4(3) 
N(5)-C(10)-C(11)-C(12) 175.49(16) 
C(10)-C(11)-C(12)-C(13) 0.3(3) 
C(11)-C(12)-C(13)-C(14) 1.0(3) 
C(12)-C(13)-C(14)-C(15) -1.4(3) 
C(11)-C(10)-C(15)-C(14) 1.0(3) 
N(5)-C(10)-C(15)-C(14) -175.88(16) 
C(13)-C(14)-C(15)-C(10) 0.5(3) 
C(9)-N(5)-C(16)-O(3) -176.36(16) 
C(10)-N(5)-C(16)-O(3) 8.8(3) 
C(9)-N(5)-C(16)-C(17) 7.50(18) 
C(10)-N(5)-C(16)-C(17) -167.31(14) 
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O(3)-C(16)-C(17)-C(19) 36.8(2) 
N(5)-C(16)-C(17)-C(19) -147.21(14) 
O(3)-C(16)-C(17)-C(18) -82.6(2) 
N(5)-C(16)-C(17)-C(18) 93.39(15) 
O(3)-C(16)-C(17)-C(7) 161.70(17) 
N(5)-C(16)-C(17)-C(7) -22.27(16) 
N(3)-C(7)-C(17)-C(19) -93.72(17) 
C(9)-C(7)-C(17)-C(19) 148.86(13) 
C(8)-C(7)-C(17)-C(19) 31.3(2) 
N(3)-C(7)-C(17)-C(16) 144.91(13) 
C(9)-C(7)-C(17)-C(16) 27.49(15) 
C(8)-C(7)-C(17)-C(16) -90.04(16) 
N(3)-C(7)-C(17)-C(18) 33.96(18) 
C(9)-C(7)-C(17)-C(18) -83.46(15) 
C(8)-C(7)-C(17)-C(18) 159.01(13) 
____________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Crystal structure and supporting data for pyrazole derivative 207b 
 
C5 C4
O2
N4
C6
N2 C3
C7
N1
O4
N3
C8
C16
C9
C17
N5
C1 C2
C11
C10
O1
C12
C15
C14
C13
 jam02, molecule; thermal ellipsoids are drawn on the 50% probability level 
  Table 1.  Crystal data and structure refinement for 207b. 
 
Identification code  207b 
Empirical formula  C18.625 H17.75 N5.75 O3.125 
Molecular formula C17 H15 N5 O3 x 0.75 (C2 H3 N) x 0.125 (C H4 O) 
Formula weight  372.29 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n (#14) 
Unit cell dimensions a = 13.394(2) Å  α= 90°. 
 b = 3.8267(6) Å  β= 92.688(3)°. 
 c = 33.470(5) Å  γ = 90°. 
Volume 1713.6(5) Å3 
Z 4 
Density (calculated) 1.443 Mg/m3 
Absorption coefficient 0.103 mm–1 
F(000) 779 
Crystal size 1.00 x 0.10 x 0.05 mm3 
Theta range for data collection 1.67 to 28.35°. 
Index ranges –17<=h<=17, –5<=k<=5, –44<=l<=44 
Reflections collected 16121 
Independent reflections 4230 [R(int) = 0.0280] 
Completeness to theta = 28.35° 99.1 %  
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Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9948 and 0.8070 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 4230 / 0 / 323 
Goodness–of–fit on F2 1.124 
Final R indices [I>2sigma(I)] R1 = 0.0653, wR2 = 0.1581 
R indices (all data) R1 = 0.0716, wR2 = 0.1617 
Largest diff. peak and hole 0.712 and –0.389 e.Å–3 
 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 207b.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________  
Atom x y z U(eq) 
______________________________________________________________________   
C(1) 6474(1) 6031(5) 2778(1) 15(1) 
C(2) 6972(1) 4984(5) 3130(1) 17(1) 
C(3) 6467(1) 5161(5) 3482(1) 16(1) 
N(1) 6980(1) 3973(5) 3855(1) 22(1) 
O(1) 7763(1) 2324(5) 3832(1) 28(1) 
O(2) 6601(1) 4682(6) 4172(1) 37(1) 
C(4) 5493(1) 6357(6) 3496(1) 18(1) 
C(5) 4998(1) 7407(5) 3142(1) 16(1) 
C(6) 5488(1) 7209(5) 2785(1) 14(1) 
N(2) 4991(1) 8199(4) 2421(1) 13(1) 
N(3) 5529(1) 9842(4) 2128(1) 15(1) 
C(7) 4050(1) 7338(5) 2282(1) 13(1) 
N(4) 3377(1) 5671(4) 2501(1) 14(1) 
C(8) 3951(1) 8532(5) 1888(1) 13(1) 
C(9) 3036(1) 7973(5) 1639(1) 14(1) 
O(4) 2272(1) 6763(4) 1784(1) 18(1) 
N(5) 3080(1) 8782(5) 1244(1) 17(1) 
C(10) 2333(2) 8435(5) 933(1) 18(1) 
C(11) 1413(2) 6846(6) 977(1) 23(1) 
C(12) 745(2) 6558(7) 647(1) 29(1) 
C(13) 977(2) 7824(7) 281(1) 34(1) 
C(14) 1878(2) 9490(7) 240(1) 36(1) 
C(15) 2558(2) 9791(7) 563(1) 27(1) 
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C(16) 4900(1) 10054(5) 1814(1) 14(1) 
C(17) 5246(2) 11775(5) 1445(1) 17(1) 
N(6) a) 4802(2) 6425(10) 590(1) 41(1) 
C(19) a) 5518(3) 5013(13) 480(1) 41(1) 
C(20) a) 6369(3) 3298(14) 354(1) 48(1) 
O(5) b) 5110(20) 4770(80) 351(8) 76(7) 
C(21) b) 5403(19) 5370(80) –18(8) 50(6) 
______________________________________________________________________  
a)
 s.o.f. fixed to 0.75   b) s.o.f. fixed to 0.125; only isotropic refinement possible (s.o.f.: site occupation factor) 
 
Table 3.   Bond lengths [Å] and angles [°] for  207b. 
______________________________________  
C(1)–C(2)  1.385(3) 
C(1)–C(6)  1.397(3) 
C(1)–H(1)  0.94(3) 
C(2)–C(3)  1.387(3) 
C(2)–H(2)  0.96(2) 
C(3)–C(4)  1.386(3) 
C(3)–N(1)  1.468(2) 
N(1)–O(2)  1.227(2) 
N(1)–O(1)  1.229(2) 
C(4)–C(5)  1.390(3) 
C(4)–H(4)  0.97(2) 
C(5)–C(6)  1.394(3) 
C(5)–H(5)  0.95(3) 
C(6)–N(2)  1.411(2) 
N(2)–C(7)  1.363(2) 
N(2)–N(3)  1.393(2) 
N(3)–C(16)  1.320(2) 
C(7)–N(4)  1.350(2) 
C(7)–C(8)  1.395(2) 
N(4)–H(1N4)  0.84(3) 
N(4)–H(2N4)  0.90(3) 
C(8)–C(16)  1.430(2) 
C(8)–C(9)  1.465(2) 
C(9)–O(4)  1.243(2) 
C(9)–N(5)  1.361(2) 
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N(5)–C(10)  1.417(2) 
N(5)–H(1N5)  0.86(3) 
C(10)–C(15)  1.389(3) 
C(10)–C(11)  1.389(3) 
C(11)–C(12)  1.393(3) 
C(11)–H(11)  1.00(3) 
C(12)–C(13)  1.368(4) 
C(12)–H(12)  0.94(3) 
C(13)–C(14)  1.377(4) 
C(13)–H(13)  0.98(3) 
C(14)–C(15)  1.384(3) 
C(14)–H(14)  0.99(3) 
C(15)–H(15)  0.95(3) 
C(16)–C(17)  1.491(3) 
C(17)–H(17A)  0.99(3) 
C(17)–H(17B)  0.97(3) 
C(17)–H(17C)  0.94(3) 
N(6)–C(19)  1.175(5) 
C(19)–C(20)  1.397(6) 
C(20)–H(20A)  0.9800 
C(20)–H(20B)  0.9800 
C(20)–H(20C)  0.9800 
O(5)–C(21)  1.33(4) 
O(5)–H(1O5)  0.8400 
C(21)–H(21A)  0.9800 
C(21)–H(21B)  0.9800 
C(21)–H(21C)  0.9800 
  
C(2)–C(1)–C(6) 119.88(17) 
C(2)–C(1)–H(1) 120.8(16) 
C(6)–C(1)–H(1) 119.3(16) 
C(1)–C(2)–C(3) 118.28(17) 
C(1)–C(2)–H(2) 121.8(14) 
C(3)–C(2)–H(2) 119.9(14) 
C(4)–C(3)–C(2) 122.85(18) 
C(4)–C(3)–N(1) 118.47(17) 
C(2)–C(3)–N(1) 118.67(17) 
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O(2)–N(1)–O(1) 123.85(18) 
O(2)–N(1)–C(3) 118.04(17) 
O(1)–N(1)–C(3) 118.12(17) 
C(3)–C(4)–C(5) 118.62(18) 
C(3)–C(4)–H(4) 118.7(14) 
C(5)–C(4)–H(4) 122.7(15) 
C(4)–C(5)–C(6) 119.41(17) 
C(4)–C(5)–H(5) 119.1(15) 
C(6)–C(5)–H(5) 121.4(15) 
C(5)–C(6)–C(1) 120.95(17) 
C(5)–C(6)–N(2) 120.25(16) 
C(1)–C(6)–N(2) 118.79(16) 
C(7)–N(2)–N(3) 111.61(15) 
C(7)–N(2)–C(6) 128.42(16) 
N(3)–N(2)–C(6) 119.27(15) 
C(16)–N(3)–N(2) 104.93(15) 
N(4)–C(7)–N(2) 123.93(17) 
N(4)–C(7)–C(8) 129.24(17) 
N(2)–C(7)–C(8) 106.82(16) 
C(7)–N(4)–H(1N4) 115.2(17) 
C(7)–N(4)–H(2N4) 121.8(18) 
H(1N4)–N(4)–H(2N4) 116(3) 
C(7)–C(8)–C(16) 104.61(16) 
C(7)–C(8)–C(9) 121.93(16) 
C(16)–C(8)–C(9) 133.39(17) 
O(4)–C(9)–N(5) 122.46(17) 
O(4)–C(9)–C(8) 121.05(17) 
N(5)–C(9)–C(8) 116.48(16) 
C(9)–N(5)–C(10) 129.25(17) 
C(9)–N(5)–H(1N5) 115.6(17) 
C(10)–N(5)–H(1N5) 115.1(17) 
C(15)–C(10)–C(11) 119.39(19) 
C(15)–C(10)–N(5) 116.51(18) 
C(11)–C(10)–N(5) 124.10(18) 
C(10)–C(11)–C(12) 119.3(2) 
C(10)–C(11)–H(11) 119.1(15) 
C(12)–C(11)–H(11) 121.6(15) 
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C(13)–C(12)–C(11) 121.2(2) 
C(13)–C(12)–H(12) 117.8(18) 
C(11)–C(12)–H(12) 121.0(18) 
C(12)–C(13)–C(14) 119.3(2) 
C(12)–C(13)–H(13) 122.4(19) 
C(14)–C(13)–H(13) 118.3(18) 
C(13)–C(14)–C(15) 120.6(2) 
C(13)–C(14)–H(14) 119.9(18) 
C(15)–C(14)–H(14) 119.4(18) 
C(14)–C(15)–C(10) 120.1(2) 
C(14)–C(15)–H(15) 121.5(17) 
C(10)–C(15)–H(15) 118.4(17) 
N(3)–C(16)–C(8) 111.99(16) 
N(3)–C(16)–C(17) 118.43(16) 
C(8)–C(16)–C(17) 129.58(17) 
C(16)–C(17)–H(17A) 112.1(15) 
C(16)–C(17)–H(17B) 111.5(15) 
H(17A)–C(17)–H(17B) 104(2) 
C(16)–C(17)–H(17C) 109.2(17) 
H(17A)–C(17)–H(17C) 110(2) 
H(17B)–C(17)–H(17C) 110(2) 
N(6)–C(19)–C(20) 179.1(5) 
C(19)–C(20)–H(20A) 109.5 
C(19)–C(20)–H(20B) 109.5 
H(20A)–C(20)–H(20B) 109.5 
C(19)–C(20)–H(20C) 109.5 
H(20A)–C(20)–H(20C) 109.5 
H(20B)–C(20)–H(20C) 109.5 
C(21)–O(5)–H(1O5) 109.5 
______________________________________  
Symmetry transformations used to generate equivalent atoms: 
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for 207b.  The anisotropic 
displacement factor exponent takes the form:  –2pi2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
_________________________________________________________________________________  
Atom U11 U22  U33 U23 U13 U12 
_________________________________________________________________________________  
C(1) 14(1)  17(1) 15(1)  –3(1) 1(1)  –1(1) 
C(2) 13(1)  18(1) 20(1)  –2(1) –1(1)  1(1) 
C(3) 16(1)  18(1) 14(1)  1(1) –4(1)  –1(1) 
N(1) 18(1)  29(1) 17(1)  2(1) –3(1)  –1(1) 
O(1) 21(1)  34(1) 27(1)  5(1) –6(1)  7(1) 
O(2) 31(1)  63(1) 15(1)  4(1) –2(1)  9(1) 
C(4) 17(1)  21(1) 15(1)  –2(1) 2(1)  1(1) 
C(5) 13(1)  17(1) 18(1)  –2(1) 1(1)  0(1) 
C(6) 14(1)  12(1) 15(1)  –1(1) –2(1)  –2(1) 
N(2) 12(1)  16(1) 13(1)  1(1) 1(1)  –1(1) 
N(3) 15(1)  16(1) 14(1)  2(1) 3(1)  –2(1) 
C(7) 13(1)  10(1) 14(1)  –3(1) 0(1)  2(1) 
N(4) 11(1)  17(1) 14(1)  2(1) 0(1)  –2(1) 
C(8) 14(1)  12(1) 13(1)  –1(1) 2(1)  0(1) 
C(9) 15(1)  12(1) 14(1)  –2(1) 1(1)  1(1) 
O(4) 15(1)  24(1) 16(1)  0(1) 1(1)  –4(1) 
N(5) 14(1)  23(1) 14(1)  2(1) 0(1)  –3(1) 
C(10) 21(1)  17(1) 14(1)  –2(1) –3(1)  2(1) 
C(11) 22(1)  26(1) 18(1)  0(1) –3(1)  –2(1) 
C(12) 27(1)  30(1) 28(1)  –1(1) –10(1)  –7(1) 
C(13) 45(1)  31(1) 25(1)  3(1) –19(1)  –10(1) 
C(14) 51(2)  39(1) 18(1)  7(1) –8(1)  –13(1) 
C(15) 33(1)  30(1) 18(1)  4(1) –3(1)  –10(1) 
C(16) 14(1)  13(1) 14(1)  –3(1) 2(1)  0(1) 
C(17) 17(1)  18(1) 15(1)  1(1) 2(1)  –4(1) 
N(6) a) 29(1)  61(2) 32(2)  2(2) 3(1)  8(2) 
C(19) a) 35(2)  63(3) 22(2)  –6(2) –10(1)  2(2) 
C(20) a) 39(2)  76(3) 30(2)  –11(2) 2(2)  –1(2) 
_________________________________________________________________________________  
a)
 s.o.f. fixed to 0.75 (s.o.f.: site occupation factor)
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 207b. 
______________________________________________________________________  
Atom x  y  z  U(eq) 
______________________________________________________________________  
H(1) 6791(19) 5940(70) 2533(8) 21(6) 
H(2) 7645(18) 4140(70) 3135(7) 19(6) 
H(4) 5186(18) 6430(70) 3753(7) 18(6) 
H(5) 4347(19) 8370(70) 3152(7) 20(6) 
H(1N4) 2884(19) 4830(70) 2370(7) 20(6) 
H(2N4) 3560(20) 4550(80) 2730(9) 30(7) 
H(1N5) 3648(19) 9510(70) 1171(7) 20(6) 
H(11) 1253(19) 5870(80) 1245(8) 26(7) 
H(12) 120(20) 5500(80) 669(8) 36(8) 
H(13) 530(20) 7550(90) 43(9) 43(8) 
H(14) 2060(20) 10320(90) –26(10) 44(9) 
H(15) 3190(20) 10900(80) 538(8) 33(7) 
H(17A) 5320(18) 10090(70) 1225(7) 21(6) 
H(17B) 4756(19) 13440(70) 1337(8) 24(6) 
H(17C) 5860(20) 12900(80) 1504(8) 31(7) 
H(20A) a) 6959 4754 413 72 
H(20B) a) 6298 2876 65 72 
H(20C) a) 6446 1062 495 72 
H(1O5) b) 5611 4362 503 114 
H(21A) b) 5069 7468 –127 74 
H(21B) b) 5228 3363 –189 74 
H(21C) b) 6129 5721 –10 74 
______________________________________________________________________  
a)
 s.o.f. fixed to 0.75   b) s.o.f. fixed to 0.125 (s.o.f.: site occupation factor) 
 
 Table 6.  Torsion angles [°] for 207b. 
____________________________________________  
C(6)–C(1)–C(2)–C(3) –0.3(3) 
C(1)–C(2)–C(3)–C(4) –0.4(3) 
C(1)–C(2)–C(3)–N(1) 178.48(18) 
C(4)–C(3)–N(1)–O(2) –13.3(3) 
C(2)–C(3)–N(1)–O(2) 167.8(2) 
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C(4)–C(3)–N(1)–O(1) 166.62(19) 
C(2)–C(3)–N(1)–O(1) –12.3(3) 
C(2)–C(3)–C(4)–C(5) 0.4(3) 
N(1)–C(3)–C(4)–C(5) –178.53(18) 
C(3)–C(4)–C(5)–C(6) 0.4(3) 
C(4)–C(5)–C(6)–C(1) –1.1(3) 
C(4)–C(5)–C(6)–N(2) 178.77(18) 
C(2)–C(1)–C(6)–C(5) 1.1(3) 
C(2)–C(1)–C(6)–N(2) –178.82(18) 
C(5)–C(6)–N(2)–C(7) –45.9(3) 
C(1)–C(6)–N(2)–C(7) 134.0(2) 
C(5)–C(6)–N(2)–N(3) 144.46(18) 
C(1)–C(6)–N(2)–N(3) –35.6(3) 
C(7)–N(2)–N(3)–C(16) 1.6(2) 
C(6)–N(2)–N(3)–C(16) 172.83(16) 
N(3)–N(2)–C(7)–N(4) 178.86(17) 
C(6)–N(2)–C(7)–N(4) 8.6(3) 
N(3)–N(2)–C(7)–C(8) –1.7(2) 
C(6)–N(2)–C(7)–C(8) –171.91(17) 
N(4)–C(7)–C(8)–C(16) –179.51(19) 
N(2)–C(7)–C(8)–C(16) 1.0(2) 
N(4)–C(7)–C(8)–C(9) –2.2(3) 
N(2)–C(7)–C(8)–C(9) 178.38(16) 
C(7)–C(8)–C(9)–O(4) 8.3(3) 
C(16)–C(8)–C(9)–O(4) –175.3(2) 
C(7)–C(8)–C(9)–N(5) –170.48(17) 
C(16)–C(8)–C(9)–N(5) 6.0(3) 
O(4)–C(9)–N(5)–C(10) –0.6(3) 
C(8)–C(9)–N(5)–C(10) 178.15(19) 
C(9)–N(5)–C(10)–C(15) 174.0(2) 
C(9)–N(5)–C(10)–C(11) –6.1(3) 
C(15)–C(10)–C(11)–C(12) 1.7(3) 
N(5)–C(10)–C(11)–C(12) –178.1(2) 
C(10)–C(11)–C(12)–C(13) –0.3(4) 
C(11)–C(12)–C(13)–C(14) –1.6(4) 
C(12)–C(13)–C(14)–C(15) 2.1(4) 
C(13)–C(14)–C(15)–C(10) –0.6(4) 
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C(11)–C(10)–C(15)–C(14) –1.3(4) 
N(5)–C(10)–C(15)–C(14) 178.6(2) 
N(2)–N(3)–C(16)–C(8) –0.9(2) 
N(2)–N(3)–C(16)–C(17) 178.80(16) 
C(7)–C(8)–C(16)–N(3) –0.1(2) 
C(9)–C(8)–C(16)–N(3) –176.98(19) 
C(7)–C(8)–C(16)–C(17) –179.71(19) 
C(9)–C(8)–C(16)–C(17) 3.4(4) 
____________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Abstract – The base induced cyclisations of azoacetates to azetidinones 
were investigated. In addition to the isolation of the desired products, it was 
found that 2-iminopyrrolidine-5-one derivatives as well as N-acyl hydrazides 
could be isolated when metal cyanides were employed as base. These entities 
were further modified to form pyrrolidine-2,5-diones and diazetidinones 
respectively.
INTRODUCTION 
The search for new β-lactam species as antibacterial agents has been in decline in recent times due to 
problems encountered with the rapid development of resistant strains of bacteria. However due to the low 
levels of toxicity inherent to these compounds there has been a simultaneous surge in interest in any 
newly generated species in ancillary roles. Monocyclic β-lactams with non-classical features, bearing 
simple aryl and alkyl moieties have been of particular interest recently in a variety of roles ranging from 
anti-cancer agents,1 and HIV-1 protease inhibitors,2 to anti-fungal agents.3 The synthesis of some 
azetidinones and diazetidinones through the reaction of the appropriate azoacetates with various bases has 
been previously reported by this group.4 Herein we report in full the experimental details of these 
procedures and the related spectral data. In addition to these published intramolecular ring closures it has 
been discovered that products of intermolecular reactions between the azoacetate and the cyanide ion can 
be isolated in reasonable yields in some cases. The generation of the 2-iminopyrrolidine-5-one derivatives 
is presumably due to a nucleophilic displacement of the acetate group by the cyanide ion to form the 
nitrile entity followed by spontaneous cyclisation. Relatively few examples of synthetic routes to these 
  
molecules can be found in the mainstream literature.5 However it will be shown here that these 
compounds provide a valuable route to the synthetically and medicinally versatile pyrrolidine-2,5-dione 
(succinimide) molecules.6 The azoacetate derived from α,α-dimethyl ethylacetoacetate was found to form 
an N-acyl hydrazide rearrangement product that could be isolated and subsequently, after hydrolysis of 
the ester moiety, cyclised to form a diazetidinone derivative. It was found that azo functionality in the 
azetidinones reported here could be easily oxidized to give the corresponding azoxy species. The scope of 
this reaction to furnish further compounds is currently under investigation. Also discussed is the 
unexpected cyclisation of the α,α-unsubstituted azoacetate derivatives to form pyrazole ring derivatives. 
RESULTS AND DISCUSSION 
The azoacetates in question were synthesized in several steps from simple inexpensive starting materials 
using facile procedures. Where possible commercially available acetoacetanilides were used as starting 
materials, the remainder were generated by simply heating the appropriately substituted aniline (2a-e) (1 
molar equivalents) with ethyl acetoacetate (1) (5 molar equivalents) to 160 ºC until the evolution of 
ethanol had ceased, after removing the bulk of the remaining ethyl acetoacetate by vacuum distillation the 
desired acetoacetanilides could be easily crystallized by scratching the reaction vessel.7  
Table 1. Synthesis of acetoacetanilides from ethyl acetoacetate 
 
 
 
 
 
 
 
Entry Substrate R1 R2 R3 Product Yield (%) 
1 2a H H Br 3a 90 
2 2b H H OMe 3b 88 
3 2c Me Me H 3c 91 
4 2d H H Me 3d 85 
5 2e H H CO2Et 3e 77 
These were further purified by recrystallization from EtOAc/hexane before being used in the next stage. 
Dimethylation of the acetoacetanilides (3a-j) was achieved by refluxing overnight with an excess of 
methyl iodide (6 molar equivalents) and potassium carbonate (3 molar equivalents). In the case of the 
methyl, benzyl substituted example 7 the substrate acetoacetanilide was initially methylated using methyl 
iodide in a 1:1:1.5 ratio of substrate : base : methyl iodide. This resulted in the production of the mono-
methylated species 6 as the major product but also resulted in the production of some of the di-methylated 
1 2 
3 
160 0C 
O
O OEt
H2N
R1 R2
R3
O
O NH
R1
R2
R3
+
  
product 5j. It was found that the desired mono-methylated compound could be isolated in pure form after 
several recrystallizations from ethanol. The subsequent benzylation was carried out under similar reaction 
conditions using an excess of benzyl chloride as alkylating agent.  
 
Table 2. Alkylation of ester and anilides 
 
 
 
 
 
Entry Substrate Y = OEt or NH-Ar Product a Yield (%) 
 
 R1 R2 R3   
1 1 - - - 4 80 
2 3a H H Br 5a 79 
3 3b H H OMe 5b 78 
4 3c Me Me H 5c 80 
5 3d H H Me 5d 83 
6 3e H H COOEt 5e 70 
7b 3f H H H 5f 80 
8b 3g Me H Me 5g 67 
9b 3h Me H H 5h 75 
10b 3i OMe H H 5i 74 
11b 3j H H Cl 5j 69 
12b 3j H H Cl 6 74 
13 6 H H Cl 7 90 
a In all entries R4 = CH3, except in entry 12 (Product 6) where, R4 = H, and entry 13 (Product 7) where, R4 
= Bn, bStarting materials were commercially available acetoacetanilides. 
 
4-Nitrophenylhydrazone derivatives were prepared of the starting materials ethyl acetoacetate (1) and the 
acetoacetanilide (3f) along with α,α-disubstituted ethyl acetoacetate (4) and all of the α,α-disubstituted 
acetoacetanilides (5a-j and 7, Table 3) by stirring the substrates in a slight excess (1.1 molar equivalents) 
of 4-nitrophenylhydrazine in MeOH under mild acidic conditions (~5% acetic acid).8 This procedure 
routinely furnished the desired hydrazones in reasonable yields (50-72%). 
Substrate Y X R’ Product a 
1 OEt I Me 4 
3 NH-Ar I Me 5 
3 NH-Ar I Me 6 
6 NH-Ar Cl Bn 7 
 
O
O
Y
O
O
Y
Me
R4
R’— X / K2CO3   
R1 R2
R3Ar =  
  
 
Table 3. Synthesis of 4-nitrophenylhydrazone derivatives 
 
 
 
 
 
 
 
 
 
 
a
 With reference to aromatic groups Ar, substitutions at R1, R2 and R3 are as shown in Table 2 
 
The synthesis of the azoacetates of these hydrazones was found to be equally facile (Table 4), once again 
it was found that merely stirring the substrate hydrazones overnight in a mildly acidic CH2Cl2 solution 
(10% acetic acid) containing a slight excess (1.1 molar equivalents) of Pb(OAc)4 was sufficient to effect 
the desired transformation.9 After a standard work-up, flash chromatography was used to separate the 
azoacetates from any persistent lead salt residues 
Table 4. Synthesis of azoacetate derivatives 
 
 
 
 
 
 
 
 
 
 
a
 With reference to aromatic groups Ar, substitutions at R1, R2 and R3 are as shown in Table 2 
The reactions of the azoacetates with various bases produced the most interesting results (Scheme 1). It 
was found that the azoacetates derived from α,α-dimethylated acetoacetanilide or α-methyl-α-benzyl 
acetoacetanilide could be cyclised to azetidinones (18f, 18j and 19) upon treatment with K2CO3 under 
reflux in acetone. It was also found that the cyclisation could be carried out in other conditions; 
Substrate Y R4 R5 Product Yield(%) 
1 OEt H H 8 55 
3f a NH-Ar H H 9f 59 
4 OEt Me Me 10 65 
5a-j a NH-Ar Me Me 11a-j 50-72 
7 a NH-Ar Me Bn 12 39 
Substrate Y R4 R5 Product Yield(%) 
8 OEt H H 13 65 
9f a NH-Ar H H 14f 68 
10 OEt Me Me 15 77 
11a-ja NH-Ar Me Me 16a-j 70-89 
12a NH-Ar Me Bn 17 56 
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azetidinones (18a-j) were also isolated when the reaction was carried out in n-propanol using KCN as 
base. When the reactions of previously reported azoacetates (16f and 16j) were more closely examined it 
was found that in addition to the reported rearrangement products 20f and 20j, an additional cyclised 
compound could be isolated in both cases. The isolation of these 2-iminopyrrolidine-5-one products (21f 
and 21j) is a relatively rare example of the incorporation of cyanide moiety into a heterocyclic system in a 
one step process. It would seem that both the basic and nucleophilic properties of the cyanide species 
have an effect on the formation of reaction products in this case. The formation of these products has been 
confirmed by spectral analysis (NMR, IR, MS) and in the case of azetidinone (18j) and 2-
iminopyrrolidine-5-one derivative (21f) by X-ray crystal structure determination (Figures 1a and b.) 
 
 
 
 
 
substrate  product 
16a-j    18f and j 
17    19 
 
 
 
 
  
 
Scheme 1 
The formation of these three products are clearly as a result of different reaction mechanisms, they do 
however all conform to previously postulated reaction pathways. Instances of the base induced 
abstraction of the relatively acidic amido-hydrogen, followed by cyclisation through loss of a leaving 
group (Scheme 2a) can be commonly found in the literature related to β-lactam formation.10 However the 
acetate moiety acting as leaving group in this manner under such mild conditions has, to our knowledge, 
not been previously reported. Of note amongst the azetidinone products isolated was compound 18e, it 
was found that the transesterification product of the azetidinone was isolated. The action of the 
base/propanol media in this case resulted in the isolation of the 4-propyl ester derivative as sole 
azetidinone product in this case. Also two diastereomeric forms of azetidinone derivative (19) were 
isolated and could be differentiated on the basis of differing chemical shift values for key NMR spectral 
values (e.g. benzyl CH2 shift). 
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Figure 1a: X-Ray crystal structure of azetidinone 18j 
 
 
 
 
 
 
 
 
 
Figure 1b: X-Ray crystal structure of 2-iminopyrrolidine-5-one derivative 21f 
The α-azo-α-nitrile functionality is a known species and it has been demonstrated that in certain cases, the 
nitrile group can be introduced at a position α to an azo-group by reaction of a hydrazone with metal 
cyanides.11 The intermolecular nucleophilic displacement of a leaving group by the cyanide species to 
form a nitrile followed by cyclisation, as in the case of the formation 2-iminopyrrolidine-5-ones (21f and 
21j) has also previously been studied by Nisole et al.12 The isolation 2-iminopyrrolidine-5-ones directly 
upon treatment of carbamoylated chloroenamines with metal cyanides in alcohol have similarly been 
observed by Vilsmaier et al.13 In that case, the cyclisation took place spontaneously under the action of 
the basic reaction media with a similar mechanism proposed; some parallels can be drawn to the 
observations made here, in so far as the isolation of the nitrile intermediate was not achieved. Since the 
formation of the cyclised product through incorporation of the cyanide ion is evident, it is reasonable to 
assume that the intermediate 22 in Scheme 2b, plays a role.  
It is proposed that the rearrangement of azoacetates (16f and 16j) to N-acyl hydrazides (20f and 20j) takes 
place via an alcoholysis mechanism involving the formation of an azocarbinol  species (a.k.a. α-hydroxy 
phenylazo compounds) such as intermediate 23 in Scheme 2c. It seems most likely that it is this species 
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that undergoes the rearrangement. The transformation of azoacetates to azocarbinols in this way has 
previously been shown to be possible.14Barton et al utilized 2-t-butyl-1,1,3,3-tetramethyl guanidine base 
(Barton’s base) to effect this type of transformation in ethanol, however efforts to isolate intermediate 23 
in a similar manner failed. The azocarbinol species in general is notoriously unstable, and it would seem 
that the formation of the rearrangement product is the favored process in this case.  
In order to further investigate the versatility of the compounds synthesized, some supplementary reactions 
were carried out on the products mentioned thus far and it was found that a further array of interesting 
compounds could be created. In the case of the N-acyl hydrazide derivative (24) isolated from the 
reaction of azoacetate (15) with potassium cyanide it was found that the ester moiety could be easily 
hydrolyzed to the carboxylic acid 25 and this could then be cyclised to give a diazetidinone product (26, 
Scheme 3). The structure of the rearrangement product 24 was confirmed by X-Ray crystallography. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3 
 
 
 
 
 
 
 
 
 
Figure 2: X-Ray crystal structure of rearrangement product 24 
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Among the many published synthetic routes to the versatile succinimide compounds perhaps the simplest 
is the acid catalyzed hydrolysis of 2-iminopyrrolidine-5-ones.15 The appearances of several versions of 
the procedure in the literature show it to be a robust high-yielding technique that can be used when a 
variety of functional groups are present adjacent to the imino functionality. In the example presented here 
(Scheme 4) a smooth transition with high yield was achieved. 2-iminopyrrolidine-5-one (21f) was 
converted to the corresponding succinimide (27f). The substrate 21f was introduced to a refluxing 
solution of aqueous acetic acid and allowed to reflux for a further 24 h after which the desired 
succinimide was easily extracted into organic solvent (CH2Cl2) and purified by flash chromatography. 
 
 
 
 
 
 
 
Scheme 4 
It was found that the azoxy derivative 28h of azetidinone (18h) could be generated through reaction with 
hydrogen peroxide in the presence of acetic acid. Although all spectral data supports the formation of the 
azoxy functionality at a position adjacent to the phenyl group, since an X-Ray crystal structure of the 
product was not obtained in this case this characterization is somewhat tentatively assigned. The 
formation of the azoxy functionality is in little doubt; however guidelines to the assignment of the 
position of the azoxy oxygen found in the literature were at times contradictory and at best speculative. 
Some consensus seems to have been reached on the issue of the increase in the deshielding effect on 
groups adjacent to the newly formed azoxy group by comparison to the parent azo compound. The 
creation of the azoxy group presented here was indeed accompanied by a large downfield shift by the 
aromatic proton signals adjacent to the proposed site of the azoxy oxygen. 
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Scheme 5 
The production of the 2-iminopyrrolidine-5-one derivative (21f) raised the question of what might happen 
under similar conditions with an α,α-unsubstitued azoacetate. The investigations of this question led to an 
unexpected cyclisation. It was found that when these substrates 13 and 14f were subjected to identical 
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conditions to those used previously with the α,α-dimethylated azoacetate derivatives, that once again a 
cyano unit was incorporated into the cyclic product. However, in this case the absence of alkyl groups at 
positions α to the carbonyl allows for the formation of the pyrazole derivatives (29 and 30f) as the 
intermolecular reaction products.16  
 
 
 
 
 
 
 
 
 
 
Scheme 6 
Confirmation of the structure has been established by X-Ray crystal structure analysis in the case of 
compound 30f. Although the isolation of these compounds has been previously reported, different 
methodologies were employed in the synthesis. Furthermore, the crystal structure of this species has not 
been published to date. 
 
 
 
 
 
 
 
 
Figure 3. X-Ray crystal structure of pyrazole derivative 30f 
 
Scheme 7 depicts a proposed mechanism for the formation of pyrazole derivative (29) from the 
corresponding azoacetate derivative (13). In light of the basic reaction conditions, the formation of the 
pyrazole is presumably due to initial elimination of a unit of acetic acid aided by stabilization of the 
product provided by the neighboring phenylazo group. Nucleophilic addition at this newly formed double 
bond provides a cyano substituted hydrazone substrate for cyclisation to the pyrazole ring, as has been 
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previously proposed by Shawali et al.17 In that case the proposed formation of the hydrazone species was 
as a result of the condensation of a hydrazidic halide and ethyl cyanoacetate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7 
In conclusion the results presented here, demonstrate the synthetic versatility of these azoacetates derived 
from simple, inexpensive starting material. The examples shown here of both endo- and exocyclic 
incorporation of the azo functionality into heterocyclic systems demonstrate the value of a previously 
unexplored resource in the synthetic sphere. A range of products from established medicinally important 
families of compounds have been synthesized through simple modifications using facile procedures. It is 
deemed noteworthy to point out that the synthesis of products based solely on 4-nitrophenyl hydrazone 
derivatives was due to their inherent stability to the acidic conditions required for condensation. Some 
arylhydrazone derivatives of β-keto esters are prone to spontaneous cyclisation giving, pyrazoles and 
pyrazolones.18 Our research has not been based exclusively on arylhydrazones of this type, however these 
compounds were chosen for presentation at this time due to the reliability and reproducibility of the 
results obtained. 
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EXPERIMENTAL 
Ethyl acetoacetate, iodomethane, benzyl chloride and substituted acetoacetanilides were purchased from 
the Sigma Aldrich chemical company and were used as received. All solvents were dried or distilled prior 
to use. Melting points were determined using a Griffin melting point apparatus and are uncorrected. 
Infrared spectra were recorded on a Perkin-Elmer 2000FT-IR spectrometer. NMR spectra were recorded 
using a Bruker AC 400 NMR spectrometer operating at 400 MHz for 1H NMR and at 100 MHz for 13C 
NMR. The 1H and 13C NMR chemical shifts (ppm) are relative to TMS and all coupling constants (J) are 
in Hertz (Hz).  
 
X-Ray crystallographic data 
"CCDC 272234 (18j), CCDC 686905 (21f), CCDC 686907 (24), and CCDC 686906 (30f), contains the 
supplementary crystallographic data for this paper. These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting 
The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 
1223 336033." 
 
Preparation of acetoacetanilides (3a-e) 
These compounds were prepared according to a general procedure a representative example is given. 
Synthesis of 4-bromoacetoacetanilide (3a) 
Ethyl acetoacetate (65.1 g, 0.5 mol) was heated to 160 oC in a round bottomed flask with reflux condenser 
fitted. To this was added 4-bromoaniline (17.0 g, 0.1 mol). When the evolution of EtOH began the 
reaction was allowed to reflux for 2-3 h until the reaction was complete (TLC) before the EtOH was 
distilled off. The bulk of the remaining ethyl acetoacetate was removed by vacuum distillation at 90o C, 
50mbar. The resulting oily residue was scratched with a glass rod to promote precipitation. The 
precipitate was filtered and washed with hexane before being recrystallised from an EtOAc:hexane 30:70 
mixture. Yield  (22.8 g, 90.1 %); mp 132-135 ºC; 1H NMR (400MHz, DMSO-d6): δ =, 2.21 (3H, s, CH3), 
3.56 (2H, s, CH2), 7.48 (2H, ArH, J = 8.8), 7.55 (2H, d, ArH, J = 8.8) 10.21 (1H, s, NH); 13C NMR 
(100MHz, DMSO-d6) 30.2, 52.3, 114.9, 120.9, 131.5, 138.2, 165.2, 202.7; IR (KBr) 3292, 1718, 1661, 
1607, 1554, 1491, 1396, 1162, 1075, 832, 505 cm-1. 
 
Preparation of α,α-dimethylethylacetoacetate (4) and α,α-dimethylacetoacetanilides (5a-j) 
These compounds were prepared according to a general procedure a representative example is given. 
Synthesis of α,α-dimethyl-4-bromoacetoacetanilide (5a) 
(6.62 g, 25.9 mmol) of 4-bromoacetoacetanilide was dissolved in 150 ml of acetone, to this was added 
K2CO3 (7.8 g, 56.4 mmol) and the reaction was set to reflux. Once the reaction had reached reflux 
  
temperature iodomethane (22.45 g, 158.2 mmol) was added and the reaction was allowed to reflux 
overnight. The solvent was reduced to 1/5 of the original volume by rotary evaporation and the entire 
contents of the reaction vessel were poured into a beaker containing 200 ml of ice-water. The product 
formed an oil and was extracted with CH2Cl2 (5 x 50 ml). The organic extracts were combined, dried over 
magnesium sulfate and evaporated to an oil under reduced pressure. A small portion of the oil was 
removed and precipitation was induced by scratching, this was then returned to the bulk in order to seed 
the crystallization of the remaining oil. The solid was filtered and washed with hexane, this was further 
recrystallized from an EtOAc:hexane 70:30 mixture. Yield  (5.84 g, 79.4 %); mp 85-87 ºC; 1H NMR 
(400MHz, DMSO-d6): δ =, 1.37 (6H, s, 2 x CH3), 2.15 (3H, s, CH3), 7.48 (2H, ArH, J = 9.2), 7.61 (2H, d, 
ArH, J = 8.8), 9.57 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 21.8, 25.7, 56.5, 115.3, 122.2, 131.3, 
138.2, 171.8, 207.2; IR (KBr) 3361, 1684, 1531, 1490, 1394, 1310, 1239, 1240, 1117, 1071, 818 cm-1. 
 
Preparation of α-methyl-4-chloroacetoacetanilide (6) and α-methyl-α-benzyl- 4-
chloroacetoacetanilide (7) 
Synthesis of α-methyl-4-chloroacetoacetanilide (6)  
(10.8 g, 51.2 mmol) of 4-chloroacetoacetanilide (3j) was dissolved in acetone (75 ml) and) K2CO3 (7.2 g, 
52.0 mmol) was added and the reaction brought to reflux. Iodomethane (10.66 g, 75.1 mmol) was added 
dropwise with stirring to the reaction vessel over 1 h and the reaction was allowed to reflux for a further 2 
h. The reaction mixture was cooled and poured into ice-water (150 ml) and allowed to stir for 30 min, a 
white precipitate (6) was collected and recrystallized several times from aqueous EtOH to remove any 
dimethylated product (5j). Yield: (8.59 g, 74.4%); mp 125-129 ºC; 1H NMR (400MHz, DMSO-d6): δ =, 
1.23 (3H, d, CH3, J = 6.8), 2.17 (3H, s, CH3), 3.65 (1H, q, CH, J = 6.8), 7.37 (2H, d, ArH, J = 8.8), 7.50 
(2H, d, ArH, J = 8.8), 10.34 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 13.0, 28.2, 54.5, 120.8, 127.1, 
128.6, 137.8, 168.9, 204.3. IR (KBr) 3241, 1720, 1654, 1604, 1543, 1494, 1403, 1081, 826 cm-1. 
 
Synthesis of α-methyl-α-benzyl-4-chloroacetoacetanilide (7) 
(6.8 g, 30.2 mmol) of α-methyl-4-chloroacetoacetanilide (6) was dissolved in acetone 50 ml and (7.2 g, 
52.0 mmol) of K2CO3 was added and the reaction brought to reflux. Benzyl chloride (6.58 g, 52.0 mmol) 
was added dropwise with stirring to the reaction vessel over 1 h and the reaction was allowed to reflux 
overnight. The reaction mixture was cooled and poured into ice-water (150 ml) and allowed to stir for 30 
min, a white precipitate (7) was collected and recrystallized from an EtOAc:hexane 70:30 mixture. Yield: 
(8.53 g, 89.5%); mp 124-127 ºC; 1H NMR (400MHz, DMSO-d6): δ =, 1.27 (3H, s, CH3), 2.20 (3H, s, 
CH3), 3.07 (1H, d, CH2, J = 13.6), 3.36 (1H, d, CH2, J = 13.6), 7.11-7.23 (5H, m, ArH), 7.77 (2H, d, 
ArH, J = 8.8), 7.43 (2H, d, ArH, J = 8.8), 9.68 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 18.7, 26.3, 
  
39.7, 61.3, 122.3, 126.5, 127.6, 128.0, 128.1, 130.1, 136.7, 137.5, 170.2, 206.3; IR (KBr) 3328, 1720, 
1654, 1604, 1543, 1494, 1403, 1081, 826 cm-1. 
 
Preparation of hydrazone derivatives (8, 9a and f, 10, 11a-j, 12) 
These compounds were prepared according to a general procedure a representative example is given. 
Synthesis of 4-nitrophenyl hydrazone derivative of α,α-dimethyl-4-bromoacetoacetanilide (11a) 
(4.0 g, 14.0 mmol) of 2,2-dimethyl-4-bromoacetoacetanilide (5a) was dissolved in MeOH 75 ml, (2.6 g, 
16.8 mmol) of 4-nitrophenylhydrazine was dissolved in warm acetic acid (3.25 ml) and added to the 
stirring reaction vessel. After 1-2 min a yellow precipitate began to fall from solution, the reaction was 
allowed to stir overnight and the precipitate collected and dried. Yield  (4.01 g, 68 %); mp 197-200 ºC; 1H 
NMR (400MHz, DMSO-d6): δ = 1.48 (6H, s, 2 x CH3), 1.96 (3H, s, CH3), 7.27 (2H, d, ArH, J = 8.8), 
7.50 (2H, d, ArH, J = 9.2), 7.65 (2H, d, ArH, J = 8.8), 8.12 (2H, d, ArH, J = 8.8), 9.43 (1H, s, NH), 9.97 
(1H, s, NH); 13C NMR (100MHz, DMSO-d6) 13.7, 23.5, 51.3, 111.6, 115.1, 122.5, 125.8, 131.2, 138.1, 
138.5, 151.8, 151.9, 173.5; IR (KBr) 3322, 1671, 1596, 1492, 1324, 1260, 1113, 1089, 841, 821 cm-1. 
 
Preparation of azoacetate derivatives (13, 14a and f, 15, 16a-j, 17) 
These compounds were prepared according to a general procedure a representative example is given. 
Synthesis of azoacetate derivative of α,α-dimethyl-4-bromoacetoacetanilide (16a)  
(3.0 g, 7.15 mmol) of the hydrazone substrate (11a) was dissolved in CH2Cl2 (100 ml). To this was added 
(3.8 g, 8.6 mmol) of lead tetraacetate with stirring. 5 ml of glacial acetic acid was added to aid the 
dissolution of the lead tetraacetate and the solution was allowed to stir overnight. When the reaction was 
judged complete (TLC) the solvent volume was reduced by 75% and the remaining CH2Cl2 solution was 
washed alternately with 5 x 50 ml portions of water and 5 % aqueous sodium bicarbonate solution. The 
organic portion was dried over magnesium sulfate and evaporated to dryness and any persistent lead 
residues were removed by flash chromatography using a 25 : 75 EtOAc : hexane mixture as eluent. Yield 
(2.80 g, 82%); mp 202-205 ºC; 1H NMR (400MHz, DMSO-d6): δ =, 1.28 (3H, s, CH3), 1.40 (3H, s, CH3), 
1.86 (3H, s, CH3), 2.18 (3H, s, CH3), 7.48 (2H, d, ArH, J = 8.8), 7.57 (2H, d, ArH, J = 9.2), 7.75 (2H, d, 
ArH, J = 8.8), 8.37 (2H, d, ArH, J = 8.8). 9.19 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 17.2, 20.5, 
20.6, 21.5, 51.0, 103.6, 115.5, 123.0, 123.2, 125.0, 131.2, 138.0, 148.5, 153.9, 168.8, 171.1; IR (KBr) 
3324, 1731, 1687, 1605, 1539, 1344, 1240, 1175, 868 cm-1. 
 
Preparation of azetidinones derivatives (18f and 19) procedure 1 
Synthesis of azetidinone derivative (18f) using procedure 1 
Anhydrous potassium carbonate (0.5 g, 3.6 mmol) was added to azoacetate 16f (1.2 g, 3 mmol) in 50 ml 
of refluxing acetone. The solution was allowed to reflux for 22 h after which time (TLC) showed the 
  
reaction to be complete. The insoluble material was filtered from the solution and the filtrate evaporated 
to dryness. The azetidinone product (18f) was isolated after silica gel column chromatography using 
CHCl3 as eluent. Yield  (0.223 g, 22 %); mp 87-89 ºC; 1H NMR (400MHz, CDCl3): δ = 1.08 (3H, s, 
CH3), 1.50 (3H, s, CH3), 1.92 (3H, s, CH3), 7.15-7.11 (1H, m, ArH), 7.35-7.03 (2H, m, ArH), 7.43 (2H, d, 
ArH, J = 8.8), 7.88 (2H, d, ArH, J = 8.8), 8.37 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 17.3, 
19.1, 19.2, 60.5, 90.2, 118.3, 123.4, 124.4, 124.9, 129.1, 137.2, 149.2, 154.1, 170.5; IR (KBr) 1759, 1599, 
1527, 1495, 1368, 1346, 862, 756, 690 cm-1. 
 
Synthesis of azetidinone derivative (19) using procedure 1 
(19a) Yield  (8.3%); mp 139-141 ºC; 1H NMR (400MHz, CDCl3): δ = 0.85 (3H, s, CH3), 1.94 (3H, s, 
CH3), 3.01 (1H, d, CH, J = 14.4),  3.32 (1H, d, CH, J = 14.4), 7.27-7.07 (9H, m, ArH,), 7.78 (2H, d, ArH, 
J = 8.8), 8.29 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 16.8, 17.8, 30.6, 64.6, 91.1, 120.0, 
125.3, 124.9, 127.2, 128.5, 128.5, 129.1, 129.9 136.1, 136.6, 149.7, 154.2 170.0; IR (KBr) 1745, 1527, 
1494, 1383, 1342, 1091, 827, 692 cm-1. Anal. Calcd. for C24H21ClN4O3: C, 64.21; H, 4.72; N, 12.48. 
Found: C; 64.01, H; 4.84, N; 12.18. 
(19b) Yield  (11.6%); mp 137-139 ºC; 1H NMR (400MHz, CDCl3): δ = 1.43 (3H, s, CH3), 1.99 (3H, s, 
CH3), 2.67 (1H, d, CH, J = 14.4), 2.90 (1H, d, CH, J = 14.8), 7.27-7.10 (9H, m, ArH,), 7.87 (2H, d, ArH, 
J = 8.8), 8.36 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 15.1, 15.9, 36.3, 62.7, 89.2, 118.0, 
122.0, 123.3, 125.2, 126.7, 127.5, 127.9, 128.4, 134.2, 134.7,147.8, 152.3, 168.0; IR (KBr) 1757, 1528, 
1494, 1367, 1345,1180, 1092, 820, 745 cm-1. 
Preparation of azetidinones derivatives (18a-j) procedure 2 
Synthesis of azetidinone derivative (18a) using procedure 2 
(1g, 2.1 mmol) of the azoacetate derivative (16a) was dissolved in hot propanol (40 ml) to which (0.15 g, 
2.3 mmol) of potassium cyanide was added. The solution was allowed to reflux for 30 min, after which 
TLC showed development of product spots and total consumption of the starting material, this was 
evaporated to dryness. Water (100 ml) was added to the reaction vessel and this was extracted with 
EtOAc (2 x 25 ml) followed by CH2Cl2 (2 x 25 ml). The combined extracts were dried over magnesium 
sulfate and upon evaporation to dryness an orange oil was collected. The product was isolated after 
column chromatography. Yield  (0.14 g, 16 %); mp 155-158 ºC; 1H NMR (400MHz, CDCl3): δ = 1.19 
(3H, s, CH3), 1.42 (3H, s, CH3), 1.62 (3H, s, CH3), 7.18 (2H, d, ArH, J =8.8), 7.55 (2H, d, ArH, J =8.8), 
7.76 (2H, d, ArH, J = 9.2), 8.28 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 13.3, 17.8, 24.4, 49.3, 
83.0, 122.5, 123.4, 124.9, 127.7, 130.8, 132.4, 153.8, 174.0, 180.1; IR (KBr) 1755, 1520, 1489, 1362, 
1347, 827, 753 cm-1. Anal. Calcd. for C18H17BrN4O3: C, 51.81; H, 4.11; N, 13.43, Found: C; 52.10, H; 
4.28, N; 13.21. 
 
  
Synthesis of azetidinone derivative (18b) using procedure 2 
Yield  (0.15 g, 20 %); mp 95-98 ºC; 1H NMR (400MHz, CDCl3): δ = 0.98 (3H, s, CH3), 1.40 (3H, s, 
CH3), 1.77 (3H, s, CH3), 3.71 (3H, s, OCH3), 6.77 (2H, d, ArH, J =9.2), 7.28 (2H, d, ArH, J =9.2), 7.79 
(2H, d, ArH, J = 9.2), 8.28 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 17.2, 19.1, 19.2, 55.5, 
60.4, 90.3, 114.3, 120.3 123.3, 124.8, 130.2, 149.2, 154.1, 156.5, 170.2; IR (KBr) 1759, 1513, 1392, 
1346, 1247, 1184, 1164, 1031, 860, 828, 751, 688 cm-1
.
 
 
Synthesis of azetidinone derivative (18c) using procedure 2 
Yield  (0.21 g, 25 %); mp 112-116 ºC; 1H NMR (400MHz, CDCl3): δ = 1.08 (3H, s, CH3), 1.45 (3H, s, 
CH3), 1.62 (3H, s, CH3), 2.24 (3H, s, CH3), 2.25 (3H, s, CH3), 7.06-6.96 (3H, m, ArH), 7.76 (2H, d, ArH, 
J = 9.2), 8.29 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 15.2, 17.4, 19.3, 19.9, 20.7, 59.6, 91.8, 
123.2, 124.3, 124.9, 125.8, 129.8, 132.9, 135.1, 138.5, 149.1, 154.2, 171.6; IR (KBr) 1757, 1526, 1471, 
1366, 1345, 1134, 1093, 869,792, 752, 688 cm-1. Anal. Calcd. for C20H22N4O3: C, 65.56; H, 6.05; N, 
15.29, Found: C; 65.61, H; 6.02, N; 15.20. 
 
Synthesis of azetidinone derivative (18d) using procedure 2 
Yield  (0.13 g, 15%); mp 103-107 ºC; 1H NMR (400MHz, CDCl3): δ = 1.07 (3H, s, CH3), 1.49 (3H, s, 
CH3), 1.89 (3H, s, CH3), 2.33 (3H, s, CH3), 7.13 (2H, d, ArH, J =8.0), 7.32 (2H, d, ArH, J =8.4), 7.88 
(2H, d, ArH, J = 9.2), 8.37 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 17.3, 19.1, 19.2, 21.0, 
60.4, 90.1, 118.3, 123.4, 124.9, 129.6, 134.1, 134.6, 149.2, 154.1, 170.3; IR (KBr) 1751, 1523, 1513, 
1347, 1164, 1131, 861, 817, 752, 688 cm-1. Anal. Calcd. for C19H20N4O3: C, 64.76; H, 5.72; N, 15.90, 
Found: C; 64.81, H; 5.73, N; 15.85. 
 
Synthesis of azetidinone derivative (18e) using procedure 2 
In the case of azetidinone derivative (18e) it was the propanol transesterification product that was 
isolated 
Yield  (0.10 g, 11 %); mp 97-100 ºC; 1H NMR (400MHz, CDCl3): δ = 0.94 (2H, t J =7.6), 1.00 (3H, s, 
CH3), 1.29 (2H,m), 1.31 (3H, s, CH3), 1.72-1.67 (1H, m), 1.88 (3H, s, CH3), 4.18 (1H, t, J =6.4), 4.27 
(1H, q, J =5.2), 7.38 (2H, d, ArH, J =8.8), 7.78 (2H, d, ArH, J =8.8), 7.91 (2H, d, ArH, J = 9.2), 8.27 
(2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 9.5, 13.3, 16.5, 17.9, 18.1, 59.8, 65.5, 89.2, 116.3, 
122.4, 123.9, 124.9, 129.7, 140.0, 148.3, 152.9, 165.0, 169.6; IR (KBr) 1749, 1709, 1509, 1352, 1270, 
849, 769 cm-1.  
 
 
 
  
Synthesis of azetidinone derivative (18f) using procedure 2 
Azetidinone derivative (18f) was prepared using procedure 2 as outlined above; two additional 
compounds were isolated during the chromatographic separation (20f and 21f). 
(18f) Yield (0.10 g, 12 %). Spectra identical to those reported using procedure 1 
 
(20f) Yield  (0.14 g, 16 %); mp 195-197 ºC 1H NMR (400MHz, DMSO-d6): δ = 1.49 (3H, s, CH3), 1.53 
(3H, s, CH3), 1.92 (3H, s, CH3), 6.96 (1H, s br, ArH),7.07 (1H, t, ArH, J = 7.2), 7.33-7.26 (3H, m, ArH), 
7.61 (2H, d, ArH, J = 7.6), 8.15 (2H, s br, ArH), 9.06 (1H, s br, NH), 9.48 (1H, s br, NH); 13C NMR 
(100MHz, DMSO-d6) 21.7, 22.9, 24.3, 65.6, 110.5 (d, J = 222), 120.8, 123.5, 126.2 (d, J = 69), 128.3, 
138.7, 138.9, 154.2, 171.8, 172.8. IR (KBr) 3338, 3288, 1647, 1592, 1522, 1329, 1272, 1108, 750, 695 
cm-1. 
 
(21f) Yield  (0.17 g, 18 %); mp 142-145 ºC 1H NMR (400MHz, DMSO-d6): δ = 1.19 (3H, s, CH3), 1.42 
(3H, s, CH3), 1.61 (3H, s, CH3), 7.34-7.28 (2H, m, ArH), 7.41-7.39 (1H, m, ArH), 7.52-7.47 (2H, m, ArH, 
), 7.76 (2H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 9.2); 9.00 (1H, s NH); 13C NMR (100MHz, DMSO-
d6) 13.3, 17.9, 24.4, 49.3, 83.1, 123.4, 124.8, 126.3, 128.7, 129.2, 131.9, 149.3, 153.9, 174.3, 180.5; IR 
(KBr) 1661, 1528, 1377, 1346, 1161, 1107, 862 cm-1 
 
Synthesis of azetidinone derivative (18g) using procedure 2 
Yield  (0.21 g, 25%); orange oil; 1H NMR (400MHz, CDCl3): δ = 1.06 (3H, s, CH3), 1.44 (3H, s, CH3), 
1.63 (3H, s, CH3), 2.23 (3H, s, CH3), 2.32 (3H, s, CH3), 6.88 (1H, d, ArH, J =8.0), 7.02 (2H, d, ArH, J 
=8.0), 7.75 (2H, d, ArH, J = 9.2), 8.28 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 17.5, 18.9, 
19.3, 19.8, 21.1, 59.5, 91.7, 123.1, 124.9, 126.3, 127.1, 130.5, 131.9, 136.2, 138.1, 149.1, 154.2, 171.5; 
IR (liquid film) 1762, 1527, 1504 1370, 1347, 1139, 862, 753, 739 cm-1. 
 
Synthesis of azetidinone derivative (18h) using procedure 2 
Yield  (0.18 g, 22%); mp 108-110 ºC; 1H NMR (400MHz, CDCl3): δ = 1.06 (3H, s, CH3), 1.45 (3H, s, 
CH3), 1.65 (3H, s, CH3), 2.37 (3H, s, CH3), 7.22-7.06 (4H, m, ArH,), 7.76 (2H, d, ArH, J = 8.8), 8.29 
(2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 17.6, 19.1, 19.3, 19.9, 59.6, 91.8, 128.2, 124.9, 126.2, 
126.4, 128.2, 131.3, 133.3, 136.4, 149.1, 154.1, 171.3; IR (KBr) 1761, 1530, 1493, 1346, 1133, 874, 769 
cm-1. Anal. Calcd for C19H20N4O3: C, 64.76; H, 5.72; N, 15.90. Found: C; 64.66, H; 5.69, N; 15.83. 
 
Synthesis of azetidinone derivative (18i) using procedure 2 
Yield  (0.14 g, 16 %); mp 98-100 ºC; 1H NMR (400MHz, CDCl3): δ = 1.04 (3H, s, CH3), 1.44 (3H, s, 
CH3), 1.60 (3H, s, CH3), 3.67 (3H, s, OCH3), 6.89-6.85 (2H, m, ArH,), 7.19-7.15 (1H, m, ArH,), 7.60-
  
7.58 (1H, m, ArH,), 7.79 (2H, d, ArH, J = 9.2), 8.29 (2H, d, ArH, J = 8.8); 13C NMR (100MHz, CDCl3) 
16.9, 18.9, 19.9, 55.6, 59.8, 91.5, 112.0, 120.8, 123.1, 123.9, 124.9, 127.6, 128.4, 149.0, 153.9, 154.4, 
172.4; IR (KBr) 1761, 1524, 1497, 1390, 1345, 1242, 1106, 1025, 858, 770, 752. 
 
Synthesis of azetidinone derivative (18j) using procedure 2 
(18j) Yield  (0.17 g, 20%); mp 132-134 ºC; 1H NMR (400MHz, CDCl3): δ = 0.98 (3H, s, CH3), 1.42 (3H, 
s, CH3), 1.82 (3H, s, CH3), 7.18 (2H, d, ArH, J =8.8), 7.29 (2H, d, ArH, J =9.2), 7.78 (2H, d, ArH, J = 
8.8), 8.28 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, CDCl3) 17.3, 19.0, 19.1, 60.7, 90.3, 119.5, 123.4, 
124.9, 129.1, 129.5, 135.8, 149.3, 154.0, 170.3; IR (KBr) 1753, 1534, 1346, 1144, 869, 851, 705 cm-1. 
Anal. Calcd for C18H17ClN4O3: C, 57.99; H, 4.60; N, 15.03. Found: C; 57.99, H; 4.73, N; 14.81. 
 
(21j) Yield  (0.21 g, 23%); mp 201-203 ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.07 (3H, s, CH3), 1.34 
(3H, s, CH3), 1.60 (3H, s, CH3), 7.32 (2H, d, ArH, J =8.4), 7.38 (2H, d, ArH, J =8.4), 7.89 (2H, d, ArH, J 
= 9.2), 8.40 (2H, d, ArH, J = 9.2), 9.08 (1H, s, NH); 13C NMR (100MHz, DMSO-d6) 13.8, 17.9, 22.9, 
48.5, 81.6, 123.2, 125.1, 128.8, 129.3, 132.3, 132.8, 148.7, 154.0, 165.3, 179.1. IR (KBr) 3300, 1742, 
1661, 1532, 1492, 1344, 1102, 1085, 713.7, 687.2 cm-1. 
 
Synthesis of N-acyl hydrazide derivative as rearrangement product (24) 
(1g, 2.8 mmol) of the azoacetate derivative (15) was dissolved in hot EtOH (40 ml) to which (0.24 g, 3.7 
mmol) of potassium cyanide was added. The solution was allowed to reflux overnight, before being 
evaporated to dryness. Water (100 ml) was added to the reaction vessel and this was extracted with 
EtOAc : EtO2 (15:85). The combined extracts were dried over magnesium sulfate and upon evaporation 
to a reduced volume a pale brown solid precipitated. The precipitate was filtered off and washed with 
petroleum ether and dried. Yield (0.31 g, 35 %); mp 172-174 ºC; 1H NMR (400MHz, DMSO-d6): δ = 
1.23 (3H, t, CH3, J = 6.8), 1.27 (3H, s, CH3), 1.36 (3H, s, CH3), 1.88 (3H, s, CH3), 4.16-4.06 (2H, m, 
CH2), 6.90 (1H, d, ArH , J = 7.6), 7.15 (1H, d, ArH, J = 7.6), 8.11 (1H, d, ArH, J = 8.0), 8.17 (1H, d, 
ArH, J = 7.6), 9.58 (1H, s, NH); anal. Calcd. for C13H19N3O5 requires C, 54.36; H, 6.14; N, 13.58; found 
C, 54.53; H, 6.29; N, 13.51. 
 
Synthesis of N-acyl hydrazide derivative (25) by decarboxylation 
(0.5 g, 1.6 mmol) of N-acyl hydrazide derivative (24) was added to a 2.5 molar solution of sodium 
hydroxide (3.99 g dissolved in 40 ml of water) the solution was allowed to reflux for 4 h. The pH was 
adjusted to 7-8 with conc. HCl to give a yellow precipitate which was extracted into EtOAc (3 x 20 ml) 
dried over magnesium sulfate and evaporated to dryness Yield (0.41 g, 90 %); mp 215-216 ºC; 1H NMR 
(400MHz, DMSO-d6): δ = 1.21 (3H, s, CH3), 1.32 (3H, s, CH3), 1.94 (3H, s, CH3), 6.90-6.85 (1H, m, 
  
ArH), 7.15-7.10 (1H, m, ArH),  8.27-8.23 (2H, m, ArH) 9.50 (1H, s, NH); IR (KBr) 3347, 1710, 1619, 
1599 cm-1; Anal. Calcd. for C12H15N3O5 requires C, 51.24; H, 5.38; N, 14.94. Found C, 51.12; H, 5.50; N, 
14.71. 
 
Synthesis of diazetidinone derivative (26)  
A 0.05 M solution of N-acyl hydrazide derivative (25) was made up in MeCN (0.85 g/60 ml). (3.7g, 18 
mmol) of dicyclohexylcarbodiimide was added and the reaction refluxed overnight under a nitrogen 
atmosphere. After removal of the bulk of the excess dicyclohexylcarbodiimide and dicyclohexylurea by 
filtration, the remaining organic elements were evaporated to dryness and subjected to flash column 
chromatography to separate any persistent dicyclohexylurea. The desired diazetidinone derivative (26) 
was isolated and further purified by recrystallization from pet. ether : EtOAc 20 : 80. Yield (0.35g, 45%); 
mp 112-114 ºC; 1H NMR (400MHz, CDCl3): δ = 1.70 (6H, s, 2 x CH3), 2.20 (3H, s, CH3), 7.33-7.28 (2H, 
m, ArH), 8.30-8.22 (2H, m, ArH); IR (KBr) 1796, 1696, 1627 cm-1; anal. Calcd. for C12H13N3O5 requires 
C, 54.75; H, 4.98; N, 15.96; found C, 54.38; H, 4.93; N, 15.84. 
 
Synthesis of succinimide derivative (27f) 
(200 mg, 0.54 mmol) of the 2-iminopyrrolidine-5-one derivative 21f was dissolved in 10 ml of aqueous 
acetic acid. The solution was heated to 50 oC for 24 h, 100 oC for a further 24 h and finally refluxed for 4 
h after which TLC showed total consumption of the starting material. The solution was allowed to cool 
and added to ice-water (100 ml) which induced precipitation of a pale yellow solid that was filtered from 
solution. Yield (153 mg, 78 %); product decomposed in air over 24 h; 1H NMR (400MHz, CDCl3): δ = 
1.19 (3H, s, CH3), 1.42 (3H, s, CH3), 1.61 (3H, s, CH3), 7.30-7.25 (2H, m, ArH), 7.35-7.32 (1H, m, ArH), 
7.43-7.37 (2H, m, ArH), 7.76 (2H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 9.2); 13C NMR (100MHz, 
CDCl3) 13.3, 17.9, 24.4, 49.3, 83.1, 123.4, 124.8, 126.3, 128.7, 129.2, 131.9, 149.3, 153.9, 174.3, 180.5; 
IR (KBr) 1719, 1529, 1396, 1374, 1346, 1146, 1126 cm-1. 
 
Synthesis of azetidinone derivative (28h) 
(100 mg, 0.28 mmol) of the azetidinone derivative (18h) was dissolved in glacial acetic acid (25 ml) and 
heated to 80 oC, to this was added 0.5 ml of hydrogen peroxide solution (35% by weight) at 15 min 
intervals over 3 h. After 5 h the reaction mixture was treated with 2 ml of the hydrogen peroxide solution 
and allowed to stir at 80 oC overnight. A further 2 ml of hydrogen peroxide solution was added to the 
reaction mixture and the reaction allowed to stir for a further 3 h after which no starting material could be 
detected by TLC The reaction was cooled to room temperature and poured into 150 ml of ice-water which 
induced precipitation of a pale yellow solid that was filtered from solution. Yield (66 mg, 63.9 %); mp 
132-134 ºC; 1H NMR (400MHz, CDCl3): δ = 1.29 (3H, s, CH3), 1.51(3H, s, CH3), 1.69 (3H, s, CH3), 2.37 
  
(3H, s, CH3), 7.24-7.17 (3H, m, ArH,), 7.38 (1H, d, ArH, J = 8.8), 8.26 (2H, d, ArH, J = 9.6), 8.29 (2H, 
d, ArH, J = 10.0); 13C NMR (100MHz, CDCl3) 14.5, 17.7, 18.7, 19.0, 60.3, 86.3, 123.4, 124.6, 126.6, 
127.2, 128.6, 131.3, 132.5, 136.7, 149.9, 150.4, 171.0; IR (KBr) 1752, 1535, 1485, 1465, 1385, 1346, 
1310, 868, 850, 760, 703 cm-1. 
 
Synthesis of pyrazole derivatives (29 and 30f) 
Synthesis of pyrazole derivative (29) 
(1 g, 3.1 mmol) of the azoacetate derivative (13) was dissolved in hot n-PrOH (40 ml) to which (0.3 g, 4.6 
mmol) of potassium cyanide was added. The solution was allowed to reflux for 4 h, before being 
evaporated to dryness. Water (100 ml) was added to the reaction vessel and this was extracted with 
CH2Cl2 (15:85). The combined extracts were dried over magnesium sulfate and upon evaporation to a 
reduced volume a pale brown solid precipitated. The precipitate was filtered off and washed with 
petroleum ether and the product isolated after flash chromatography. Yield (0.13 g, 15 %) mp 210-212 
ºC; 1H NMR (400MHz, DMSO-d6): δ = 1.27 (3H, t, CH3, J = 7.2), 2.26 (3H, s, CH3), 4.20 (2H, q, CH2, J 
= 7.2), 6.64 (2H, s br, CH2), 7.81 (2H, d, ArH , J = 7.2), 8.32 (2H, d, ArH, J = 7.2); 13C NMR (100MHz, 
DMSO-d6) 14.3, 14.4, 59.1, 93.9, 123.0, 124.9, 143.1, 144.9, 150.6, 151.2, 164.0; IR (KBr) 3349, 1676, 
1548, 1344, 1286, 1131, 1112, 857, 789 cm-1. 
 
Synthesis of pyrazole derivative (30f) 
Yield (0.12 g, 15 %); mp 181-183 ºC; 1H NMR (400MHz, DMSO-d6): δ = 2.94 (3H, s, CH3), 6.60 (2H, s 
br, CH2), 7.06 (1H, t, ArH , J = 7.6), 7.32 (2H, t, ArH, J = 7.6), 7.63 (2H, d, ArH , J = 7.6), 7.88 (2H, d, 
ArH
 
, J = 9.2), 8.35 (2H, d, ArH, J = 9.2), 8.85 (1H, s, NH,); 13C NMR (100MHz, DMSO-d6) 14.2, 98.4, 
120.4, 122.6, 123.3, 124.9, 128.5, 138.8, 143.3, 144.7, 148.2, 150.7, 163.3; IR (KBr) 3455, 3429, 3313, 
1650, 1599, 1543, 1495, 1343, 864, 745, 684 cm-1. 
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